OPTIONS XII
for the Control of INFLUENZA

29 September - 2 October 2024
Brisbane Convention and Exhibition Centre
Queensland, Australia

FULL PROGRAM

CSL SEQIRUS INVITES YOU TO

STRENGTHENING INFLUENZA PROTECTION

A symposium on paediatric, pandemic and pioneering solutions

Join Chair Dr Sarah Londrigan and a panel of experts to explore the advancement of influenza protection in paediatric, adult and pandemic vaccines

---

Date: Monday 30 September 2024
Time: 1:00pm – 2:00pm AEST
Room: Great Halls 1 & 2, Brisbane Convention & Exhibition Centre

1:05pm	Symposium welcome and introductions
1:10pm	Paediatrics: Shielding the vulnerable – advancing influenza prevention with cell-based vaccines *With Professor Terry Nolan AO*
1:25pm	Progress in influenza vaccine technology: adjuvants, antigens and beyond *With Professor Colin Russell*
1:40pm	The pandemic threat of avian influenza viruses: progress and prospects for vaccine solutions *With Professor Kanta Subbarao*
1:55pm	Q&A

CSL Seqirus

Seqirus (Australia) Pty Ltd Melbourne. ABN: 66 120 398 067. www.cslseqirus.com.au.
CSL Seqirus Medical Information: 1800 642 865. Seqirus™ is a trademark of Seqirus UK Limited or its affiliates.
Date of preparation: August 2024. AU-FLU-24-0073. SEQ0542.

Table of Contents

Sponsors and Supporters **5**
Exhibitors **6**
Organising Committees **7**
Award Information **8**
Travel Fellowship Awards 8
Other Sponsor Awards 8
Welcome Messages **9**
Welcome Message from the Chair, Organising Committee, OPTIONS XII 9
Welcome Message from the Chair, ISIRV 10
Welcome Message from the Scientific Committee Chair, Options XII 10
General Information **11**
Venue Floor Plans **14**
Brisbane Convention & Exhibition Centre 15
Schedule at a Glance **17**
Sunday 29 September 2024 18
Monday 30 September 2024 19
Tuesday 1 October 2024 20
Wednesday 2 October 2024 21
Full Program **23**
Day 1 - Sunday 29 September 2024 23
Day 2 - Monday 30 September 2024 25
Day 3 - Tuesday 1 October 2024 30
Day 4 - Wednesday 2 October 2024 34
Plenary and Keynote Speakers **38**
Plenary Speakers 38
Keynote Speakers 45
Early Career Researcher - Career Development Lunch **52**
Social Events Program **53**
Welcome Reception and Posters 53
Early Career Researcher (ECR) Trivia Night 53
Conference Party 53
About Brisbane **54**
Experience Queensland **55**
Industry Sponsored Symposia **58**
Sunday 29 September 2024 58
Monday 30 September 2024 58
Tuesday 1 October 2024 58
Oral Presentations Listings **60**
Poster Session 1 ..... **73**
Poster Session 2 ..... **94**
Exhibition **115**
Exhibition Floor Plan 115
Exhibitor Listing 115
Sponsor and Exhibitor Profiles 116

Please join us for an AstraZeneca-sponsored symposium at OPTIONS XII for the Control of Influenza 2024!

From virus to vaccine: the journey to a seasonal influenza vaccine

Sunday 29 September 2024 | 13:35–14:35 AEST

Plenary Halls 1 & 2, Brisbane Convention & Exhibition Centre, Brisbane

Join our expert faculty for an exploration of seasonal influenza vaccines. Discover the latest advancements in our understanding and prevention of influenza, from global surveillance to experience with implementation in national immunisation programs.

Time (AEST)	Title	Speaker
13:35–13:40	Welcome and introduction	Peter Openshaw
13:40–13:48	Predicting the unpredictable: advancements in influenza surveillance	Ian Barr
13:48–13:56	Charting the course: preparation and production of seasonal influenza vaccines	Lauren Parker
13:56–14:04	Mapping disease burden: exploring the potential benefits of vaccination	Cheryl Cohen
14:04–14:12	Path to prevention: considerations for childhood influenza vaccination	Christopher Blyth
14:12–14:35	Panel discussion and Q&A	All

Peter Openshaw
(Chairperson)
Professor of Experimental Medicine, Imperial College London, London, UK

Lauren Parker
Scientific and Technical Lead, AstraZeneca, London, UK

Christopher Blyth
The Kids Research Institute Australia and University of Western Australia, Perth, Australia

Ian Barr
Deputy Director of the WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia

Cheryl Cohen
University of the Witwatersrand, Johannesburg, South Africa

This industry symposium is organised and funded by AstraZeneca Limited UK.
1 Francis Crick Avenue, Cambridge, Cambridgeshire CB2 0RE, United Kingdom.

AstraZeneca

Thank you to our Sponsors and Supporters

Platinum Sponsors

CSL Seqirus

AstraZeneca

Roche

sanofi

moderna

Pfizer

Supporters

TOURISM & EVENTS Queensland

BUSINESS EVENTS AUSTRALIA

brisbane australia

THE UNIVERSITY OF QUEENSLAND AUSTRALIA

vaxxas

VISMEDERI ANALYSES FOR LIFE IMPROVEMENT

sanofi

moderna

Exhibitors

sanofi

CSL Seqirus

moderna

GSK

isirv
International Society for Influenza and other Respiratory Virus Diseases

GISAID

Roche

Pfizer

hVIVO

ESWI
SCIENTISTS FIGHTING INFLUENZA AND OTHER ACUTE RESPIRATORY VIRUSES

AstraZeneca

C.T.L.
Cellular Technology Limited

vaxxas

Organising Committees

Organising Committee

Kirsty Short (CHAIR)
University of Queensland, Australia

Ian Barr
Peter Doherty Institute Deputy Director, University of Melbourne

Chris Blyth
University of Western Australia (UWA), Australia

Brendon Chua
The University of Melbourne at the Peter Doherty Institute, Australia

Keng Yih Chew
University of Queensland, Australia

Alan Hampson
Consultant / Melbourne, Australia: OPTIONS III Chair

Lance Jennings
Consultant / NZ: ISIRV Past-Chair, OPTIONS IX Co-Chair, OPTIONS X Co-Chair

Larisa Labzin
University of Queensland, Australia

Sarah Londrigan
The University of Melbourne at the Peter Doherty Institute, Australia

Patrick Reading
The University of Melbourne at the Peter Doherty Institute, Australia

Sophie Valkenburg
The University of Melbourne at the Peter Doherty Institute, Australia

Carolien van de Sandt
The University of Melbourne at the Peter Doherty Institute, Australia

Wenqing Zhang
Head Global Influenza Program, WHO, Geneva, Switzerland

Scientific Program Committee

Rebecca Cox	University of Bergen, Norway
S. Mark Tompkins	University of Georgia, Atlanta, USA
Benjamin John Cowling	The University of Hong Kong, Hong Kong
Katherine Kedzierska	The University of Melbourne, Australia
Viviana A Simon	Icahn School of Medicine at Mount Sinai, New York, USA
Kirsten Spann	Queensland University of Technology (QUT), Australia
Sheena Sullivan	The University of Melbourne, Australia
Norio Sugaya	School of Medicine, Keio University, Japan
Sook San Wong	The University of Hong Kong, Hong Kong
Paul Young	University of Queensland, Australia

Award Information

Travel Fellowship Awards

We would like to acknowledge the generosity of all our sponsors who facilitated travel scholarships and educational activities at Options XII, including those who provided support for our younger scientists and those from low and middle income countries to attend the meeting.

Samuel Ago, Ghana
Felix Albati, Mozambique
Carissa Aurelia, Australia
Jorim Ayugi, Kenya
Antoine Brault, France
Rubina Bunjun, South Africa
Cheuk Long Chow, Hong Kong
Fahmida Chowdhury, Bangladesh
Rifaldy Fajar, Indonesia
Ann-Claire Gourinat, New Caledonia
Yiyang Guo, Hong Kong
Vu Mai Phuong Hoang, Vietnam
Ariful Islam, Bangladesh
Jude Jayamaha, Sri Lanka
Jyoti Jethani, India
Erik Karlsson, KH
Ghazi Kayali, UAE
Anand Krishnan, India
Aidyn Kydyrmanov, KZ
Benjamin Larsen, USA
Yoke Lee Low, Malaysia
Anders Madsen, Norway
Angella Manele, Solomon Islands
Serena Marchi, Italy
Rita Mark, Papua New Guinea
Arne Matthys, Belgium
Benjamin Meyer, Switzerland
Mahesh Moorthy, India
Boitumelo Motsoeneng, South Africa
Ravi Naidu, Fiji
Sadegh Niazi, Australia
Evangeline Obodai, Ghana
Michael Otieno, Kenya
Teerada Ponpinit, Thailand
Claudia Priddey, New Zealand
Juan Pu, China
Rachael Pung, Singapore
Sean Ray, USA
Agustina Rimondi, Argentina
Amaya Rojo-Fernandez, USA
Louise Rowntree, Australia
Soledad Ruiz, Chile
Raquel Saludo, Guam
Stephany Sánchez-Ovando, Australia
Kevin Selva, Australia
Sandra Semi, Samoa
Xiao Shang, China
Anika Singanayagam, UK
Jurre Siegers, Cambodia
Patrick Sotto, Guam
Vasiti Uluiviti, Guam
Michelle Vu, USA
Wuji Zhang, Australia
Wenting Zuo, China

Other Sponsor Awards

We wish to thank the below institutes and centres for sponsoring prizes for a number of our abstract presenters.

AWARDEE	SPONSOR NAME
Charlotte Kristensen	The Doherty Institute - *Pathogenesis and Transmission Session Prize*
Stephanie Williams	The Australian Centre for Disease Preparedness - *Zoonotic Respiratory Viruses Session Prize*
Zengyang Shao	The Doherty Institute - *Viral Evolution and Public Health Genomics Session Prize*
Jiapei Yu	The Hudson Institute of Medical Research - *Innate and Mucosal Immunity Session Prize*
Kohei Oishi	The Monash Biomedicine Discovery Institute - *Virus Host Cell-Interactions Session Prize*

Welcome Messages

Welcome Message from the Chair, Organising Committee, OPTIONS XII

The 12th edition of OPTIONS for the Control of Influenza marks a long-awaited return to Australia. OPTIONS III was held in Cairns, 1996, so it has certainly been a while.

The OPTIONS Conference is an exceptional gathering.

Now held every 2 years, it brings together leading researchers, practitioners, industry representatives and policy makers from all around the world to explore and advance our understanding of influenza and its impact on human and animal health. The program has also expanded to feature spotlights on the latest advances in the fields of SARS-CoV-2 and RSV.

Other highlights for this edition:

Early Career Researchers (ECRs): OPTIONS XII has a special focus on students and ECRs with approximately 80 scholarships being awarded to younger scientists alongside multiple student and ECR networking and career development opportunities.

First Nations Health: This conference dedicates special attention to the unique health challenges faced by First Nations populations. Discussions will explore culturally sensitive approaches to prevention, community enagement and healthcare delivery.

Interdisciplinary Science: We strongly believe that interdisciplinary collaboration is key to unravelling the complexities of influenza. Through interactive workshops, panel discussions, and cross-disciplinary sessions, the conference will foster collaboration between scientists, industry partners, practitioners and policy makers from diverse fields, including virology, immunology, epidemiology, public health, clinical medicine and policy development.

Knowledge Exchange and Networking: This conference provides a vibrant platform for attendees to engage in meaningful discussions, share best practices, and forge new collaborations. Interactive poster sessions, networking events, and social activities will facilitate connections and knowledge exchange among participants.

Policy and Advocacy: Recognizing the importance of policy and advocacy in tackling influenza and improving public health, the conference will feature sessions focused on policy development, implementation, and resource allocation. Discussions will emphasize interdisciplinary approaches to inform evidence-based policies.

Welcome Messages

Welcome Message from the Chair, ISIRV

The International Society for Influenza and other Respiratory Virus Diseases (ISIRV) is a professional scientific society and registered charity in the United Kingdom. Formally launched in 2005, ISIRV's constant mission over the last two decades has been to provide a forum for international scientists from government, academia, and the private sector to exchange information, stimulate collaboration, and provide education for the promotion, prevention, detection, treatment, and control of influenza and other respiratory virus diseases throughout the world.

To achieve our charitable and educational aims, ISIRV co-ordinates a variety of conferences, meetings, and events, aimed at scientists at all stages of their career, to disseminate information on cutting-edge research and scientific advances and to help in nurturing future generations of respiratory virus experts.

Options for the Control of Influenza, ISIRV's flagship meeting series, is the only global scientific meeting with a dedicated focus on influenza. Currently held every 2 years, this conference brings together the global scientific community across several days for a varied scientific program tackling a range real-word issues pertinent to the respiratory virus community. In recent years, the scope of these meetings has expanded to spotlight SARS-CoV-2, RSV, and other emerging respiratory infections, integrated into four parallel tracks.

Running each Options meeting is a complex process with a multitude of moving parts. The success of the series is rooted in the society's approach to rotating the meeting location across the world with each cycle, taking into consideration and adapting to the relevant issues faced by the host's geographic region, and ensuring our expert speakers reflect the diversity of our international colleagues and their fields of practice. Each program at Options is unique, though underpinned by a commitment to showcase strong and innovative scientific work that generates discussion and pushes the study and treatment of respiratory viruses ever forward.

Welcome Message from the Scientific Committee Chair, Options XII

We are delighted to welcome you to OPTIONS XII on behalf of the scientific committee.

The exciting program will cover the latest advances in influenza and other respiratory viruses with five tracks covering Virology and Pathogenesis, Clinical Science and Vaccinology, Public Health and Policy, Other Respiratory Viruses (including SARS-CoV-2 and RSV) and a Cross Cutting Interdisciplinary track. We are proud to have a special focus on early career scientists with the preparatory mini school, an inspirational talk with Australian Nobel Laureate Peter Doherty, an early career development lunch, a dedicated networking evening for the next generation of scientists and many scholarships and awards. The program will also highlight the burden of respiratory viruses and vaccine implementation in First Nations and underserved communities, not to mention the latest developments in universal influenza vaccines, RSV vaccine implementation, antivirals, HPAI H5N1 and the ongoing challenges of SARS-CoV-2. We are incredibly grateful to the many contributors to OPTIONS XII especially the tireless work of the local and scientific organising committees, the speakers, all the abstract reviewers, chairs, oral and poster presenters; all of whom have ensured OPTIONS XII is the leading scientific influenza conference. We also wish to thank all our sponsors and the ICMS Australia for their immense support.

The International Society for Influenza and other Respiratory Viruses is the leading global scientific society in our field, and we invite you to join us to advance our global community. We hope that OPTIONS XII provides a unique opportunity to network, catch up with old friends/colleagues, make new friends and contribute and showcase the advancement of the best science in respiratory viruses. Most of all enjoy the hospitality of Brisbane, ISIRV and the 12th OPTIONS meeting.

General Information

Brisbane Convention & Exhibition Centre

Address: Cnr Merivale and Glenelg Streets,
South Bank Queensland 4101

Telephone: (07) 3308 3063
Website: www.bcec.com.au

ATMs

ATMs are located on the Foyer Level concourse outside the Exhibition Halls of the Brisbane Convention & Exhibition Centre. ATMs for most major banks can also be found along Grey Street, South Bank, just a short walk from the venue.

Banking Hours

Normal banking hours are Monday to Thursday 9.30am-4.00pm and Friday 9.30am-5.00pm excluding Public Holidays.

Car Parking

The Convention Centre's undercover car park can be accessed from Merivale or Grey Street and is a maximum of AUD $35 per day. The car park is open 24 hours a day with onsite security.

Catering

Morning tea, lunch and afternoon tea will be available in the Exhibition and is included in the registration fee. Please refer to the program for catering times.

Certificate of Attendance

A certificate of Attendance will be sent to each delegate post Conference via email.

Cloakroom

A cloakroom is located at the Customer Service Desk located in the Foyer of the Brisbane Convention & Exhibition Centre, providing storage for visitors and delegates' belongings.

Currency

Decimal currency is used in Australia-units are dollars and cents. Current exchange rates can be obtained from your bank or a bureau de change. All major credit cards are widely accepted in Australia.

Dietary Requirements

If you have advised the Conference Secretariat of special dietary requirements, please speak to a member of the catering staff during the catering breaks, or at any of the social functions that you may be attending. Catering staff will have a list of those with special dietary requirements.

Disclaimer

The Conference Committee reserves the right to make changes to the Conference program at any time without notice. Please note that this program is correct at the time of printing.

Dress Code

The Conference dress code is smart casual. Dress codes for social functions can be found in the social function section of this book.

Duplication/Recording

Unauthorised flash photography, audiotaping, video recording, digital taping or any other form of duplication is prohibited during the Conference sessions.

Electricity

The electrical supply in Australia is 240 volts, 50 Hz. The connection for appliances is a flat 3-pim plug of unique design. Most hotels provide 110V outlets for shavers.

Emergency Details

In an emergency telephone 000 for Ambulance, Fire Service or Police.

Exhibition

The Conference Exhibition is located within Great Halls 3 & 4 on the foyer/ground level of the Convention Centre. The Exhibition will be open at the following times:

Sunday 29 September 2024
07:30-20:30

Monday 30 September 2024
07:30-20:30

Tuesday 1 October 2024
07:30-17:00

Wednesday 2 October 2024
07:30-16:30

Lost and Found

Any found item may be turned into the Registration Desk located in the Merivale Street Foyer. Enquiries about lost items can be directed to the Registration Desk.

Mobile Phones & Charging Stations

Australia operates on a 4G/LTE and 5G digital network. Delegates are asked to switch off their mobile phones or set them to silent when attending sessions. Charging stations are available within the exhibition.

General Information

Name Badges

For security purposes, delegates, speakers, sponsors and exhibitors are asked to wear their name badges at all times when within the venue. Entrance into sessions is restricted for registered delegates only. If you misplace your name badge, please go to the Registration Desk to arrange a replacement.

Parent Rooms

Our Parent Rooms feature all you need to feed and change in privacy and comfort. You can find Parents' Rooms located on Merivale Street Main Foyer, just behind Merivales Cafe and one located on Grey Street Main Foyer next to the Information Desk.

You will also find change tables in all of the uni-sex accessible toilets throughout the Centre.

In addition to the Public Parents' Rooms, there will be a Parents' Room exclusive to OPTIONS XII delegates located in the Great Hall VIP Suite 3 where Plenary Sessions will be streamed. Access via Mezzanine Level.

Prayer Room

Separated male and female prayer rooms including washing facilities are located in the convention centre off the main foyer.

Poster Sessions

There will be two poster sessions run as part of the congress.

Poster Sessions

Location: Exhibition Hall 1 and Great Hall 1 & 2

Please have your poster displayed on your dedicated poster board by 10:50am the morning of 29 September for viewing during the catering breaks throughout the day. It is recommended that presenters stand next to their poster during the catering breaks to respond to any questions viewers may have.

There will then be a dedicated poster session for all poster presenters held from 6:30pm-8:30pm where you will be able to present and engage with viewers. If your poster is in the exhibition, your poster must be removed by no later than 17:00 on 1 October 2024.

Poster Session 1

Session Date: Sunday 29 September | **Time:** 18:30 – 20:30

Theme	Poster Board Numbers			
Clinical Sciences and Vaccinology	P001-P018	P175-P243	P783, P785, P787	
Interdisciplinary Session	P040-P058	P052-P057	P281-P306	
Public Health and Policy	P077-P108	P244-P306, P307-P418	P640, P781-P782	P788-P789
Virology and Pathogenesis	P141-P157	P419-P477		

Poster Session 2

Session Date: Monday 30 September | **Time:** 18:30 – 20:30

Theme	Poster Board Numbers			
Clinical Sciences and Vaccinology	P019-P039	P059-P76	P478-P546	P797-P798
Interdisciplinary Session	P059-P076	P547-P609	P790-P791	P795, P799
Public Health and Policy	P084, P109-P128	P610-P685	P686-P721	P796-P798, P800-P802
Virology and Pathogenesis	P130-P140	P158-P174	P722-P779	P793-P794

Program

Every endeavour has been made to produce an accurate program. If you are presenting at the Conference, please confirm your presentation time as contained in this program. The Conference App will have the latest information regarding the program.

Registration Desk

The Registration Desk is on the ground floor of the Brisbane Convention and Exhibition Centre; it will be open during the following times:

Sunday 29 September
07:00-17:00

Monday 30 September
07:00-17:00

Tuesday 1 October
07:00-16:00

Wednesday 2 October
07:00-16:00

Shopping

Shops open from 9.00am to 5.30pm during the week with late night shopping on Thursdays and Friday to 9.00pm. On Saturdays and Sunday, most shops are open between 10.00am and 5.00pm.

Smoking

Smoking is not permitted in the Brisbane Convention and Exhibition Centre. Smokers must always remain at least 4 metres from any doorway when smoking. Fines can be imposed for smoking in prohibited places.

Speakers

Please ensure that you are available in your presentation room at least 15 minutes prior to the start of the session. Speakers are requested to report to the speaker preparation room at least 3 hours before their scheduled presentation with their presentation on a USB to allow sufficient time to upload and check their audio-visual presentations with the technician.

The Speakers' Preparation Room is M10 on the yellow Mezzanine Level. It is open at the following times:

Sunday 29 September
07:00-17:00

Monday 30 September
07:00-17:00

Tuesday 1 October
07:00-16:00

Wednesday 2 October
07:00-16:00

Taxes

A Goods and Services Tax (GST) of 10% applies to all consumer goods and is included in retail prices.

Tipping

Service charges are not added to accounts by hotels and restaurants. You may tip taxi drivers, hotel porters and restaurant wait-staff (up to about 10% of the bill) if you wish to acknowledge exceptional service. At any time, tipping is your choice.

Weather

See the Australian Bureau of Meteorology website (www.bom.gov.au) for daily information.

Wi-Fi

Free wireless internet is available for Conference delegates. To connect join the BCEC link network. There is no password required.

Venue Floor Plans

LOCATION AND ACCESS MAP

BCEC ON MERIVALE STREET AND GREY STREET



OUR CITY, YOUR CANVAS.

BRISBANE CONVENTION & EXHIBITION CENTRE

Venue Floor Plans

Brisbane Convention & Exhibition Centre

Rooms in Use

OPTIONS XII will take place in the Great Hall.

Meeting Room	Description
Great Hall 1 and 2	Welcome to Country, Opening and Closing Plenary sessions and Schild Award lecture
Great Hall 1 and 2	Panel Discussion, Plenary and Concurrent session room
Great Hall 1and 2	Industry Symposia
Great Hall VIP Suite 3	Exclusive Parents' Room (Access via Mezzanine Level)
Mezzanine M1 and M2	Concurrent Sessions
Mezzanine M3	Concurrent Sessions and Late Breaking Abstracts
Mezzanine M4	Concurrent Sessions

Exhibition Level



Mezzanine Level



VIP Suite:

Exclusive OPTIONS XII Parents' Room (Suite 3) where Plenary Sessions will be streamed.

Join us for our

OPTIONS XII 2024 Symposium

Addressing Influenza Disease Burden: Current Challenges and Emerging Vaccine Strategies Against a Persistent Threat

Tuesday 1st October, 10:30–11:30 AEST (Great Hall 1 + 2)

Agenda

Welcome and Introduction
Michael Nissen, FFSc (RCPA), (Chair and Moderator)
University of Queensland (UQCCR) & Queensland Adult Specialist Immunisation Service (QASIS), Brisbane, Australia

Influenza Disease Burden: Potential Considerations
Raina MacIntyre, FRACP, FAFPHM, M App Epid, PhD
The Kirby Institute, UNSW, Sydney, Australia

Viral Evolution of Influenza: Challenges and Implications for Public Health
Colin Russell, PhD
Amsterdam University Medical Center, Amsterdam, Netherlands

Seasonal Influenza Vaccines: Emerging Technologies and Public Health Impact
Terry Nolan, AO, FAHMS
University of Melbourne and MCRI, Melbourne, Australia

Panel Discussion and Q&A
All speakers moderated by
Michael Nissen

Visit our Moderna Medical booth (#01)

Schedule at a Glance

- **Full Program**
- **Plenary Speakers**
- **Keynote Speakers**
- **ECR Career Development Lunch Speakers**
- **Mini-School of Influenza**
- **Social Events**

We are excited to present to you Options XII! This Options will feature several never-before-seen features in the Options series including a focus on underserved populations, a session dedicated to the highest ranked abstracts from Early Career Researchers (ECRs) and a discussion with Nobel Prize winning scientist from the University of Melbourne, **Professor Peter Doherty**.

We will have a strong focus on ECR career development by hosting the School for Influenza and Other Respiratory Viruses the day before Options commences. During the conference there will also be an ECR networking evening and an ECR career development lunch (featuring a chance to network with editors from high impact journals and key members of industry). Importantly, there will be lots of prizes and scholarships available to support ECR attendance.

We will of course feature our normal lineup of leading researchers for our plenary sessions which will include sessions on the transmission of respiratory viruses, zoonotic infections, and immunology/vaccine development. We will have 24 sessions in three concurrent tracks featuring speakers selected from submitted abstracts as well as two evening poster sessions.

This year's Options will also feature a live recording of This Week in Virology (TWiV)/Immune-your chance to meet the virology podcast superstars in person.

Schedule at a Glance

Sunday 29 September 2024

TIME	ROOM	DESCRIPTION
08:00-10:20	Great Hall 1 and 2	**Welcome to Country, Opening Plenary session and Schild Award lecture**
10:20-10:50	**GREAT HALL 3 AND 4**	**MORNING TEA: EXHIBITION, POSTERS, CATERING AND NETWORKING**
10:50-11:50	Great Hall 1 and 2	**Panel Discussion:** H5N1 HPAI 1996 - 2024: What has changed and how worried should we be today?
11:50-12:50	Great Hall 1 and 2	Concurrent Session: **Challenges in the clinical development of vaccines with enhanced neuraminidase immunogenicity**
	Mezzanine M1 and M2	Concurrent Session: **Influenza and Diabetes (ESWI)**
	Mezzanine M3	Concurrent Session: **Late Breaking Abstracts**
	Mezzanine M4	
12:50-13:35	**GREAT HALL 3 AND 4**	**LUNCH AND POSTER VIEWING**
13:35-14:35	Great Hall 1 and 2	Industry Symposium: AstraZeneca
14:50-15:50		Industry Symposium: Pfizer
15:50-16:20	**GREAT HALL 3 AND 4**	**AFTERNOON TEA: EXHIBITION, POSTERS, CATERING AND NETWORKING**
16:20-18:40	Great Hall 1 and 2	**Plenary:** First Nations populations: Respiratory Disease, Vaccination, and Implementation
18:30-20:30	Great Hall 3 and 4	**Welcome Reception and Poster Session 1**
20:30-late	Pig N'Whistle	**ECR Networking Event (Sponsored by ISIRV)**

Schedule at a Glance

Monday 30 September 2024

TIME	ROOM	DESCRIPTION
08:00-10:00	Great Hall 1 and 2	**Plenary:** Transmission
10:00-10:30	**GREAT HALL 3 AND 4**	**MORNING TEA: EXHIBITION, POSTERS, CATERING AND NETWORKING**
10:30-12:00	Great Hall 1 and 2	Concurrent Session: **Public Health and Policy:** Forecasting, seasonality and surveillance
	Mezzanine M1 and M2	Concurrent Session: **Interdisciplinary Session:** Respiratory viruses in underserved populations
	Mezzanine M3	Concurrent Session: **NIV IG Session:** Avian influenza at the species interface
	Mezzanine M4	Concurrent Session: **Clinical Sciences and Vaccinology:** Clinical trials
12:00-13:00	Mezzanine M3	**ECR Career Development Lunch**
12:00-13:00	**GREAT HALL 3 AND 4**	**LUNCH AND POSTER VIEWING**
13:00-14:00	Great Hall 1 and 2	Industry Symposium: CSL Seqirus
14:00-15:30	Great Hall 1 and 2	Concurrent Session: **Public Health and Policy:** Vaccines 1: Real-world vaccine effectiveness
	Mezzanine M1 and M2	Concurrent Session: **Virology and Pathogenesis:** Virus-host cell interactions
	Mezzanine M3	Concurrent Session: **Other Respiratory Viruses:** Respiratory virus surveillance and burden of disease
	Mezzanine M4	Concurrent Session: **Interdisciplinary Session:** Viral evolution and public health genomics
15:30-16:00	**GREAT HALL 3 AND 4**	**AFTERNOON TEA: EXHIBITION, POSTERS, CATERING AND NETWORKING**
16:00-17:00	Great Hall 1 and 2	Industry Symposium: Roche
17:00-18:30	Great Hall 1 and 2	Concurrent Session: **Public Health and Policy:** Vaccines 2: from early development to the real world
	Mezzanine M1 and M2	Concurrent Session: **Other Respiratory Viruses:** RSV prevention and treatment
	Mezzanine M3	Concurrent Session: **Virology and Pathogenesis:** Innate and mucosal immunity to infection
	Mezzanine M4	Concurrent Session: **Interdisciplinary Session:** Imprinting, Aging and viral infection
18:30-20:30	Great Hall 3 and 4	**Poster Session 2**

Schedule at a Glance

Tuesday 1 October 2024

TIME	ROOM	DESCRIPTION
08:00-10:00	Great Hall 1 and 2	**Plenary:** Immunology and Vaccine Development
10:00-10:30	**GREAT HALL 3 AND 4**	**MORNING TEA: EXHIBITION, POSTERS, CATERING AND NETWORKING**
10:30-11:30	Great Hall 1 and 2	Industry Symposium: Moderna
11:30-13:00	Great Hall 1 and 2	Concurrent Session: **Public Health and Policy:** Vaccines 3: immunogenicity, efficacy and effectiveness
	Mezzanine M1 and M2	Concurrent Session: **Clinical Sciences and Vaccinology:** AVG IG Session
	Mezzanine M3	Concurrent Session: **Interdisciplinary Session:** Correlates of protection and immune responses to vaccination
	Mezzanine M4	Concurrent Session: **Other Respiratory Viruses:** SARS-CoV-2 and other virus transmission and evolution
13:00-14:00	**GREAT HALL 3 AND 4**	**LUNCH AND POSTER VIEWING**
14:00-15:00	Great Hall 1 and 2	Industry Symposium: Sanofi Pasteur
15:00-16:30	Great Hall 1 and 2	Concurrent Session: **Public Health and Policy:** Sero-epidemiology
	Mezzanine M1 and M2	Concurrent Session: **Clinical Sciences and Vaccinology:** Antivirals and therapeutics
	Mezzanine M3	Concurrent Session: **Virology and Pathogenesis:** Adaptive immune response to infection
	Mezzanine M4	Concurrent Session: **Other Respiratory Viruses:** Pathogenesis
16:30-17:00	**GREAT HALL 3 AND 4**	**AFTERNOON TEA: EXHIBITION, POSTERS, CATERING AND NETWORKING**
17:00-18:30	Great Hall 1 and 2	Concurrent Session: **Public Health and Policy:** Epidemiology, transmission, and control
	Mezzanine M1 and M2	Concurrent Session: **Clinical Sciences and Vaccinology:** Diagnostics, biomarkers and applications
	Mezzanine M3	Concurrent Session: **Interdisciplinary Session:** Epidemic and pandemic preparedness
	Mezzanine M4	Concurrent Session: **Other Respiratory Viruses:** SARS-CoV-2 novel treatments and prevention strategies
19:30-23:00	Eat Street Northshore	**OPTIONS XII Congress Party**

Schedule at a Glance

Wednesday 2 October 2024

TIME	ROOM	DESCRIPTION
08:00-10:00	Great Hall 1 and 2	**Plenary:** Zoonotic Infection / Emerging Viruses
10:00-10:30	**GREAT HALL 3 AND 4**	**MORNING TEA: EXHIBITION, POSTERS, CATERING AND NETWORKING**
10:30-11:30	Great Hall 1 and 2	This This Week In Virology
11:30-13:00	Great Hall 1 and 2	Concurrent Session: **Public Health and Policy:** Burden of disease
	Mezzanine M1 and M2	Concurrent Session: **Interdisciplinary Session:** Late Breaking Abstracts on H5N1 in new species
	Mezzanine M3	Concurrent Session: **Virology and Pathogenesis:** Pathogenesis and transmission
	Mezzanine M4	Concurrent Session: **Other Respiratory Viruses:** SARS-CoV-2 vaccines
13:00-14:00	**GREAT HALL 3 AND 4**	**LUNCH AND POSTER VIEWING**
14:00-15:30	Great Hall 1 and 2	Concurrent Session: **Public Health and Policy:** Surveillance
	Mezzanine M1 and M2	Concurrent Session: **Clinical Sciences and Vaccinology:** Novel vaccines and platforms
	Mezzanine M3	Concurrent Session: **Virology and Pathogenesis:** Zoonotic respiratory viruses - mechanisms of zoonoses
	Mezzanine M4	Concurrent Session: **Interdisciplinary Session:** Past pandemics and future solutions
15:30-16:00	**GREAT HALL 3 AND 4**	**AFTERNOON TEA: EXHIBITION, POSTERS, CATERING AND NETWORKING**
16:00-17:30		**Closing Ceremony, Awards, Closing remarks and thanks**

THIS CONTENT IS INTENDED FOR HEALTHCARE PROFESSIONALS ONLY.

Combatting Co-circulation of Respiratory Viruses:

Meeting the Public Health Challenge

Join us for a Pfizer-sponsored integrated symposium at OPTIONS XII 2024

Sunday 29th September 2024 | 14:50–15:50 AEST | Great Hall 1 & 2

Agenda

Timings (AEST)	Speaker(s)	Session title
14.50–14:53	Prof. Michael Moore AM (Chair) *Australia*	Welcome and introduction
14:54–15:08	Prof. Charles Feldman *South Africa*	Addressing the burden of infectious respiratory diseases
15:09–15:23	Prof. Raina MacIntyre *Australia*	The public health benefits of vaccination against respiratory diseases
15:24–15:38	A/Prof. Holly Seale *Australia*	Empowering communities: Building vaccine confidence and acceptance
15:39–15:48	All	Q&A session
15:49–15:50	Prof. Michael Moore AM (Chair) *Australia*	Conclusions and close

We look forward to welcoming you to our symposium at OPTIONS XII 2024

OPTIONS XII for the Control of Influenza.

This meeting is organised and funded by Pfizer Inc.

Pfizer Australia Pty Ltd. Sydney, Australia.
www.pfizer.com.au. Medical Information: 1800 675 229.
PP-UNP-GLB-2446 | August 2024

Day 1 - Sunday 29 September 2024

07:00-12:00	*Registrations and Poster Set Up*			
ROOM:	**GREAT HALL 1 AND 2**			
08:00-10:20	**Welcome to Country, Plenary Speakers and Schild Award**			
08:00-08:25	Welcome to Country and Opening Remarks			
08:25-09:00	**Opening Plenary Session** *Chairs: Kirsty Short and Maria Zambon*			
	Jeremy Farrar, World Health Organization, Switzerland Influenza - From the outside looking in			
09:00-09:35	**Mark von Itzstein,** Griffith University, Australia The glycointeractome of clinically-significant respiratory viruses and drug discovery			
09:35-09:45	**Introducing Schild Lecture** *Maria Zambon and Mark Tompkins*			
09:45-10:20	**Schild Lecture** **Florian Krammer,** Icahn School of Medicine at Mount Sinai, USA; Medical University of Vienna, Austria			
10:20-10:50	**MORNING TEA**			
ROOM:	**GREAT HALL 1 AND 2**			
10:50-11:50	Panel Discussion **H5N1 HPAI 1996 - 2024: What has changed and how worried should we be today?** *Chair: Kanta Subbarao* **Jeremy Farrar, Amelia Coggon, Yoshi Kawaoka, Erik Karlsson, Florian Krammer, Amy Baker**			
ROOM:	**GREAT HALL 1 AND 2**	**MEZZANINE ROOM M3**	**MEZZANINE ROOM M4**	**MEZZANINE ROOM M1 AND M2**
11:50-12:50	**Challenges in the clinical development of vaccines with enhanced neuraminidase immunogenicity** *Sponsored by* moderna *Chair: Florian Krammer* **Panel Discussion: Marios Koutsakos, Jerry Weir, Rebecca Cox, Aubree Gordon, Sheena Sullivan**	**Late Breaking Abstracts** *Chairs: Ultan Power and Fred Hayden*	**Late Breaking Abstracts** *Chairs: Melanie Wu and Shashank Tripathi*	**Influenza and Diabetes (ESWI)** *Chair: Kirsty Short* **Panel Discussion: Oana Sandulescu, Katina Hulme, Tor Biering-Sorensen**
11:50-12:03		**Hannah Stacey:** Evidence of local B-cell immunity following live-attenuated influenza vaccination of humans	**Colin Russell:** Later seasonal influenza virus vaccine strain selection can improve match of vaccine viruses to circulating viruses	
12:03-12:16		**Martha Alexander-Miller:** Antibody Function Predicts Viral Control in Newborn African Green Monkeys Immunized with an Influenza Virus HA Stem Nanoparticle	**Oliver Eales:** Biases in routine influenza surveillance indicators used to monitor infection incidence and recommendations for improvement	
12:16-12:29		**Tereza Masonou:** SARS-CoV-2 infection of nasal epithelial cells from children results in greater neutrophil trans-epithelial migration, but a more activated neutrophil phenotype emerges in older adults	**Benoit Callendret:** Phase 3 Safety and Immunogenicity of an mRNA-Based Seasonal Influenza and SARS-CoV-2 Multicomponent Vaccine (mRNA-1083) Compared With Co-administered Licensed Vaccines in Adults ≥50 Years Old	
12:29-12:42		**Goran Bajic:** Cryo-EM structure and protection mechanism of human antibody lineages that recognize quaternary epitopes on influenza hemagglutinin	**Rose Miller:** Spike-directed immunity to multiple coronaviruses in ferrets	

12:50-13:35	**LUNCH AND POSTER VIEWING**
13:35-14:35	Industry Symposium: **AstraZeneca** **From virus to vaccine: the journey to a seasonal influenza vaccine** (Great Hall 1 and 2) *Chair: Peter Openshaw* **Ian Barr, Lauren Parker, Cheryl Cohen, Christopher Blyth**
14:50-15:50	Industry Symposium**: Pfizer** **Combatting Co-circulation of Respiratory Viruses: Meeting the Public Health Challenge** (Great Hall 1 and 2) *Chair: Michael Moore AM* **Charles Feldman, Raina MacIntyre, Holly Seale**
15:50-16:20	**AFTERNOON TEA**
ROOM:	**GREAT HALL 1 AND 2**
16:20-18:40	**First Nations populations:** **Respiratory Disease, Vaccination, and Implementation** *Chair: Bronwyn Fredericks*
16:30-17:00	**Katherine Kedzierska,** The University of Melbourne, Australia Defining immunity to respiratory viral infections in Australian First Nations peoples
17:00-18:00	**Panel Discussion** *Chair: Bronwyn Fredericks*
	Jane Davies, Menzies School of Health Research, Australia
	Teresa de Santis, Northern Territory Health, Australia
	Adrian Miller, CQ University, Australia
	Matire Harwood, University of Auckland, New Zealand
18:00-18:30	**A discussion with Noble Laureate Peter Doherty** *Introduction by* **Katherine Kedzierska,** The University of Melbourne, Australia
18:30-20:30	**Welcome Reception and Poster Session 1**
20:30-Late	**ECR Networking Event (Sponsored by ISIRV)**

Day 2 - Monday 30 September 2024

07:00-12:00	*Registrations and Poster Set Up*				
ROOM:	**GREAT HALL 1 AND 2**				
08:00-10:00	**Transmission**				
08:00-08:10	**Opening - Conference Business and Session welcome** *Chairs: Rebecca Cox and Mark Tompkins*				
08:10-08:45	**Cheryl Cohen,** University of the Witwatersrand, South Africa Impact of immunity on respiratory virus transmission in South Africa				
08:45-09:20	**Seema Lakdawala,** Emory University, USA Every breath you take: Transmission of Influenza Viruses				
09:20-09:55	**Aubree Gordon,** University of Michigan, USA Nicaraguan Field Studies to Examine Influenza Transmission and Immunity				
10:00-10:30	**MORNING TEA**				
ROOM:	**MEZZANINE ROOM M3**	**MEZZANINE ROOM M4**	**MEZZANINE ROOM M1 AND M2**	**GREAT HALL 1 AND 2**	
10:30-12:00	**Virology and Pathogenesis** **NIV IG Session:** **Avian influenza at the species interface** *Chairs: Diane Post and Michelle Wille*	**Clinical Sciences and Vaccinology** **Clinical trials** *Chairs: Ben Cowling and Robin Mason*	**Interdisciplinary Session** **Respiratory viruses in underserved populations** *Chairs: Cheryl Cohen and Jane Davies*	10:30-12:00	**Public Health and Policy** **Forecasting, seasonality and surveillance** *Chairs: Matt Biggerstaff and Pejman Rohani*
10:30-10:55	**Erik Karlsson**	**Ben Cowling:** Phase III CENTERSTONE study of single-dose baloxavir marboxil for the reduction of transmission of influenza in households	**Vasiti Uluiviti:** Enhancing laboratory preparedness and response to pandemics and respiratory virus surveillance in the US-affiliated Pacific Islands	10:30-10:43	**Matthew Biggerstaff:** In-season evaluation of influenza forecasts during the 2023-2024 United States influenza season
10:55-11:08	**Agustina Rimondi:** Outbreaks of HPAI H5N1 (2.3.4.4b) on Argentina's Atlantic coast: increased evidence for mammal-to-mammal transmission of a novel H5N1 clade in marine mammals.	**Jianyu Lai:** Evaluating Modes of Influenza Transmission (EMIT-2): An Ongoing Controlled Human Influenza Virus Infection Transmission Trial (CHIVITT)	**Anders Madsen:** Reducing Influenza Infection and Antiboic Use in Young Children after Quadrivalent Influenza Vaccination; Insights from Rural Bangladesh	10:43-10:56	**Rachael Pung:** Integrating passive and sentinel surveillance for robust evaluation of SARS-CoV-2 infections
11:08-11:21	**Michelle Wille:** Emergence and spread of high pathogenicity avian influenza (HPAI) H5 in wildlife of South America and Antarctica	**Pamuk Bilsel:** Co-administration of Intranasal M2SR (M2-deficient Single Replication) Influenza Vaccine with Fluzone High Dose Induces Superior Immune Responses to Fluzone High Dose in Older Adults	**Jorim Ayugi:** Illness outcomes of in-and-out patients co-infected with SARS-CoV-2 and Malaria, 2020-2022	10:56-11:09	**Brendan Case:** Charting the Course for Respiratory Virus Activity in the Southern Hemisphere: Real-Time Forecasting of Severe Acute Respiratory Infections in Paraguay, 2024

11:21-11:34	**Samuel Ago:** Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus Detected in Poultry in Ghana, 2021 to 2022.	**Alexandre Le Vert:** OVX836, A NP-Based Universal Influenza Vaccine Candidate, Triggers Effector CD4+ and Cytotoxic CD8+ T Cells in Healthy Adults	**Faletoese Asafo:** The Social and Economic impacts of Early Childhood Hospitalisation with Respiratory Infection in Pacific families in Aotearoa, New Zealand.	11:09-11:22	**Sheikh Taslim Ali:** Time-varying inference of population immunity and prediction of influenza dynamics in Hong Kong
11:34-11:47	**Carrie Reed:** Human Infection with Highly Pathogenic Avian Influenza A(H5N1) Virus in a Dairy Worker in the United States	**Amanda Rudman Spergel:** Phase 1/2 Safety and Immunogenicity of mRNA-Based Seasonal Influenza and SARS-CoV-2 Multicomponent Vaccine in Healthy Adults	**Felicity Ware:** Kohanga winter preparedness project	11:22-11:35	**David Muscatello:** Improving emergency department surveillance to nowcast severe COVID-19 and influenza infection outcomes for epidemic intelligence
11:47-12:00	**Ghazi Kayali:** Sero-evidence of human infection with H5N1 and H9N2 avian influenza viruses	**Pedro Folegatti:** Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years	**Jinal Bhiman:** Antibody dynamics during prolonged SARS-CoV-2 infection in people living with and without HIV	11:35-11:48	**Pejman Rohani:** Forecasting influenza with ensembles of seasonal models
12:00-12.13				11:48-12:01	**Warda Haque:** Surveillance of Respiratory Virus Dynamics in 2021-2022: Insights from an Influenza Vaccine Clinical Trial in Bangladesh
12:00-13:00	**MEZZANINE ROOM M3** **ECR Career Development Lunch** Susan Allison Maria Auladell Kathy Spindler	**LUNCH AND POSTER VIEWING**			
13:00-14:00	Industry Symposium: **CSL Seqirus** **Strengthening Influenza Protection:** **A symposium on paediatric, pandemic and pioneering solutions** (Great Hall 1 and 2) *Chair: Sarah Londrigan* **Terry Nolan AO, Colin Russell, Kanta Subbarao**				CSL Seqirus

ROOM:	GREAT HALL 1 AND 2	MEZZANINE ROOM M3	MEZZANINE ROOM M4	MEZZANINE ROOM M1 AND M2
14:00-15:30	**Public Health and Policy** **Vaccines 1: Real-world vaccine effectiveness** *Chairs: Annette Regan and Esther Kissling*	**Other Respiratory Viruses** **Respiratory virus surveillance and burden of disease** *Chairs: Yanshan Zhu and Viviana Simon*	**Interdisciplinary Session** **Viral evolution and public health genomics** *Chairs: Qiu Sue Huang and Juliana Leite*	**Virology and Pathogenesis** **Virus-host cell interactions** *Chairs: Anice Lowen and Kohei Oishi*
14:00-14:25	**Annette Regan:** Novel and Emerging Surveillance Systems for Monitoring the Real World Safety and Effectiveness of Vaccines in Pregnancy	**Viviana Simon:** Tracking trouble: Pathogen surveillance in a large metropolitan health care system	**David Wentworth:** Exploiting Viral Genomics to Develop and Improve Vaccines	**Ana Fernández-Sesma:** Modulation of innate immunity by influenza viruses
14:25-14:38	**Melissa Andrew:** Influenza vaccine effectiveness in the prevention of admission to Assisted Living or Long-Term Care Facilities: A report from the Canadian Immunization Research Network SOS Network	**Rhys Wenlock:** High SARS-CoV-2 incidence and asymptomatic fraction during Delta and Omicron BA.1 waves in The Gambia	**John Huddleston:** Effects of delayed sequence submission and vaccine development on long-term forecast accuracy of seasonal influenza A/H3N2	**Anice Lowen**: Dispersing inwards: how within-host dispersal shapes influenza virus diversity
14:38-14:51	**Mary Patricia Nowalk:** Exploring COVID-19 home testing and its impact on COVID-19 vaccine effectiveness estimates	**Lea Separovic:** Shift in the age distribution of pediatric and adult respiratory syncytial virus infections related to the COVID-19 pandemic: 2014/15 to 2023/24 seasons, British Columbia, Canada	**Wenjie Han:** Antigenic evolution patterns of influenza B viruses: insights into the disappearance of B/ Yamagata	**Antoni Wrobel:** Molecular determinants of influenza haemagglutinin binding to a protein receptor
14:51-15:04	**Aleda Leis:** Evaluation of test-negative design estimates of influenza vaccine effectiveness in the context of multiple, co-circulating, vaccine preventable respiratory viruses: a single-center analysis	**Songwei Shan:** Population-based disease burden associated with respiratory syncytial virus in Hong Kong, 1998-2019	**Lu Lu:** Unveiling the Complex Reassortment Patterns of Highly Pathogenic Avian Influenza H5 Virus	**Chengjun Li:** ABTB1 facilitates the replication of influenza A virus by counteracting TRIM4-mediated degradation of viral NP protein
15:04-15:17	**Susana Monge:** Comparison of two methods for the estimation of COVID-19 vaccine effectiveness of the autumnal booster within the VEBIS-EHR network in 2022/23	**Nikki Turner:** Comparison of the burden and temporal pattern of hospitalizations associated with respiratory syncytial virus (RSV) before and after the COVID-19 pandemic in New Zealand	**Yi Mo Deng:** Expanded diversity of influenza viruses following the COVID-19 pandemic-induced bottleneck in Australia	**Kohei Oishi:** Archaeal kink-turn binding protein mediates inhibition of Orthomyxovirus splicing biology
15:17-15:30	**Bette Liu:** Monitoring of COVID-19 vaccine effectiveness against COVID-19 mortality in Australia	**Emily Martin:** Evaluating the impact of viral coinfection on household transmission of respiratory viruses	**Leo Poon:** Genomic Surveillance Effectiveness on Global Dissemination of SARS-CoV-2 Omicron Variants	**Kyle Macauslane:** Influenza A virus infection induces global desialylation of host glycoproteins
15:30-16:00	**AFTERNOON TEA**			
16:00-17:00	Industry Symposium: **Roche** **Stop the flu going viral: the benefits of antivirals for patients, households and communities** (Great Hall 1 and 2) *Chair: Frederick G. Hayden* **Mei Zeng, Ben Cowling, Colin Russell**			

ROOM:	GREAT HALL 1 AND 2		MEZZANINE ROOM M3	MEZZANINE ROOM M4	MEZZANINE ROOM M1 AND M2
17:00-18:30	**Public Health and Policy** **Vaccines 2: from early development to the real world** *Chairs: Hannah Moore and Sheena Sullivan*	17:00-18:30	**Virology and Pathogenesis** **Innate and mucosal immunity to infection** *Chairs: Stephanie Langel and Helena Aagaard Laybourn*	**Interdisciplinary Session** **Imprinting, Aging and viral infection** *Chairs: Robert Booy and Sook San Wong*	**Other Respiratory Viruses** **RSV prevention and treatment** *Chairs: Kirsten Spann and Jeffrey Nielsen*
17:00-17:13	**Cheng Chang:** Pre-clinical comparison of sa-mRNA vs mRNA flu vaccines	17:00-17:25	**Peter Openshaw:** Acute and delayed effects of acute respiratory viral infections	**Carolien Van de Sandt:** Influenza virus-specific CD8+ T cells across the human lifespan: a paradoxical blend of stability and dynamic changes	**Ann Falsey:** RSV Vaccination in Older Adults: The Time Has Come
17:13-17:26	**Kelly Lindert:** Efficacy and Immunogenicity Results of Messenger RNA Influenza Vaccine in Adults 18-64	17:25-1738	**Brendon Y Chua:** High expression of oleoyl-ACP-hydrolase underpins severe and life-threatening respiratory viral diseases	**Marios Koutsakos:** Conservation of major antigenic sites within each antigenic lineage underpins immunological imprinting to the influenza B virus haemagglutinin	**Jeffery Neilsen:** Novel Ligand-Targeted Immunotherapy for the treatment of Human Respiratory Syncytial Virus
17:26-17:39	**Hyeeun Lee:** Safety profile and breakthrough infections among quadrivalent influenza vaccine(SKYCellflu) for influenza infection in South Korea during 2023-2024	17:38-17:51	**Philip Mudd:** Clonally Expanded Tissue-Resident CD8+ T Cells Recognize Conserved Influenza Viral Proteins in the Lower Airways During Acute Human Infection	**Shuyi Zhong:** Repeated vaccination effects on immunogenicity of influenza vaccine among older adults in Hong Kong	**Lea Separovic:** Respiratory syncytial virus vaccination among older adults in Canada: number needed to vaccinate and associated costs to prevent severe outcomes
17:39-17:52	**Danuta Skowronski:** XBB.1.5 vaccine effectiveness against medically-attended COVID-19, including JN.1-specific cross-protection: estimates from the community-based Canadian Sentinel Practitioner Surveillance Network	17:51-18:04	**Sarah Londrigan:** Identification of novel host proteins that are associated with macrophage control of influenza A virus replication	**David Bauer:** First antigenic exposures to SARS-CoV-2 Spike do not indelibly shape SARS-CoV-2 immunity	**Evangeline Obodai:** Proof-of-principle of a technology transfer of an RSV neutralization assay to a GAVI eligible country
17:52-18:05	**Hannah C Moore:** Integrating community attitudes with population-based epidemiological data for RSV immunisation policy: the STAMP program	18:04-18:17	**Benjamin Lindsey:** Mucosal and blood transcriptome differentiates diverse immune trajectories following vaccination with live attenuated influenza vaccine in children	**Esther Kissling:** Vaccine effectiveness against influenza A(H1N1) pdm09 and A(H3N2) and birth cohort effect: Results from the 2023–24 season European VEBIS primary care multicentre study	**Antoine Brault:** Estimates of effectiveness and impact of nirsevimab on hospitalisations for RSV bronchiolitis in France, 2023-2024 : a modelling study

18:05-18:30	**Panel discussion**	18:17-18:30	**Jiapei Yu:** Time-resolved scRNA-seq reveals transcription dynamics of polarized macrophages with influenza A virus infection and antigen presentation to T cells	**Isaac Cheuk Long Chow:** Impact of Influenza A(H3N2) virus infection on the antibody landscapes of hemagglutinin and neuraminidase protein in older adults.	**Christopher Blyth:** Evaluating the Nirsevimab RSV prevention program in Western Australia - early insights into program impact
18:30-20:30	Poster Session 2				

Day 3 - Tuesday 1 October 2024

07:00-12:00	*Registrations and Poster Set Up*
ROOM:	**GREAT HALL 1 AND 2**
08:00-10:00	**Immunology and Vaccine Development**
08:00-08:10	**Opening - Conference Business and Session welcome** Chairs: Katherine Kedzierska and Chris Chiu
08:10-08:45	**Stephanie Langel,** Case Western Reserve University, USA Influenza and the Mammary Gland: Vaccine Strategies That Boost Breast Milk Anti-Influenza Immunity
08:45-09:20	**Stephanie Gras,** La Trobe University, Australia The good, the bad and the ugly: the role of HLA in COVID-19
09:20-09:55	**Ali Ellebedy,** Washington University School of Medicine, St Louis, USA B cell responses to mRNA vaccination: Lesson from the pandemic
10:00 -10:30	**MORNING TEA**
10:30-11:30	Industry Symposium: **Moderna** **Addressing Influenza Disease Burden:** **Current Challenges and Emerging Vaccine Strategies Against a Persistent Threat** (Great Hall 1 and 2) *Chair: Michael Nissen* **Raina MacIntyre, Colin Russell, Terry Nolan AO**

ROOM:	GREAT HALL 1 AND 2	MEZZANINE ROOM M4		MEZZANINE ROOM M3	MEZZANINE ROOM M1 AND M2
11:30-13:00	**Public Health and Policy** **Vaccines 3: immunogenicity, efficacy and effectiveness** *Chairs: Sascha Ellington and Stephany Sanchez-Ovando*	**Other Respiratory Viruses** **SARS-CoV-2 and other virus transmission and evolution** *Chairs: Larisa Labzin and Benjamin Meyer*	11:30-13:00	**Interdisciplinary Session** **Correlates of protection and immune responses to vaccination** *Chairs: Ann Falsey and Nancy Leung*	**Clinical Sciences and Vaccinology** **AVG IG Session** *Chairs: Kimberly Armstrong and Michael Ison*
11:30-11:43	**Sascha Ellington:** Influence of Birth Cohort on 2023-2024 Influenza Vaccine Effectiveness Against A(H1N1)pdm09-Associated Illness in the United States	**Carlos Grijalva:** Role of immunity in the transmission of SARS-CoV-2 infections in households: evidence from case-ascertained studies	11:30-11:55	**Chris Chiu:** Immune correlates of symptomatic and asymptomatic disease following controlled human influenza virus infection	**Cameron Wolfe:** COVID therapeutics 2024: As the tsunami recedes, where are we?
11:43-11:56	**Ausenda Machado:** COVID-19 vaccine effectiveness in the paediatric population aged 5–17 years: a multicentre cohort study using electronic health records in six European countries	**Ooiean Teng:** Biomarkers of early SARS-CoV-2 infection prior to the onset of respiratory symptom	11:55-12:07	**Brendan Flannery:** Application of test-negative design for serologic correlates of protection against laboratory-confirmed influenza and COVID-19	**Ultan Power:** Identification and Validation of Azatadine-Dimaleate as a Potent Antiviral against SARS-CoV-2: Potential for Clinical Development Alone or in Combination with Remdesivir

11:56-12:09	**Stephany Sanchez-Ovando:** Influenza vaccine A(H1N1)pdm09 strain change effects on immunogenicity among repeatedly vaccinate healthcare workers	**Simon Cauchemez:** A new modelling framework to decipher the contribution of RNA viral loads dynamics on household transmission of SARS-CoV-2	12:07-12:20	**Yang Wang:** Population susceptibility prior to Omicron emergence, and antibody correlates of protection against first and second omicron waves: findings from the HIVE study	**Yuko Tsuge:** Analysis of the ensitrelvir treatment-emergent amino acid substitutions observed in the SCORPIO-SR phase 3 trial
12:09-12:22	**Angie Rose:** Vaccine effectiveness against influenza A in older adults and the impact of chronic conditions: Results from the I-MOVE and VEBIS European hospital networks, 2015/16–2023/24	**Benjamin Meyer:** Mucosal Immunity: the key to reduce SARS-CoV-2 transmission?	12:20-12:33	**Tim Russell:** Real-time estimation of immunological responses against emerging SARS-CoV-2 variants	**Nadine Sicard:** Implementation evaluation of the nirmatrelvir/ritonavir (Paxlovid TM) rollout in Canada during the COVID-19 response: lessons learned for pandemic preparedness
12:22-12:35	**Ben Cowling:** Repeated influenza vaccination effects in a randomized placebo-controlled trial (the DRIVE study)	**Sadegh Niazi:** Unveiling Airborne Risks: Assessing Respiratory Virus Transmission Through Cough Particles	12:33-12:46	**Sophie Valkenburg:** Adjuvant advantage in a longitudinal randomized control trial of alternating enhanced influenza vaccines in older adults	**Ryuta Uraki:** Drug Susceptibility and the Potential for Drug-Resistant SARS-CoV-2 Emergence in Immunocompromised Animals
12:35-12:48	**Emily Rayens:** Comparative effectiveness of cell-based vs. egg-based influenza vaccines in prevention of influenza hospitalization during the 2022-2023 season among adults 18-64 years	**Harm van Bakel:** The role of persistent infections in SARS-CoV-2 evolution	12:46-12:59	**Boitumelo Motsoeneng:** Hemagglutinin stalk-specific Fc-mediated functions are associated with protection against influenza-illness after seasonal influenza vaccination in pregnant women	**Mirella Salvatore:** Emergence of antiviral resistance in the immunocompromised host with SARS-CoV2 infection
12:48-13:01	**Alicia Stein:** Relative vaccine effectiveness of cell-based versus egg-based quadrivalent influenza vaccines against test-confirmed influenza in the United States 2022-23 influenza season	**Amaya Rojo Fernandez:** CIDS: A household cohort study of COVID-19			
13:00-14:00	**LUNCH**				
14:00-15:00	Industry Symposium: **Sanofi** **OLD disease, NEW ways to better assess vaccine performance** (Great Hall 1 and 2) *Chair: LJ Tan* **Bruno Lina, Raina McIntyre, Tor Biering-Sorensen**				

ROOM:	GREAT HALL 1 AND 2	MEZZANINE ROOM M3	MEZZANINE ROOM M4	MEZZANINE ROOM M1 AND M2
15:00-16:30	**Public Health and Policy** **Sero-epidemiology** *Chairs: Aubree Gordon and Bingyi Yang*	**Virology and Pathogenesis** **Adaptive immune response to infection** *Chairs: Annette Fox and Thi Hoang Oanh Nguyen*	**Other Respiratory Viruses** **Pathogenesis** *Chairs: Julie McAuley and Anika Singanayagam*	**Clinical Sciences and Vaccinology** **Antivirals and therapeutics** *Chairs: Elena Govorkova and Jude Jayamaha*
15:00-15:25	**Sheena Sullivan:** Methodological considerations in sero-epidemiology studies	**Paul Thomas:** Defining specific cellular correlates of protection against influenza	**Stanley Perlman:** Long term sequelae in SARS-CoV-2-infected mice and humans	**Emi Takashita:** Antiviral susceptibilities of influenza virus and SARS-CoV-2
15:25-15:38	**Zhunan Li:** Serologic evidence of co-circulation of three respiratory viruses from a longitudinal population immunity study in the United States	**Ian Wilson:** Diverse binding modes of VH1-69 encoded antibodies to the influenza virus HA stem	**Louise Rowntree**: Long COVID patients establish and maintain SARS-CoV-2-specific CD8+ T cells with effector phenotype	**James Antoon:** Oseltamivir Use and Risk of Serious Neuropsychiatric Events in Children and Adolescents
15:38-15:51	**Serena Marchi:** Prevalence of influenza B/ Yamagata viruses from season 2012/2013 to 2021/2022 in Italy as an indication of a potential lineage extinction	**Caroline Page**: Differential immune responses elicited from contemporary influenza B infection allow for asymmetric cross-protection between the lineages	**Anika Singanayagam:** Development and early results from a SARS-CoV-2 Delta variant human infection challenge model	**Fahmida Chowdhury**: Antimicrobial Use Patterns among Patients with Influenza-associated Severe Acute Respiratory Infections at Tertiary-care Hospitals in Bangladesh (2010–2023)
15:51-16:04	**Nokuthula Linda**: Influenza sero-protection during the COVID-19 pandemic: HUTS Community Cohort Study, South Africa, 2021	**Thi Hoang Oanh Nguyen:** Recovery from severe and fatal influenza virus infection relies on effective adaptive immunity: post-COVID-19 pandemic experience	**Helen Mostafavi**: Mechanisms driving endothelial dysfunction in acute COVID-19	**Taylor Sandison:** Safety Data from Phase 1 and Phase 2a Studies of CD388, a Drug Fc-conjugate for Seasonal Pan-Influenza Prophylaxis
16:04-16:17	**Weijia Xiong:** Using antibody titers as a measure of influenza population immunity: insights from a longitudinal serology study in Hong Kong, 2009-2014	**Kristin G-I Mohn:** Immune kinetics in hospitalized patients following moderate and severe influenza infection.	**Jane Sinclair:** Cardiovascular symptoms of PASC are associated with trace-level circulatory cytokines that affect the function of primary human cardiomyocytes	**Jeremy C. Jones**: Baloxavir antiviral intervention protects ferrets from severe influenza A(H5N1) clade 2.3.4.4b viral disease and neuroinvasion
16:17-16:30	**Raquel Guiomar:** Higher susceptibility in younger adults born from 1970 to 1976 for influenza A(H1N1) infection: results from a repeated seroprevalence survey 2016 to 2023	**Wuji Zhang**: Interferon pathways are enhanced in influenza-specific B cells following influenza virus infection compared to vaccination	**Julie McAuley:** Identifying the neurological impact of COVID-19 in a mouse of model of SARS-CoV-2 infection	**Larisa Gubareva:** Monitoring susceptibility of influenza viruses to baloxavir: update on testing algorithm and findings
16:30-17:00	**AFTERNOON TEA** ***ALL POSTERS IN EXHIBITION HALL 1 TO BE REMOVED**			

ROOM:	GREAT HALL 1 AND 2	MEZZANINE ROOM M3	MEZZANINE ROOM M4	MEZZANINE ROOM M1 AND M2
17:00-18:30	**Public Health and Policy** **Epidemiology, transmission, and control** *Chairs: Emily Ricotta and Marc-Alain Widdowson*	**Interdisciplinary Session** **Epidemic and pandemic preparedness** *Chairs: Florian Krammer and Christine Oshansky*	**Other Respiratory Viruses** **SARS-CoV-2 novel treatments and prevention strategies** *Chairs: Kanta Subbarao and Rubina Bunjun*	**Clinical Sciences and Vaccinology** **Diagnostics, biomarkers and applications** *Chairs: Ryan Thwaites and Maria Zambon*
17:00-17:25	**Emily Ricotta:** Why improving observational studies is critical for ensuring high-quality infectious disease policy	**Jodie McVernon:** Modelling to support equitable benefits from vaccines and countermeasures against 'Disease X'	**Kanta Subbarao:** A comparison of antibody responses following homologous and heterologous COVID-19 vaccines and breakthrough infections in previously naïve and convalescent individuals	**Ryan Thwaites:** Early mucosal responses to respiratory viruses in natural infections and human challenge studies
17:25-17:38	**Sue Huang**: Impact of COVID-19 and influenza on SHIVERS longitudinal community and household cohorts in New Zealand	**Marciela Degrace:** Protection from Pandemic Influenza on Day 1: BARDA's Vision for Influenza Vaccine Development	**Stephan Ludwig:** Clinical Proof of Concept for a Novel Host-Targeted Anti-Infective Strategy Against COVID-19 and Other Acute Respiratory Viral Diseases	**Jeremy Chase Crawford:** OLAH and its main catalytic products act as early biomarkers of life-threatening illness from diverse viral respiratory infections
17:38-17:51	**Sarah Cox:** Years: Influenza Incidence among Children and Adults 6 Months to 49 Years: The Cascadia Prospective Cohort Study, United States, 2022-2023	**Magdi Samaan**: Pandemic Risk Assessment of Avian Influenza A(H5N1) Clade 2.3.4.4b Viruses Using the WHO TIPRA	**Teresa Aydillo:** Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines	**Benjamin Larsen:** Using occluded Cas13 to detect influenza mutations at the point of care
17:51-18:04	**Nancy Hiu Lan Leung:** Multiple introductions and co-transmission of respiratory viruses in same households (TReV study)	**Honglei Sun:** Potential epidemic or even pandemic of H3Ny avian influenza A virus: public health concern and preparedness	**Rubina Bunjun:** Cross-reactive antibody responses to SARS-CoV-2 in South Africa	**Luca Ferretti:** Digital contact tracing: insights from a new tool to reduce and understand the transmission of respiratory pathogens
18:04-18:17	**Jonathan Temte:** Factors associated with transmission across three waves of SARS-COV-2 in a prospective community-based study of households with school-aged children – Dane County, Wisconsin, 2020-2022	**Wan Ting Teo:** A conceptual approach for pandemic preparedness planning against Disease X	**Sam Afkhami:** A next-generation inhaled aerosol COVID-19 vaccine fills the gap in respiratory mucosal immunity in humans	**Jurre Siegers:** Evolutionary Dynamics and Zoonotic Potential of H6, H10, and H11 Avian Influenza Viruses: A Comprehensive Study from Cambodia, 2019-2022
18:17-18:30	**Cayla Reddy:** Influenza antibody titres before and during the COVID-19 pandemic: A community cohort study in South Africa (PHIRST, PHIRST-C)	**Alvin X. Han:** A novel mathematical framework to inform global antiviral stockpile size and distribution for influenza pandemic mitigation	**David Hodgson:** Memory B cell proliferation drives differences in neutralising responses between ChAdOx1 and BNT162b2 vaccines	**Georgina Mccallum**: The Host Response as a Novel Diagnostic Biomarker for 'Pre-positive' viral infection
	60 minute gap between Congress and Social			
19:30-23:00	**OPTIONS XII Congress Party @ Eat Street Northshore**			

Day 4 - Wednesday 2 October 2024

07:00-08:00	Registrations				
	GREAT HALL 1 AND 2				
08:00-10:00	**Zoonotic Infection / Emerging Viruses**				
08:00-08:10	**Opening - Congress Business and Session welcome** Chairs: Stacey Schultz-Cherry and Michelle Wille				
08:10-08:45	**Malik Peiris,** University of Hong Kong, Hong Kong MERS coronavirus remains a pandemic threat?				
08:45-09:20	**Marianna Leguia,** Pontificia Universidad Catolica del Peru, Peru Highly Pathogenic Avian Influenza A (H5N1) in Marine Mammals and Seabirds in Peru				
09:20-09:55	**Andrew Bowman,** The Ohio State University, USA Bovine influenza: Holy cow!				
10:00-10:30	**MORNING TEA**				
10:30-11:30	**This Week In Virology** (Great Hall 1 and 2)				
ROOM:	**GREAT HALL 1 AND 2**	**MEZZANINE ROOM M3**	**MEZZANINE ROOM M4**	**MEZZANINE ROOM M1 AND M2**	
11:30-13:00	**Public Health and Policy** **Burden of disease** *Chairs: Danielle Iuliano and Jessica Y. Wong*	**Virology and Pathogenesis** **Pathogenesis and transmission** *Chairs: Ian Wilson and Philipp Peter Petric*	**Other Respiratory Viruses** **SARS-CoV-2 vaccines** *Chairs: Carissa Aurelia and Stanley Perlman*	11:30-13:00	**Interdisciplinary Session** **Late Breaking Abstracts on H5N1 in new species** *Chairs: Andrew Bowman and Agustina Rimondi*
11:30-11:55	**Danielle Iuliano:** Modernizing influenza burden estimation and the necessity of rethinking assumptions	**Stacey Schultz-Cherry:** Influenza in indigenous communities	**Michael Chan:** Experimental platform of human respiratory tract for risk assessment of emerging respiratory virus infection	11:30-11:43	**Amy Baker:** Experimental reproduction of viral replication and disease in dairy calves and lactating cows inoculated with highly pathogenic avian influenza H5N1 clade 2.3.4.4b
11:55-12:08	**Jessie Goldsmith:** Using data from the COVID period to improve our understanding of the burden of influenza mortality	**Charlotte Kristensen:** Mind-Boggling: Influenza A Virus Presence in the Brain of Inoculated Pigs and Ferrets	**Deborah Cromer:** Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates	11:43-11:56	**Jenna Guthmiller:** A single mutation in dairy cow-associated H5N1 viruses increases receptor binding breadth
12:08-12:21	**Anand Krishnan**: Influenza among older adults in India: Disease burden and cost-effectiveness of introduction of a vaccination program	**Lisa Kercher:** The use of telemetry and whole-body plethysmography for acquiring real-time physiological data for improved host response analysis during an influenza virus infection in ferrets.	**Vivek Shinde:** Safety and Immunogenicity of an investigational influenza protein vaccine and COVID and influenza combination protein vaccine	11:56-12:09	**Douglas Reed:** Inhalation of aerosolized A/Chile/25945/2023 (clade 2.3.4.4b H5N1) virus triggers fever, severe respiratory disease, and a lethal outcome in cynomolgus macaques

12:21-12:34	**Janine Paynter:** Population-based SARI-influenza in 2022 vs pre-pandemic baseline in Auckland, New Zealand	**Mark Zanin:** S213P in the non-structural protein 1 of subtype H1N1 avian influenza A viruses mediates airborne transmissibility in the ferret model.	**Yang Wang:** A 10-valent composite mRNA vaccine against both influenza and COVID-19	12:09-12:22	**Patrick Reading:** Bovine Myxovirus resistance protein 1 mediates antiviral activity against against human and avian influenza A viruses
12:34-12:47	**Jessica Y. Wong:** Influenza-associated excess mortality associated with influenza B in Hong Kong, 2014-2019	**Stacey Bartlett:** The role of nasal inflammation in the transmission of influenza A virus in an infant mouse model	**Kevin Selva:** Boosting four-mula: Characterizing elevated IgG4 following repeated COVID-19 mRNA boosters.	12:22-12:35	**Justin Shepard:** Bovine A(H5N1) Influenza Virus Receptor Binding Specificity
12:47-13:00	**Nicole Wolter:** Attributable fraction of influenza and respiratory syncytial virus in infants aged <1 year hospitalized with respiratory and non-respiratory illness in South Africa, 2016-2018	**Michelle Vu:** Impact of multiple donors on transmission efficiencies in the ferret playpen model	**Carissa Aurelia:** Functional consequence of increased IgG4 levels upon repeated SARS-CoV-2 mRNA vaccination.	12:35-12:48	**Jonathan Heeney:** A Computationally Designed pan-H5Nx Vaccine Induces Broad Subtype Neutralising Antibody Responses Compared to Whole Inactivated H5 Vaccines
				12:48-13:00	**Charlotte Kristensen:** In Situ Expression of Influenza A Virus Receptors in the Bovine Mammary Gland Elucidated by Lectin Histochemistry

13:00-14:00 **LUNCH**

ROOM:	GREAT HALL 1 AND 2	MEZZANINE ROOM M3	MEZZANINE ROOM M4	MEZZANINE ROOM M1 AND M2
14:00-15:30	**Public Health and Policy** **Surveillance** *Chairs: Erik Karlsson and Wilhelmina Strasheim*	**Virology and Pathogenesis** **Zoonotic respiratory viruses: mechanisms of zoonoses** *Chairs: Juan Pu and Malik Peiris*	**Interdisciplinary Session** **Past pandemics and future solutions** *Chairs: Georgia McCallum and Patrick Reading*	**Clinical Sciences and Vaccinology** **Novel vaccines and platforms** *Sponsored by* **Vaxxas** vaxxas *Chairs: Arne Matthys and Shane Crotty*
14:00-14:25	**Nicole Wolter:** Adapting sentinel surveillance to address priority diseases in South Africa:	**Massimo Palmarini:** Human genetic barriers to spillover of avian influenza viruses	**Svenn-Erik Mamelund:** Old data gives new clues to the "mother" of all pandemics	**Paul Young:** The Molecular Clamp Platform: A broadly applicable solution to the manufacture of subunit vaccines for respiratory viruses

14:25-14:38	**Félix Alberto Gundane Albati:** Establishment of epidemic parameters and thresholds for assessing the severity of Pandemic Influenza in Mozambique between 2015 and 2024.	**Nico Joel Halwe:** The bat-derived H9N2 Influenza A virus displays pre-pandemic traits despite a limited host range	**Mark-Alain Widdowson:** WHO's Unity Studies: a standardised preparedness framework critical for the investigation and study of novel or re-emerging respiratory pathogens for an effective and proportionate response	**Irina Isakova-Sivak:** Development of a modified trivalent live attenuated influenza vaccine for combined protection against seasonal influenza and COVID-19
14:38-14:51	**Wenqing Zhang**: Epidemic patterns of respiratory syncytial virus in select countries participating in the WHO pilot surveillance project, 2017–23	**Juan Pu:** An emerging PB2-627 polymorphism increases the pandemic potential of avian influenza virus by breaking through ANP32 host restriction in mammalian and avian hosts	**Lauren Steele:** Unlocking Spatially resolved Transcriptomic and Proteomic Secrets of Century-Old Lungs from the 1918 'Spanish' Influenza Pandemic	**Tomer Hertz:** The M2SR intranasal H3N2 single-replication live influenza vaccine induces more potent and broad mucosal sIgA response in older adults than the high-dose inactivated FluzoneHD vaccine
14:51-15:04	**Eva Kozanli:** Co-infection and co-circulation dynamics of SARS-CoV-2 in the Dutch respiratory season of 2022/2023	**Stephanie Williams:** Avian influenza A virus polymerase gene leads to temperature-resistant viral RNA genome replication	**Matthew Miller:** Next Generation Approaches for Broadly Protective Mucosal Vaccines	**Angus Forster**: Lower doses of quadrivalent seasonal influenza vaccine generate significantly improved antibody titres delivered with a simple to apply skin patch (phase 1 study)
15:04-15:17	**Camille Esneau:** The PREVENT Study – An Assessment of Virus Circulation in the Hunter New England Community	**Mark Anthony Casel:** Amino acid changes in HA in HPAI H5N1 viruses alter receptor binding affinity and enhance virulence in mammalian hosts	**David Muller**: Understanding the enhanced immune responses to High-Density Microarray Patch vaccination through spatial transcriptomics and antibody repertoire analysis	**Sean Ray:** A minimalist, self-adjuvanting vaccine achieves robust immune response to conserved influenza peptide M2e
15:17-15:30	**Ariful Islam:** Integration of SARS-CoV-2 testing into influenza sentinel surveillance for pandemic preparedness: Findings from Hospital-based Influenza Surveillance in Bangladesh, 2020-2023	**Francesco Bonfante:** Genetically diverse European H3Nx avian influenza viruses rapidly select pre-pandemic adaptive mutations at the level of the hemagglutinin gene upon one passage in ferrets	**Yiyang Guo:** Optimizing Situational Awareness During the COVID-19 Pandemic: A Syndromic Surveillance Approach for Early Detection of Symptom Combinations	**Juan Manuel Carreño Quiroz:** Development of a multivalent nucleoside-modified mRNA vaccine that broadly protects against influenza A and B viruses
15:30-16:00	**AFTERNOON TEA** ***ALL POSTERS IN GREAT HALL TO BE REMOVED**			
ROOM:	**GREAT HALL 1 AND 2**			
16:00-17:30	**Closing Ceremony** Chairs: Kirsty Short and Mark Tompkins			
16:00-16:35	**Maria van Kerkhove,** World Health Organization, Switzerland			
16:35-17:10	**Steven Riley,** Imperial College, United Kingdom Public health dynamics for respiratory viruses: pandemic times and afterwards			
17:10-17:20	**Awards**			
17:20-17:30	Closing remarks and thanks			

Roche-Sponsored Symposium at
OPTIONS XII for the Control of Influenza

Pass the salt,
not the flu

Stop the flu going viral: the benefits of antivirals for patients, households and communities

Monday 30 September 2024 | 16:00–17:00 AEST
Great Hall 1 & 2, Brisbane Convention & Exhibition Centre, Brisbane, Australia

Speakers

Frederick G. Hayden (Chair)
University of Virginia School of Medicine, USA

Mei Zeng
Children's Hospital of Fudan University, China

Ben Cowling
University of Hong Kong, Hong Kong SAR

Colin Russell
University of Amsterdam, The Netherlands

Chair's welcome

Dear colleagues,

It is with great pleasure that I invite you to this Roche-sponsored symposium: *Stop the flu going viral: the benefits of antivirals for patients, households and communities.*

Influenza continues to represent a major global health concern.[1] Each year, seasonal influenza causes 3–5 million cases of severe illness and up to 650,000 deaths,[1] and the threat of a future influenza pandemic remains ever present.[2] Therefore, it is crucial that we continue to advance our understanding of how both seasonal and pandemic influenza viruses spread from person to person, so that we can effectively utilise prevention and treatment strategies to minimise transmission.

In our symposium, we will start by reviewing the recent clinical experience with influenza antivirals in China. We will then explore the impact of antivirals on influenza transmission within a household, and the potential population-level benefits of reducing seasonal and pandemic influenza transmission. Finally, we will host a panel discussion, where you will be given the opportunity to contribute to the debate alongside our distinguished faculty members Professors Mei Zeng, Ben Cowling and Colin Russell.

On behalf of the faculty, I look forward to welcoming you to our symposium!

Best regards,

Frederick G. Hayden, M.D.
University of Virginia School of Medicine, Charlottesville, Virginia, USA

Programme

Welcome and introduction	**Frederick G. Hayden (Chair)** USA
Patients: clinical management of influenza in children and adolescents in China	**Mei Zeng** China
Households: protect people by reducing transmission	**Ben Cowling** Hong Kong SAR
Communities: impact of reduced transmission on epidemics and pandemics	**Colin Russell** The Netherlands
Panel discussion and close	**All**

1. World Health Organization 2023. Influenza (Seasonal). Available at: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal). Accessed September 2024.
2. World Health Organization 2023. Influenza (Avian and other zoonotic). Available at: https://www.who.int/news-room/fact-sheets/detail/influenza-%28avian-and-other-zoonotic%29. Accessed September 2024.

Roche Products Pty Limited, ABN 70 000 132 865, Level 8, 30–34 Hickson Road, Sydney, NSW 2000.
Medical Information: www.medinfo.roche.com/australia or 1800 233 950.
M-AU-00003715 | September 2024

Plenary and Keynote Speakers

Plenary Speakers

Andrew Bowman
The Ohio State University, USA

Dr. Bowman is an associate professor in the Department of Veterinary Preventive Medicine at The Ohio State University. He is an expert in viral infectious diseases, veterinary public health, and epidemiology. He leads applied field research projects investigating the epidemiology of influenza and SARS-CoV-2 in animal populations, with a focus on transmission across the animal-human interface. Before his return to academia, Dr. Bowman was a practicing veterinarian focused on food animal production.

Cheryl Cohen
Wits University, South Africa

Cheryl Cohen is Professor in epidemiology at the University of the Witwatersrand and heads the Centre for Respiratory Disease and Meningitis at the National Institute for Communicable Diseases in South Africa. She leads a team responsible for national surveillance and generation of evidence to guide policy for control of respiratory diseases and meningitis for South Africa. Her research focuses on key pathogens such as influenza, respiratory syncytial virus (RSV), SARS-CoV-2 and pneumococcus, among others. Key research areas include burden of disease, transmission, risk groups for severe illness and assessment of the impact and effectiveness of interventions, such as vaccination. She is a member of several national and international advisory committees and working groups mainly related to influenza, SARS-CoV-2 and other respiratory diseases.

Jane Davies
Menzies School of Health Research Royal Darwin Hospital, Australia

A/Prof Jane Davies is a Principal Research Fellow at the Menzies School of Health Research and Co-Director of Infectious Diseases at Royal Darwin Hospital. Her research focuses on understanding and optimising care for viral infections with a focus on First Nations peoples in the Northern Territory of Australia. She leads work around Hepatitis B & C, influenza and COVID-19 as well as working clinically as an Infectious Diseases and General Medicine Physician at the Royal Darwin Hospital.



Teresa De Santis
Northern Territory Government, Australia

Teresa is a proud Tiwi woman, working and living on Larrakia Country in the Northern Territory, she works as an Aboriginal Health Practitioner Coordinator (AHP) in Population and Primary health care for NT Health. Motivated to commence training by wanting to work to achieve better health outcomes for her mob, over the last 20 years she has worked as an AHP both in Darwin and remotely, completed an Advanced Diploma of Aboriginal and/or Torres Strait islander Primary Health Care and a Diploma of Leadership and Management. Teresa has been an integral part of the NT Hepatitis B research program for 5 years, she has been pivotal in the co-design, development and implementation of the Accredited First Nations Workers hepatitis B course and is an ongoing course presenter and facilitator. She is an author on multiple peer reviewed papers and an invited member of the Commonwealth commissioned team establishing a roadmap to liver cancer control for Australia. In both settings Teresa has been invited as a cultural and HBV content expert, she is also a long-term member of the Menzies Infectious Diseases Indigenous Reference Group. During the COVID-19 pandemic Teresa pivoted her cultural, clinical and research knowledge to become a member of the COVID-19 Resource Action and Information Group and Co-chair the NT COVID-19 Aboriginal Workforce Group. COVID-training packages were co-designed using the frameworks developed during the HBV program to ensure cultural safety. Teresa continues to generously contribute her cultural knowledge to ensuring that messages are communicated in a culturally safe way.

Plenary Speakers

Peter Doherty
Laureate Professor Emeritus
The University of Melbourne, Australia

Trained initially as a veterinarian, Peter Doherty is Australian immunologist and pathologist who, with Rolf Zinkernagel of Switzerland, received the Nobel Prize for Physiology or Medicine in 1996 for their discovery of how the body's immune system distinguishes virus-infected cells from normal cells. After leading a research laboratory at the Wistar Institute, Philadelphia, and teaching at the University of Pennsylvania (1975-82), Peter headed the department of experimental pathology at the John Curtin School of Medical Research in Canberra (1982-88) and served as chairman (1988-2001) of the department of immunology at St. Jude Children's Research Hospital in Memphis, Tennessee, where he still holds the Michael F Tamer Chair of Biomedical Research. In 2002, he joined the faculty of medicine at the University of Melbourne, and from 2014, has been at the Peter Doherty Institute (PDI) for Infection and Immunity, a joint venture between the university and the Royal Melbourne Hospital. The Nobel award led to an increasing involvement in public science communication, both in his own area of viral pathogenesis and immunity and in topics related to environmental sustainability and climate change. He is active on social media and was a prominent commentator through the first two years of COVID-19 https://www.doherty.edu.au/news-events/setting-it-straight .

After working on infection and immunity at one level or other for 60 years, he moved to emeritus status at the University of Melbourne in July 2023, though he continues to be the Patron of the PDI. Peter is the author of many books, including The Beginner's Guide to Winning the Nobel Prize: A Life in Science (2005), Sentinel Chickens: What Birds Tell Us About Our Health and the World (2012), Pandemics: what everyone needs to know (2013) The Knowledge Wars (2015), The Incidental Tourist (2018), An Insider's Plague Year (2021) and most recently Empire, War, Tennis and Me (2022).

Ali Ellebedy
Washington University School of Medicine, USA

Ali Ellebedy is a viral immunologist with 18 years of experience studying B cell responses to viral infections and vaccination. He was born in Egypt and graduated with a B.S. in pharmaceutical sciences from Cairo University in 2004. In 2006, he moved to the US, where he studied innate and adaptive immune responses to influenza viruses at St Jude Children's Research Hospital in Memphis, TN, for his Ph.D. He then moved to Emory University in Atlanta, GA, where he was a postdoctoral fellow in Rafi Ahmed's laboratory, studying human B cell responses to viruses. In 2017, Ali joined the Department of Pathology and Immunology at Washington University School of Medicine in St. Louis as an assistant professor. His team studies the factors dictating the breadth and durability of antibody responses to viral infections and vaccinations in humans. They discovered a new class of broadly protective human anti-influenza virus antibodies. In response to the SARS-CoV-2 pandemic, his team published seminal studies defining the breadth and persistence of humoral immune responses to SARS-CoV-2 infection and vaccination in humans. He is currently the Leo Loeb Professor and Co-Director of the Center for Vaccines and Immunity to Microbial Pathogens at Washington University School of Medicine.

Plenary Speakers

Jeremy Farrar

World Health Organization, Switzerland

As Chief Scientist, Jeremy Farrar will oversee the work of the Science Division, bringing together experts and networks working in science and innovation from around the world to guide, develop and deliver high quality health policies and services to the people who need them most. Prior to joining WHO, Dr Farrar was Director of the Wellcome Trust. In his 9 years there, he oversaw a series of major reforms, restructuring and growth, with Wellcome now collaborating with partners around the world and focused on fundamental discovery research and three challenge areas of: infectious diseases; climate and health; and mental health, all with a commitment to ensuring that equity, diversity and inclusion are central to the science they support. Before joining Wellcome, Dr Farrar spent over 17 years as Director of the Clinical Research Unit at the Hospital for Tropical Diseases in Ho Chi Minh City in Viet Nam. His clinical and research interests have been in integrated health research across a range of infectious diseases and noncommunicable illness including emerging infections, influenza, infections of the brain, dengue, typhoid, malaria, tuberculosis, antimicrobial resistance, opportunistic infections related to HIV and stroke. Dr Farrar was the founding chair of WHO's R&D Blueprint and the founding director of the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) that led on to the work of the RECOVERY Trial and the UK COVID-19 Genomics UK Consortium. Dr Farrar trained in neurology and infectious diseases in London, Edinburgh and Oxford in the United Kingdom and in Melbourne in Australia. He has a PhD in Immunology from the University of Oxford in the United Kingdom in partnership with the University of California in San Francisco in the United States of America.

Bronwyn Fredericks

The University of Queensland, Australia

Professor Bronwyn Fredericks has over 30 years of experience working in and with the tertiary sector, State and Federal Governments, and Aboriginal and Torres Strait Islander community-based organisations. Bronwyn was appointed as the Pro Vice-Chancellor (Indigenous Engagement) at The University of Queensland in 2018 and Deputy Vice-Chancellor (Indigenous Engagement) in 2023. As Deputy Vice-Chancellor (Indigenous Engagement), Professor Fredericks is responsible for leading the implementation of the Indigenous strategy and strengthening leadership within the University in relation to Indigenous Engagement, as well as building links with the community. In 2022, Professor Fredericks was awarded the Inaugural National NAIDOC Award in Education in recognition for her many years of service and hard work in education. Prior to joining UQ, Bronwyn was Professor and Pro-Vice-Chancellor (Indigenous Engagement) at Central Queensland University (CQU). She was also the Chairperson of CQU's Academic Board and the BHP Billiton Mitsubishi Alliance Chair in Indigenous Engagement. She led CQU's Reconciliation Action Plan process and the Office of Indigenous Engagement Change Proposal-initiatives which focused on realigning functions and activities to maximise resources provided for Indigenous education and support. In 2017 Professor Fredericks was appointed as one of two Commissioners with the Queensland Productivity Commission (QPC) and was the presiding commissioner leading the Inquiry into Service Provision in Discrete and Remote Aboriginal and Torres Strait Islander Communities. In 2019, she was a Commissioner with the Inquiry into Imprisonment and Recidivism, and in 2018, a Commissioner with the Inquiry into Manufacturing in Queensland. Bronwyn has been a recipient of research awards and fellowships, including both Endeavour and NHMRC awards and in recognition of her research, Bronwyn received the inaugural 2019 Public Health Award in Indigenous Health.

Aubree Gordon

University of Michigan, USA

Aubree Gordon is a Professor of Epidemiology and Global Public Health at the University of Michigan. Her research focuses on the dynamics of respiratory virus transmission, natural history, susceptibility to respiratory viruses, and the development of immunity. She has established several large field studies of influenza and/or SARS-CoV-2 in both Managua, Nicaragua and the Michigan, United States. Her group aims to answer fundamental questions that are of the utmost priority for the understanding of influenza and SARS-CoV-2 and the development of next-generation vaccines.

Plenary Speakers

Stephanie Gras

La Trobe University, Australia

Prof Stephanie Gras is head of the Viral & Structural Immunology laboratory and Deputy Director of the La Trobe Institute for Molecular Science (LIMS) at La Trobe University, Melbourne, Australia. She is an internationally recognised leader in the field of T cell Immunology and Structural Biology with a sustained record of high-quality publications in peer reviewed journals (> 130 publications in Nature, Science, Immunity, Nature Immunology, Science Immunology, Nature Communications, PNAS ...), with a successful record of research funding (NHMRC, MRFF, ARC, VMRAF, Commercial contract & philanthropy), and is strongly committed to advance supportive and equitable research environments. Prof Gras is currently an NHMRC Senior Research Fellow and has been awarded four fellowships over her career (Monash, ARC Future Fellowship, NHMRC CDF2 and SRFA). She has been awarded the Georgina Sweet Award for Women in Biomedical Science (2017), SCANZ Sandy Mathieson Medal (2022), ASBMB Shimadzu Medal (2023). Prof Gras' research is instrumental on providing a better understanding of the first key event in T cell-mediated immunity towards pathogens: the antigen recognition mechanism. Notably her work has elucidated the link between HLA and asymptomatic COVID profile, link between TCR docking orientation and T cell activation. Understanding antigen recognition using structural biology offers tremendous opportunities to design new therapies that mobilise, reprogram or boost the immune system.

Matire Harwood

University of Auckland, New Zealand

Associate Professor Matire Harwood MBChB (University of Auckland), PhD Medicine (University of Otago), Ngāpuhi. Matire is a Māori health academic based in Tāmaki Makaurau. She divides her time between the Faculty of Medical and Health Sciences, where she is Deputy Dean, and work as a General Practitioner. She has served on several national Boards and Advisory Committees including Waitematā District Health Board, Health Research Council, COVID-19 Technical Advisory Group at the Ministry of Health and the Hauora Māori Advisory Committee to New Zealand's Minister of Health. Matire has been recognised for her work with numerous awards across research, teaching and leadership. These include the 2017 L'Oréal UNESCO New Zealand 'For Women in Science Fellowship' for research in Indigenous health, the Health Research Council's Te Tohu Rapuora award in 2019 for leadership in research to improve Māori health, the Royal New Zealand College of General Practitioners Community Service Medal in 2022 and the Butland Award in 2023 for Excellence in Research Supervision. She received the King's Service Medal in June 2024 for her contribution to indigenous Māori health.

Katherine Kedzierska

Peter Doherty Institute for Infection and Immunity, University of Melbourne, Australia

Prof Katherine Kedzierska is Deputy Head of the Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity. Katherine received her PhD from Monash University in 2002 for her studies on the mechanisms underlying defective immune functions after HIV infection. Her PhD work was recognised by the 2001 Premier's Commendation for Medical Research, 2002 Monash University Mollie Holman Doctoral Medal and an NHMRC Peter Doherty Postdoctoral Fellowship to pursue her postdoctoral research with Laureate Professor Peter Doherty at University of Melbourne. Her postdoctoral work was focused on the early establishment of influenza-specific CD8+ T cell memory, TCR repertoire diversity and viral escape in a mouse model of influenza virus infection. In 2007, she got awarded an NHMRC RD Wright Fellowship and grant funding to establish her own research team. She is currently an NHMRC Investigator Fellow and a group leader of 'Human T cell Laboratory' in Department of Microbiology and Immunology at University of Melbourne. Her research interests include human T cell immunity to pandemic, seasonal and newly emerged respiratory viruses, anti-viral immunity in the young, the elderly, pregnant women and Indigenous Australians, viral escape and generation of immunological memory in human viral infection. She also studies human immunity to SARS-CoV2 infection and vaccination. To date, Katherine has published 237 manuscript. She is a recipient of prestigious awards, including 2023 Eureka Prize for Infectious Diseases, 2016 Australian Academy of Science Jacque Miller Medal, 2011 NHMRC Excellence Award and 2011 Scopus Young Researcher of the Year Award. She is an Adjunct Professor at the Hokkaido University, Japan. In 2019, she was elected as a Fellow of the Australian Academy of Health and Medical Science (AAHMS).

Plenary Speakers

Florian Krammer

Icahn School of Medicine at Mount Sinai, USA

Florian Krammer, PhD, graduated from the University of Natural Resources and Life Sciences, Vienna. He received his postdoctoral training in the laboratory of Dr. Peter Palese at the Icahn School of Medicine at Mount Sinai, New York working on hemagglutinin stalk-based immunity and universal influenza virus vaccines. In 2014 he became an independent principal investigator and is currently the endowed Mount Sinai Professor of Vaccinology at the Icahn School of Medicine at Mount Sinai. He is also the co-director of the Center for Vaccine Research and Pandemic Preparedness (C-VaRPP). Dr. Krammer has a second appointment at the Ignaz Semmelweis Institute at the Medical University of Vienna. Dr. Krammer's work focuses on understanding the mechanisms of interactions between antibodies and viral surface glycoproteins and on translating this work into novel, broadly protective vaccines and therapeutics. The main target is influenza virus but he is also working on coronaviruses, flaviviruses, hantaviruses, filoviruses and arenaviruses. He has published more than 400 papers on these topics. Since 2019, Dr. Krammer has served as principal investigator of the Sinai-Emory Multi-Institutional Collaborative Influenza Vaccine Innovation Center (SEM-CIVIC), which develops improved seasonal and universal influenza virus vaccines that induce long-lasting protection against drifted seasonal, zoonotic and future pandemic influenza viruses.

Seema Lakdawala

Emory University, USA

Dr. Lakdawala (lock-da-wall-a) trained as a molecular virologist at the Salk Institute in San Diego, CA and at the NIH in 2009 began studying airborne transmission of emerging influenza viruses. During this time she made important discoveries regarding the presence of influenza viruses in aerosols of varying sizes, and the defined the soft palate as an important site for viral adaptation and transmission. Dr. Lakdawala started an independent laboratory at the University of Pittsburgh School of Medicine in 2015 studying influenza virus transmission, pathogenesis, and assembly across scales; she moved her research program to Emory University in August of 2022.

The Lakdawala Lab uses sophisticated microscopy and biochemistry to examine viral replication within infected cells, animal models to study barriers to airborne transmission of influenza viruses, and environmental engineering to examine persistence of viruses in the air. During the COVID-19 pandemic they began examining the importance of public health interventions across communities, resulting in an interactive dashboard, www.PHIGHTCOVID.org, to inform policy makers nationwide. Their research has been featured in the popular press numerous times. In addition, during the pandemic, Dr. Lakdawala has given over 40 interviews on the transmission of respiratory viruses to a variety of news outlets. Notable honors for Dr. Lakdawala include the 2020 ASV Ann Palmenberg Junior Investigator Award, Organizing committee for the National Academies of Sciences workshop on SARS-CoV-2 Airborne Transmission in Aug of 2020, and a 2024 National Academies of Sciences Kavli Fellow. In 2023, Dr. Lakdawala helped establish the Emory Center for Transmission of Airborne Pathogens (Emory C-TAP) and is a co-director.

Stephanie Langel

Case Western Reserve University, USA

Dr. Langel received her PhD at Ohio State University studying emerging coronaviruses (pre-pandemic) and did postdoctoral training at Duke University developing vaccine strategies that target breast milk. Dr. Langel's lab is focused on understanding anti-influenza breast milk immunity and its impact on influenza infection in both mom and baby. To accomplish this, the Langel lab is using translational animal models, human clinical samples, and single cell technologies. The Langel lab's overall goal is to improve maternal and neonatal health around the world.

Plenary Speakers

Mariana Leguia
Pontificia Universidad Catolica del Peru, Peru

Holds a B.A. in Biology from Lawrence University (Wisconsin, USA) where she graduated summa cum laude as a Fulbright scholar, and a Ph.D. in Molecular Biology, Cell Biology and Biochemistry from Brown University (Rhode Island, USA). She then pursued post-doctoral work in Synthetic Biology at both Lawrence Berkeley National Laboratory (Berkeley, USA) and the University of California (Berkeley, USA). In 2011 she returned to Peru to direct the Genomics and Pathogen Discovery Unit of the Virology Department at the U.S. Naval Medical Research Unit No. 6 (Lima, Peru). Since January 2018 she directs the Genomics Laboratory at the Pontificia Universidad Catolica del Peru (PUCP). Her research focuses on infectious diseases caused by viruses and bacteria, especially those that are endemic to the region, and how these affects public health in Peru and around the world. Her laboratory uses advanced genomics techniques, including next-generation sequencing, RNA-seq and ribosome profiling, to develop diagnostics, discover novel pathogens that may affect human and animal health, optimize vaccines, and find genomic markers for disease risk. She has been the recipient of numerous awards and more recently was appointed by the Peruvian government to serve as an expert advisor during several infectious disease outbreaks, such as during the COVID-19 pandemic and the current dengue outbreak.

Adrian Miller
CQUniversity, Australia

Professor Miller is a Jirrbal man from North Queensland. He is the Deputy Vice-President Indigenous Engagement, the BHP Chair in Indigenous Engagement and Director of the Jawun Research Centre at CQUniversity. He is an established Public Health scholar known nationally and internationally for his research and leadership in First Nations public health research, in particular, infectious diseases. He maintains strong links to various other prestigious health research and educational institutions.

Malik Peiris
The University Of Hong Kong, Hong Kong

Malik Peiris is currently Professor of Virology at the School of Public Health at The University of Hong Kong. He is a clinical and public health virologist, with an interest in emerging virus disease at the animal-human interface, including influenza and coronaviruses (SARS-CoV, MERS-CoV, SARS-CoV-2). In 2003, he identified the novel coronavirus that caused SARS and contributed to understanding its origins, diagnosis and control. More recently, he works on zoonotic, seasonal and pandemic influenza, MERS and COVID-19 using a One Health approach and is interested in drivers of virus spill-over at the animal human-interface and interventions to reduce spill-over risk. He has been elected as Fellow of the Royal Society of London and as a Foreign Member of the US National Academy of Sciences.

Steven Riley
Imperial College London, UK

Professor Steven Riley is the Director of Data & Analytics at the UK Health Security Agency. He conducts field studies, analyses data and uses mathematical models to look at scientific questions that are relevant to public health. Prior to the COVID-19 pandemic, he worked mainly on outbreaks and influenza, with an interest in spatial transmission processes, contact patterns and complex exposure histories. During the pandemic, up to October 2021, he contributed through the Imperial College COVID-19 Response Team, the Scientific Pandemic Influenza-Modelling (SPI-M) committee and the Realtime Assessment of Community Transmission (REACT) study. Since October 2021, Dr Riley has been 90% seconded to the UK Health Security Agency as the Director General for Data Analytics and Surveillance.

Plenary Speakers

Maria van Kerkhove
World Health Organization, Switzerland

Dr. Maria Van Kerkhove is the Acting Director of the Department of Epidemic and Pandemic Prevention and Preparedness as well as the COVID-19 Technical Lead of the World Health Organization (WHO) and Head of the Emerging Diseases and Zoonoses Unit in the WHO's Health Emergencies Program. Dr. Maria Van Kerkhove's work focused on zoonotic, respiratory and emerging/re-emerging diseases such as avian influenza, MERS, SARS, COVID-19, Ebola, Marburg, plague and Zika. Her research has focused on understanding and mitigating factors that are associated with transmission of zoonotic pathogens between animals and humans, the epidemiology of zoonotic pathogens, and ensuring that scientific research and field experiences directly inform public health policies for action.

Mark von Itzstein
Griffith University, Australia

Professor Mark von Itzstein AO is an elected Fellow of both the Australian Academy of Science and the Australian Academy (2003) of Health & Medical Sciences (2015), and a joint recipient of the prestigious Australia Prize (1996). He was also appointed as an Officer of the Order of Australia (General Division) in 2019 and has won numerous national and international awards during his career. Professor von Itzstein led the team responsible for the design, synthesis and biological evaluation of the anti-influenza drug, Relenza®, which has been approved for the treatment of influenza worldwide since 1999. This discovery is considered to be a significant outcome and flagship in glycotherapeutic and antiviral drug development in the last century and has further consolidated the world platform of using carbohydrates as drugs and carbohydrate-recognising proteins as drug discovery targets. Professor von Itzstein was the Founding Director of Griffith University's Institute for Glycomics for over 23 years and since February 2024 he has been appointed as a Distinguished Professor within the Institute. The Institute for Glycomics is the only one of its kind in the southern hemisphere and only one of a few in the world. The Institute's researchers collaborate with leading scientists around the globe to build a critical mass around research in areas of clinically significant diseases. Professor von Itzstein is an NHMRC Investigator L3 since 2021 and has a major research effort in the area of drug discovery focused on influenza, parainfluenza and other viruses, drug-resistant bacteria and cancer. He has international standing in glycoscience and drug discovery particularly in the area of anti-infective drug discovery. Professor von Itzstein has published over 240 papers and invited reviews and has extensively patented his research.

Keynote Speakers

Michael Chan
The University of Hong Kong, Hong Kong

Professor Michael Chan received his PhD degree in Medical Science from the Chinese University of Hong Kong, followed by the post-doctoral fellowships in infectious diseases at The University of Hong Kong since 2004. Professor Chan's main research interests are the virus-host interaction and pathogenesis of influenza virus and coronavirus. Major focuses of his work are: (1) Risk assessment for tropism, replication and pathogenesis of influenza virus and coronavirus using ex vivo explants and organoids (2) Mechanism of lung injury upon severe influenza virus and coronavirus infection (3) Human nasal/nasopharyngeal, airway and alveolar organoids, personalized diseases and immune organoids development and risk assessment for emerging respiratory viruses (4) Role of human distal airway stem cells in respiratory epithelium regeneration upon virus infection. (5) Role of mesenchymal stromal cells and exosomes/microvesicles in reverse influenza H5N1 associated acute lung injury (6) Novel therapeutic options for severe human influenza virus and coronavirus infection. Professor Chan is ranked by Essential Science Indicator (ISI) as a "top 1% most-cited international scientist" in the world since 2009. He has published over 85 manuscripts; many of them are in high impact journals including Lancet Respiratory Medicine, Nature, Nature Medicine, Nature Microbiology, PNAS, etc. Professor Chan has played a number of scientific advisory roles for international organizations, as member of the Reference Laboratories of the WHO CoronaVirus Network (CoViNet), and WHO TIPRA consultation panel to provide risk assessment data on emerging influenza virus. Professor Chan has been worked as the visiting scientists in the Harvard Stem Cell Institute, Harvard Medical School and the Cardiovascular Research Institute, University of California, San Francisco. Professor Chan has received research funding as a Principal Investigator from various Hong Kong and oversea research organizations, including NIAID-CEIRR, NIH (USA), Theme-based Research Scheme, Area of Excellence Scheme and GRF (RGC, Hong Kong), ITF and Health@InnoHK (ITC, Hong Kong SAR), HMRF (Hong Kong SAR) with funding over HK$108 million. Besides, he has trained and currently training 20 graduate research students. In knowledge exchange, Professor Chan has been coordinating the "Little Dr Flu" programme since 2013, which has successfully promoted the awareness of emerging respiratory virus infection and biomedical research and education among primary and secondary school students in Hong Kong.

Chris Chiu
Imperial College London, UK

Professor Chris Chiu is an Infectious Diseases physician and Immunologist. He trained as a clinician at Cambridge and Oxford Universities, followed by a PhD supported by a Wellcome Trust Clinical Research Training fellowship and then an MRC Clinician Scientist fellowship, during which he worked in Rafi Ahmed's group at Emory Vaccine Center. His research focuses on mucosal pathogenesis and protective immunity in human respiratory viral infections, including respiratory syncytial virus (RSV), influenza and SARS-CoV-2. To understand why some people suffer life-threatening illness while others have only mild/asymptomatic infection, he has developed a set of unique experimental medicine techniques using human infection challenge and vaccination. This is exemplified by his role as Chief Investigator of the first SARS-CoV-2 human challenge study, which together with his other programmes aims to enhance our understanding of how respiratory viral illnesses may be better prevented and accelerate the development of more effective vaccines.

Keynote Speakers

Ann Falsey
University of Rochester School of Medicine, USA

Dr Falsey is a Professor of Medicine at the University of Rochester School of Medicine. The focus of her research has been clinical and translational research in the field of respiratory viral infections in adults. Dr Falsey received her Doctorate in Medicine at Vanderbilt University School of Medicine. She completed her residency in Internal Medicine at Strong Memorial Hospital at the University of Rochester and Infectious Disease fellowship at Yale University and the University of Rochester. Initially, the focus of her research was defining the epidemiology and impact of respiratory syncytial virus (RSV) in adult populations. More recently, Dr Falsey has broadened her research to include numerous viral respiratory pathogens including influenza, coronaviruses, parainfluenza viruses and human metapneumovirus. She is presently the Co-PI of the University of Rochester, NIH sponsored clinical trial network, Vaccine Treatment and Evaluation Unit (VTEU). She has conducted numerous adult surveillance and vaccine studies in a variety of settings including nursing homes and senior daycare centers. A longstanding focus of her work has been the development of RSV vaccines for adult populations, and she participated in the early stages as well as the licensing vaccine trials for the recently approved RSV vaccines. When the COVID-19 pandemic hit in 2020, she and her colleagues immediately switched gears helped test and bring to market the COVID-19 vaccines. She continues to work on vaccine development and new methods of diagnosis for respiratory illnesses to improve human health.

Danielle Iuliano
US Centers for Disease Control and Prevention, USA

Danielle Iuliano is a PhD infectious diseases epidemiologist in the Influenza Division at the Centers for Disease Control and Prevention (CDC). She began her career in influenza in July 2010, however, participated in the Public Health Response through learning about and working with influenza during the 2009 Influenza A(H1N1) pandemic period. Danielle is an internationally recognized subject matter expert for respiratory pathogen disease burden and severity assessment, with most of her work on influenza viruses and SARS-CoV-2. She spent eight years supporting the division's international program by working with partners in the Western Pacific and Southeast Asia to provide technical support on surveillance, novel viruses, outbreak response, and research activities. She has supported research activities covering a variety of influenza epidemiology topics including enhanced surveillance for risk groups, novel influenza viruses, animal-human interface activities, and vaccine immunogenicity studies. She led the novel avian and swine influenza virus monitoring for the division to track both animal and human outbreaks around the world from 2013 to 2018.

Svenn-Erik Mamelund
Centre for Research on Pandemics & Society (PANSOC) at Oslo Metropolitan University, Norway

Svenn-Erik Mamelund is Professor in Pandemic Studies and Head of the Centre for Research on Pandemics & Society (PANSOC) at Oslo Metropolitan University. Mamelund received his PhD in historical demography in 2004 from the University of Oslo and has done research on pandemics for three decades. He is a leading international scholar in the fields of demography, social inequalities and history of pandemics, including the 1918-20 influenza, the 2009 "swine flu" and COVID-19. His work has been published in journals of history, epidemiology, medicine, vaccinology, and demography.
One of Mamelund' s recent accomplishments was leading a large interdisciplinary and international project on Pandemics and Indigenous Peoples at the Centre for Advanced Study at the Norwegian Academy of Science and Letters, 2022-2023.

A central focus of Mamelund' s work is turning research into policy in the field of pandemic preparedness, nationally and internationally. Mamelund was a co-author of Norway's first influenza pandemic preparedness plan published in 2000, and he has served as an invited expert for the ECDC, WHO and the UN. During COVID-19 Mamelund was highly sought after and gave interviews to the BBC World Service, the Guardian, Deutsche Welle TV, El País, and the Wall Street Journal.

Keynote Speakers

Jodie McVernon
The Peter Doherty Institute For Infection And Immunity, Australia

Professor Jodie McVernon is a public health physician and epidemiologist. For the past 18 years she has been building capacity in infectious diseases modelling in Australia and our region to inform immunization and pandemic preparedness policy. She has led nationally distributed networks of modellers informing responses to the 2009 H1N1 influenza pandemic and the COVID-19 pandemic. She has a particular interest in the inequitable impact of infectious diseases, including interventions for their control, and the need for a whole of society lens in preparedness and response.

Peter Openshaw
Imperial College London, UK

Peter Openshaw MD PhD CBE is Professor of Experimental Medicine at Imperial College London, UK. A respiratory physician and mucosal immunologist. His research focuses on how the immune response both protects against viral infection but also causes disease. He served as President of the British Society for Immunology (2013-18) and is especially well known for his work on respiratory syncytial virus (RSV), influenza and COVID-19, and for the development of human challenge in volunteers. He has served on many grant committees and Advisory Boards and has published widely on vaccinology, the immunopathogenesis of pulmonary viral diseases and lung inflammation, and the role of immune responses in lung disease.

Massimo Palmarini
MRC-University of Glasgow Centre for Virus Research, Scotland

Massimo Palmarini is the Director of the MRC-University of Glasgow Centre for Virus Research (CVR) and Chair of Virology at the University of Glasgow. A veterinarian by training, his research programmes have spanned diverse areas including virus pathogenesis, the host innate immunity to virus infections and the mechanisms of viruses cross-species transmission, focusing lately on avian influenza viruses. His work has been published in major research journals including Nature, Science, PNAS and others. Palmarini's research programme is funded by the UK Medical Research Council and the Wellcome Trust. Massimo Palmarini has been elected Fellow of the Academy of Medical Sciences, of the Royal Society of Edinburgh and of the Royal Society of Biology and he was a Wolfson-Royal Society Research Merit Awardee. He is a Wellcome Trust Investigator and received an OBE for services to Public Health in 2021.

Stanley Perlman
University of Iowa, USA

Dr. Perlman received his Ph.D. in Biophysics from M.I.T., Cambridge, Massachusetts and his M.D. from the University of Miami, Miami, Florida. He was trained in Pediatrics and Pediatric Infectious Diseases at Boston Children's Hospital, Boston, Massachusetts. He is a member of the VRBPAC of the FDA and the COVID-19 Advisory Committee of the ACIP (Advisory Committee on Immunization Practices). His current research efforts are focused on coronavirus pathogenesis, including virus-induced demyelination and the Severe Acute Respiratory Syndrome (SARS), the Middle East Respiratory Syndrome (MERS) and COVID-19. His laboratory has developed several novel animal models useful for studying pathogenesis and evaluating vaccines and anti-viral therapies. His studies are directed at understanding why aged patients and mice developed more severe disease than younger individuals after infection with SARS-CoV or SARS-CoV-2. His laboratory has developed several mouse models for COVID-19. Among other topics, his research is now focusing on the loss of sense of smell (anosmia) and taste (ageusia) and neurological disease in patients with acute SARS-CoV-2 infection and PASC (Post Acute Sequelae of COVID-19).

Keynote Speakers

Annette Regan

University of San Francisco, USA

Dr. Regan is a perinatal and pediatric infectious disease epidemiologist with experience implementing epidemiologic research and public health practice. Her research has led to the development of novel vaccine safety surveillance systems for pregnant people and epidemiological methods tailored for monitoring maternal vaccine safety and effectiveness using real world observational data. Dr. Regan has completed an MPH in epidemiology at the Rollins School of Public Health, Emory University in 2006, and a PhD in infectious diseases at the University of Western Australia in 2016. She has previously worked as an epidemiologist for state and federal public health agencies, including the US Centers for Disease Control and Prevention (CDC) and the state health department in Western Australia. Since returning to the US in 2018, she became tenured faculty at the University of San Francisco, where she lectures on epidemiologic methods, infectious disease epidemiology, and reproductive health. She currently receives funding from the National Institutes of Health to evaluate the safety of influenza and COVID-19 vaccines during pregnancy and evaluate adolescent vaccine decision-making.

Emily Ricotta

Uniformed Services University of the Health Sciences, USA

Dr. Emily Ricotta is an Assistant Professor of Epidemiology at Uniformed Services University (USU) in Bethesda, Maryland. She has over fifteen years of research experience in epidemiology and microbiology working with a variety of human infections including malaria, ebola virus disease, antimicrobial resistant pathogens, and SARS-CoV-2. Her work focuses on 1) understanding and improving data collection and management using non-randomized studies, and 2) conducting rigorous population-level infectious disease studies. Dr. Ricotta is passionate about harnessing data to understand the complexities of infectious disease epidemiology. She is committed to improving the ways we collect and analyze data for clinical research, and is involved in work advancing data standardization and management, study design, and AI/ML. Outside of the lab, Dr. Ricotta participates in global public health program monitoring and evaluation, policy development, and scientific advocacy. Before joining the faculty at USU, Dr. Ricotta was chief of the Epidemiology and Data Management Unit and an Independent Research Scholar in the Division of Intramural Research at the National Institute of Allergy and Infectious Diseases, U.S. National Institutes of Health. She received a PhD in epidemiology from the Swiss Tropical and Public Health Institute at the University of Basel in 2018 and an MSc in molecular microbiology and immunology from the Johns Hopkins Bloomberg School of Public Health in 2012.

Stacey Schultz-Cherry

St. Jude Children's Hospital, USA

Stacey Schultz-Cherry, PhD, is a Full Member and Professor in the Department of Infectious Diseases at St Jude Children's Research Hospital in Memphis, TN as well as Senior Associate Dean for Academic Affairs in the St Jude Graduate School of the Biomedical Sciences. She serves as Co-Director of not only the Center for Excellence in Influenza Research and Response but also the Collaborative Influenza Vaccine Innovation Center, both research centers supported by the National Institute of Allergy and Infectious Diseases. Dr. Schultz-Cherry received her PhD in Molecular and Cellular Pathology from the University of Alabama at Birmingham investigating extracellular matrix and growth factor interactions. After a short postdoctoral fellowship at the University of Wisconsin-Madison studying influenza virus-induced apoptosis and cellular responses, she served as a Lead Scientist at the U.S. Department of Agriculture Southeast Poultry Research Laboratory in Athens, GA, doing research on emerging highly pathogenic avian influenza viruses and astroviruses. She subsequently joined the faculty in the Department of Medical Microbiology and Immunology at the University of Wisconsin, Madison Medical School rising to become tenured Associate Professor before moving to St Jude in 2009. Dr. Schultz-Cherry is recognized internationally for her studies on the pathogenesis of influenza and enteric viruses, especially astroviruses, in high-risk populations, and on the interactions of influenza viruses among different avian species and other animals and humans. She is the author and co-author of over 200 research articles, reviews, and book chapters and has lectured internationally. She has been a member of the editorial boards of several prominent journals including the Journal of General Virology, mBio, and Plos Pathogens and is now the editor-in-chief of the Journal of Virology. Dr. Schultz-Cherry has served on the National Institutes of Health study

Keynote Speakers

sections and other of its institutional committees. She was elected President of the American Society for Virology in 2017, is the current chair of the Public and Scientific Affairs Committee for the American Society for Microbiology and is an American Academy of Microbiology Fellow. Since 2012 she has been Deputy Director of the World Health Organization Collaborating Center for Studies on the Ecology of Influenza in Animals and Birds

Ana Fernandez-Sesma
Icahn School of Medicine at Mount Sinai, USA

Dr. Fernandez-Sesma is currently a professor with tenure and the Chair of the Department of Microbiology at Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY, USA. Her research focuses on the modulation of innate immunity by viruses of human health interests, such as dengue (DENV), influenza (IAV), human immunodeficiency virus (HIV), Zika (ZIKV), and SARS-CoV-2. Her group uses mainly primary human systems, such as dendritic cells (DCs) and macrophages as well as primary lung epithelial cells and human tonsils for these studies combining molecular and immunological techniques. Her studies aim to understand the mechanisms of immune evasion used by these viruses to establish infection in humans. She currently participates in several multi-investigator projects on DENV, IAV and SARS-CoV-2 that use OMICS technologies to study immune responses to infection and vaccination. She has also participated in several study sections for the National Institutes of Health (NIH/NIAD), the Department of Defense (DoD) and the Centers of Disease Control (CDC) and served in the Scientific Council of the Division of Microbiology and Infectious Diseases (DMID) at NIH/NIAID from 2018-2022. Dr. Fernandez-Sesma chaired the NIAID Human Immunology Project Consortium (HIPC) Steering Committee from 2018-2022. She is strongly committed to graduate education and mentoring. She co-directed the Microbiology Main Training Area of the Graduate School of Biomedical Sciences at ISMMS from 2010 to 2020. She has co-authored numerous publications in Virology and Immunology journals and served on the editorial board of Journal of Virology, mSphere and PLoS Pathogens. Dr. Fernandez-Sesma is a Fellow of the American Academy of Microbiology, a recipient of the Jacobi Medallion from ISMMS and Honorary Alumni of the University of Salamanca, in Spain among other notable recognitions. Dr. Fernandez-Sesma has co-organized the 2023 and 2025 Gordon Research Conference: Viruses and Cells and delivered the Keynote lecture at the 2023 Annual Meeting for the American Society of Virology.

Viviana Simon
Icahn School of Medicine at Mount Sinai, USA

Dr. Simon Biography: Dr. Viviana Simon is a Professor of Microbiology, Medicine and Pathology at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York City, USA. She co-directs the Mount Sinai Center for Vaccine Research and Pandemic Preparedness. Professor Simon is an international leader in virology and infectious diseases who has the scientific and translational skills needed to tackle big problems in medicine. She is an Elected Fellow of the American Academy of Microbiology and serves as an Editor for the Journal of Virology. Professor Simon's research provides novel solutions to infectious diseases with high public health concern by bridging basic research and translational medicine. Her work has shaped our understanding of HIV persistence, virus-host interactions and immune responses to viral infections. Her group has been at the forefront of SARS-CoV-2 research since the very beginning of the pandemic when NYC emerged as an early epicenter. Her multidisciplinary team has provided and continues to provide much needed knowledge on pandemic preparedness and SARS-CoV-2 immunity in the context of evolving viral diversity.

Sheena Sullivan
UCLA, USA and Monash University, Australia

A/Prof Sheena Sullivan is an infectious diseases epidemiologist. Her work focusses on valid estimation of vaccine effectiveness and the underlying immunological mechanisms that influence it. She collaborates on several seroepidemiological cohort studies to characterise responses to infection and vaccination, with a special interest in how repeated vaccination harms antibody breadth.

Keynote Speakers

Paul Thomas
St. Jude Children's Research Hospital, USA

Paul G. Thomas is a Member of the Department of Host-Microbe Interactions at St. Jude Children's Research Hospital. His work focuses on understanding the principles of T-cell receptor recognition and specificity during development, infections, and tumors. Dr. Thomas obtained his undergraduate degree in Biology and Philosophy at Wake Forest University. His doctoral training at Harvard University focused on the innate immune response to Schistosoma-associated carbohydrates and their role in promoting Th2 responses. After graduate school, he relocated to St. Jude Children's Research Hospital for a postdoctoral fellowship with Dr. Peter Doherty on T-cell responses in the influenza model. In 2009 he started his independent lab, from which he has published over 200 peer-reviewed papers on TCR biology, immunological mechanisms of disease severity in human viral infections, and cellular immunology.

Emi Takashita
National Institute of Infectious Diseases, Japan

Dr. Emi Takashita is a Senior Research Scientist at the National Institute of Infectious Diseases, Japan. She studies influenza virus and SARS-CoV-2, focusing on the antiviral susceptibilities of these viruses.

Ryan Thwaites
Imperial College London, UK

Ryan Thwaites is a mucosal immunologist specialising in the human upper airway, based at the National Heart and Lung Institute, Imperial College London. Ryan's work developed the Nasosorption approach of directly sampling mucosal lining fluid from the upper airway and has applied this technique to studies of natural and experimental respiratory viral infections in infants and adults. Nasosorption is now being increasingly adopted as a gold-standard method for upper respiratory sampling. Using these samples alongside analytical tools including proteomics, immunoassays, and transcriptomics, Ryan's work aims to understand the association between early mucosal responses to a virus and the balance between subsequent protective and harmful immune responses.

David Wentworth
Centers for Disease Control and Prevention, USA

Dr. David Wentworth serves as Director of the Coronavirus and Other Respiratory Viruses Division (CORVD) in CDC's National Center for Immunization and Respiratory Diseases (NCIRD). As Director, Dr. Wentworth provides programmatic leadership and oversees studies to protect people from respiratory viruses. He also serves as Chair of the WHO-Technical Advisory Group on COVID-19 Vaccine Composition. Previously, Dr. Wentworth was the Chief of the Virology, Surveillance, and Diagnosis Branch in the Influenza Division (2014-2023). He was also Director of the WHO Collaborating Centre for Surveillance, Epidemiology and Control of Influenza at the CDC (2019-2023). Prior to joining CDC in 2014, Dr. Wentworth was Director of Viral Programs at the J. Craig Venter Institute (JCVI) from 2011 to 2014. From 2002 to 2011, Dr. Wentworth was the Director of the Influenza Virus and Coronavirus Pathogenesis laboratory at the Wadsworth Center, NYSDOH, and an Assistant Professor at the State University of New York-Albany. He received a B.S. in Poultry Science, an M.S. in Veterinary Medicine, and a Ph.D. in Virology at the University of Wisconsin-Madison (United States), where he specialized in the study of influenza viruses. He studied coronaviruses as a postdoctoral fellow, in the Department of Microbiology at the University of Colorado Health Sciences Center in Denver (United States).

Keynote Speakers

Carolien van de Sandt
University Of Melbourne At The Peter Doherty Institute, Australia

Dr Carolien van de Sandt is a Senior Research Fellow in the Department of Microbiology and Immunology at the University of Melbourne at the Peter Doherty Institute. Her principal area of expertise is in viral and aging immunology. Carolien completed her PhD in 2016 at the Erasmus University in Rotterdam in the Netherlands, where she investigated the longevity, cross-reactivity and immune evasion strategies of influenza virus-specific CD8+ T-cells, followed by two years of postdoctoral research in the laboratory of Profs Rimmelzwaan and Osterhaus. In 2018, she was awarded the prestigious European Marie Sklodowska-Curie Action (MSCA) Fellowship and the University of Melbourne's McKenzie Fellowship to join the Kedzierska laboratory, where she leads the Aging Immunity Research Program which aims to unravel the mechanisms that underly gain-and-loss- of virus-specific CD8+ T-cell function across human lifespan. During the pandemic Carolien temporarily relocated to Sanquin in the Netherlands as part of her MSCA fellowship (2020-2021) where she led her own research team studying SARS-CoV-2 immunity in healthy and autoimmune patients. In 2022 she was awarded the ARC-DECRA Fellowship to continue her Aging Immunity and T-cell Development Research at the University of Melbourne. Carolien has >50 publications including in leading journals like Nature Medicine, Nature Immunology, Immunity and Nature Communications. The importance of her work has been recognized prestigious Awards including the ESWI Claude Hannoun Prize for Best Body of Work (2023), the Viruses 2022 Early Career Investigator Award (2022) and she received the AIPS-Young Tall Poppy Award (2023) for her contributions to public outreach.

Cameron Wolfe
Duke University, USA

Professor Cameron Wolfe is an Infectious Disease Physician practicing at Duke University Medical Center, in North Carolina. His clinical work focuses on the management of immunocompromised patients, both those living with HIV infection and patients with organ and stem cell transplants. He has a dual appointment at the Duke Human Vaccine Institute, where he investigates vaccine response and clinical outcomes and treatment of respiratory viruses. Additionally, Cameron oversees the clinical management of emerging pathogens at the University, including ebola, COVID-19 and a novel influenza.

Nicole Wolter
National Institute For Communicable Diseases, South Africa

Dr Nicole Wolter is a Principal Medical Scientist in the Centre for Respiratory Diseases and Meningitis (CRDM) at the National Institute for Communicable Diseases (NICD) and the director of the WHO National Influenza Centre in South Africa. Her research interests include understanding the epidemiology, genomics and transmission of respiratory diseases in order to guide public health policy and action.

Paul Young
University Of Queensland, Australia

Paul Young is Professor of Virology, currently seconded to Research Development in the Deputy Vice-Chancellor's Office of Research and Innovation at The University of Queensland, Brisbane, Australia. He gained his PhD from the London School of Hygiene & Tropical Medicine and joined the University of Queensland in 1991. The over-arching goals of his research have been to understand the molecular basis of virus induced disease, develop new and improved diagnostics as well as vaccine and therapeutic control strategies for a number of viral pathogens of both human and animal origin. With colleagues at UQ, he co-led an Australian consortium that developed a COVID-19 vaccine in 2020, based on an innovative UQ patented platform technology. The vaccine candidate was taken through clinical trials and while the vaccine did not progress, the trials validated the potency of the platform concept. The vaccine has now been re-engineered and a new candidate has recently progressed successfully through clinical trial. Additional candidate vaccines for other human pathogens employing this platform are also under development through the spin-out Vicebio Ltd. In addition to these studies he is also working with colleagues to progress vaccine delivery via the Vaxxas micro-array patch. Prof Young is President-elect of the International Union of Microbiological Societies and has been the President of the Australian Society for Microbiology (2012-2014), the Australasian Virology Society (2001-2011) and the Asia-Pacific Society for Medical Virology (2012-2015).

Early Career Researcher - Career Development Lunch

Date: Monday 30 September 2024
Venue: Mezzanine M3
Time: 1200-1300

Susan Allison
Chief Editor-Nature
Springer Nature, Australia

Susan has a PhD from the Garvan Institute of Medical Research/UNSW and undertook postdoctoral research at the Stem Cell Center at Lund University, Sweden. She joined Nature Reviews Gastroenterology & Hepatology as an Associate Editor in 2008 and was appointed Chief Editor of Nature Reviews Nephrology in 2009. In June 2020 Susan took on an expanded role as a Consulting Editor for Nature, handling manuscripts across the biological sciences. She relocated from London back to Sydney in September 2022.

Maria Auladell
PPD, part of Thermo Fisher Scientific, Netherlands

Maria obtained her Medical Degree from the University Rovira i Virgili (Spain) in 2013, her MSc from the Autonomous University of Barcelona (Spain) in 2016, and her PhD on the immune response to seasonal influenza vaccines from the University of Melbourne (Australia) in 2021. Following her PhD, she made her move to Industry first as a Clinical Scientist and Project Manager at the Centre for Human Drug Research (CHDR) in the Netherlands (a local Contract Research Organisation (CRO)), followed by a role in Clinical Science at the global CRO Pharmaceutical Product Development (PPD), and then a position as a Medical Advisor in the Vaccines department at Pfizer. In 2024, Maria went back to PPD, part of Thermo Fisher Scientific, and she is currently an Associate Director in the Global Product Development department.

Kathy Spindler
University of Michigan, USA

Dr. Kathy Spindler is a professor of microbiology and immunology in the medical school at the University of Michigan. Spindler had 2 inspiring science teachers in junior high school, and she always knew she wanted to major in biology, which she did at Purdue University. She moved to the University of California, San Diego for her doctoral work, and she began working on viruses in her first rotation, with Dr. Masaki Hayashi. She joined that lab for the first part of her dissertation research, working on the single-stranded DNA bacteriophage FX174. She completed her Ph.D. in the laboratory of Dr. John Holland, working on "Evolution of viral RNA genomes in acute and persistent infections," using vesicular stomatitis virus.

In 1981, Spindler began her postdoc with Dr. Arnie Berk at UCLA, focused on the human adenovirus proteins encoded by E1A. Spindler moved to a faculty position at the University of Georgia (UGA) Department of Genetics in 1985, where she established studies of mouse adenovirus type 1 (MAV-1). This virus has similarities to human adenoviruses, and yet it can be studied in its natural host, using the powerful genetic and immunological tools of the mouse model. At the end of 2001, she moved to the University of Michigan, where her research into viral pathogenesis and host susceptibility to infection has expanded. She continues to teach undergraduates and graduate students, and she is currently the Chair of the Graduate Studies Committee in Microbiology and Immunology.

Spindler started her science outreach as a pen pal on science projects with elementary school children. She developed a summer genetics research program for visiting college students at UGA (SUNFIG). She currently is a member of the University of Michigan's ADVANCE advisory board. ADVANCE began as an "NSF-funded project promoting institutional transformation with respect to women faculty in science and engineering fields," and, at Michigan, it now has an expanded mission to promote diversity among faculty in all fields. Spindler served for 5 years on ADVANCE's STRIDE committee, participating in workshops both at Michigan and around the country discussing practices to maximize the likelihood that diverse candidates will be identified, recruited and promoted in the academy.

Social Events Program

Welcome Reception and Posters

Date: Sunday, 29 September 2024
Venue: Great Hall 3&4
Time: 1830-2030
(Cost to attend included with registration)

Additional tickets for non-registered partners available.

Join us for an Australiana-themed welcome reception to kick off the Conference in true Aussie style while learning about the latest research in respiratory viruses. Meet and greet our friendly local wildlife, including koalas and enjoy a selection of classic Australian foods and drinks with your peers as we celebrate the opening of OPTIONS XII in the land down under!

Early Career Researcher (ECR) Trivia Night

Date: Sunday 29 September 2024
Venue: Grenier Lane Bar, Pig N Whistle
Time: 2030
Cost to attend (for Early Career Researchers only) included with registration. ISIRV supported event. Ticket required.

Join us for an exciting ECR (Early Career Researcher) Pub Trivia Night! Test your knowledge across a range of fun and challenging topics while enjoying a relaxed evening with fellow researchers. Compete in teams for fantastic prizes, enjoy some delicious food and drinks, and make new connections in a vibrant pub setting.

Whether you're a trivia buff or just looking for a good time, this night promises to be full of laughter, learning, and camaraderie. Don't miss out on this perfect blend of brains and beers!

Conference Party

Date: Tuesday, 1 October 2024
Venue: Eat Street Northshore, Hamilton Queensland
Time:1900-2300
Cost: AUD $150.00 per person

Get ready for an unforgettable night at Brisbane's iconic Eat Street Night Markets! Join us to sample delicious dishes from around the world, sip on your favourite drinks and dance the night away. With a lively atmosphere and endless food options, this party promises to be one to remember!

Free coaches will be available to transport delegates from the BCEC to Eat Street and back to the Convention Centre.

About Brisbane

https://visit.brisbane.qld.au/inspiration/things-to-do-in-spring

Blue skies and balmy, sun-kissed days make Brisbane the place to be in spring. As one perfect day extends into the next, the city is abuzz with excitement and activity. Indoor or outdoor, rooftop bars or football stadiums, shopping or strolling, there are so many options, but here are some of the 30 best ways to spend your spring in Brisbane.

Brisbane is the capital city of Queensland, Australia and is a thriving hub for arts, culture, and technology. The city boasts a stunning riverfront, lush parks, and a vibrant nightlife. In recent years, Brisbane has become known for its growing tech industry and innovative start-ups. The city's thriving creative scene, combined with its beautiful natural surroundings. With its rich cultural heritage, modern infrastructure and thriving business sector, Brisbane is the perfect destination for multimedia professionals looking to connect, collaborate and create.

Experience Queensland

Beyond Brisbane there is a wealth of sun-kissed opportunities for leisure and pleasure in the state of Queensland. Road, rail and air links from Brisbane all provide easy access to some of the country's most awe-inspiring tourism treasures. From tropical islands with their lush rainforests and gleaming white beaches, to the rugged beauty of the outback, Queensland has it all.

By the river

South Bank in springtime

Spring is a blooming good time in Brisbane's premier riverside parkland precinct. Take a leisurely stroll or bike ride through the parklands and see the gardens natural features burst into vibrant life as spring is arguably the parkland's prettiest time for exploration. After soaking in the scenery, treat yourself to one of the many restaurants offering fresh spring menus.

City Botanic Gardens

Staying with the riverside city experiences, the City Botanic Gardens are a stunning place to reconnect with nature right in the heart of the city. There is always something happening in the warmth of spring in these gardens, visit for the Riverside markets on Sundays, Gigs and Picnics on the last Saturday of every month or if you just want to set up your own picnic and relax; the gardens are the perfect place to unwind in the Springtime.

Lunch at Howard Smith Wharves

This local and visitor favourite is a must-visit for spring lunch, Brisbane al fresco style. There is no better way to spend a warm spring day than sipping a freshly brewed beer or an icy cold wine to pair with any of the culinary delights that you will find along the river. Enjoy the gorgeous views of Brisbane as you watch the afternoon turn night.

Get out on the water

There's something extra-special about watching the sky light up in every shade of pink, purple and orange from the water. You can rent an electric GoBoat, book lunch or drinks at the Yot Club, or choose a tour of your preference with River to Bay. Whether it's cruising up and down the winding Brisbane River or exploring the expansive blue of Moreton Bay, being out on the water is as Brisbane as it gets.

Riverlife adventures

Spring is the perfect time to get adventurous in the city, and Riverlife has the perfect experiences for you. While the spring weather is here, learn how to abseil, kayak, bike, or rollerblade along the banks of the Brisbane River. Whether you want to embark on one of these adventures with a group, solo or would prefer to hire out the equipment of the day, your options to spend time in the sun are endless!

Chase the purple rain around Brisbane

Have you ever seen Brisbane erupt in a sea of purple Jacaranda trees? Starting in October through to November make sure you pack the camera any time you go outdoors because the chances are you are going to come across the vibrant purple trees in full bloom and creating a purple carpet below. If you want to create a day-trip just to admire these gems, New Farm Park is our top pick.

Brisbane adventures

Go Shopping

A change of season means a change of wardrobe…right? Make a day of it and enjoy the open-air shopping experience in the heart of the city in Queen Street Mall or wander the boutiques of the leafy James Street. Check out our **guide to Queen Street Mall**.

Sports Events

There's no better time or place to get amongst live-sport action than spring in Brisbane. Sit in one of our open-air stadiums and cheer on your favourite team. Check out some of our **key events** to add to your calendar.

Visit QAGOMA

Step into a world of creativity and culture at QAGOMA, where spectacular exhibitions await your discovery. Home to over 20,000 artworks featuring a dazzling array of Australian and International artists. Whether you're a fan of traditional masterpieces or cutting-edge contemporary pieces, QAGOMA's world-class exhibitions offer something for everyone. Explore every imaginable artistic technique and discover how art's rich history can spark your imagination.

Delicious Dining

Kiff & Culture Food & Drink Tour

Get set for a hassle-free adventure, with one of Kiff & Culture's epic food and drink tours around Brisbane. Hop on board their trendy mini-bus to be taken to some of Brisbane's top restaurants, wineries, distilleries and breweries. With their insider knowledge and local expertise, the Kiff & Culture team knows exactly where to go for an unforgettable day. All you've got to do is sit back and enjoy the ride.

Plan a food crawl up Brisbane's hottest laneway

Brisbane is full of unique, hidden, and trendy laneways bustling with culture, delicious food and not-to-be-missed bars. Discover **The City's best laneways** such as, Burnett Lane, Eagle Lane, Gresham Lane and Albert lane to discover a whole new world waiting for you. South of the river, **Fish Lane** has all the wine bars, restaurants, and cafes you need to create a choose-your-own dining and drinking adventure with friends. Or venture into Fortitude Valley for the most vibrant laneways like Bakery Lane and California Lane.

Choose a craft beer trail

With the warmer weather making its yearly come back, there's no better way to reinvigorate your exercise routine, than with some brand-new walking trails. Go too hard too soon and you'll fall off the wagon faster than you jumped on it-so ease into it with one of these light urban wanders, taking regular rest breaks at the various local craft breweries—doctor's orders.

Brisbane's trendiest eating spots

Brisbane's dining scene is abuzz with renewed energy and new openings. Stroll the city to discover the latest dining gems and book into newbies like Longwang, emme, Vertigo, Supernormal, and Naldham House just to name a few.

Take drinking sky high at Brisbane's best rooftop bars

Soak up the sunshine and raise your glasses to drinking up high at the best rooftop bars in Brisbane, which the city is certainly not short on. There's nothing quite like clinking glasses with views of the city skyline as the sunsets in the spring air.

Explore different farmers markets in Brisbane

As the early mornings are no longer as chilly, Brisbane's bustling market scene goes into overdrive. View our guide to the **best farmer's markets in Brisbane** So that you can savour a spot of brekkie, piping hot (or icy cold) coffee as the cutest pups walk alongside you and the choice of fresh pastries, produce, fruit and veg are bursting at the seams.



Industry Sponsored Symposia

Sunday 29 September 2024

AstraZeneca

Room: Great Hall 1 & 2
Time:13:35-14:35

From virus to vaccine:
the journey to a seasonal influenza vaccine

Chair: Peter Openshaw

Speakers: Ian Barr, Lauren Parker, Cheryl Cohen, Christopher Blyth

Pfizer

Room: Great Hall 1 & 2
Time:14:50-15:50

Combatting Co-circulation of Respiratory Viruses: Meeting the Public Health Challenge

Chair: Michael Moore AM

Speakers: Charles Feldman, Raina MacIntyre, Holly Seale

Monday 30 September 2024

CSL Seqirus

Room: Great Hall 1 & 2
Time: 13:00-14:00

Strengthening Influenza Protection: A symposium on paediatric, pandemic and pioneering solutions

Chair: Sarah Londrigan

Speakers: Terry Nolan AO, Colin Russell, Kanta Subbarao

Roche

Room: Great Hall 1 & 2
Time: 16:00-17:00

Stop the flu going viral: the benefits of antivirals for patients, households and communities

Chair: Frederick G. Hayden

Speakers: Mei Zeng, Ben Cowling, Colin Russell

Tuesday 1 October 2024

Moderna

Room: Great Hall 1 & 2
Time: 10:30-11:30

Addressing Influenza Disease Burden: Current Challenges and Emerging Vaccine Strategies Against a Persistent Threat

Chair: Michael Nissen

Speakers: Raina MacIntyre, Colin Russell, Terry Nolan AO

Sanofi

Room: Great Hall 1 & 2
Time: 14:00-15:00

OLD disease, NEW ways to better assess vaccine performance

Chair: LJ Tan

Speakers: Bruno Lina, Raina McIntyre, Tor Biering-Sorensen

Join us for the Symposium Sponsored by Sanofi at the OPTIONS XII 2024 Congress, Brisbane

"OLD disease, NEW ways to better assess vaccine performance"

01 October 2024
(Tuesday)

14:00-15:00 pm AEST*

Hall 1 & 2

*Add to Calendar

*Australian Eastern Standard Time

Chair

LJ Tan
Chief Policy & Partnerships Officer at Immunize.org; Co-Chair, National Adult & Influenza Immunization Summit, Illinois, USA

Faculty

Bruno Lina

Head of Virology Lab of the Hospices Civils de Lyon, France; Director of the French National Reference Centre for respiratory viruses

- How is the circulatory pattern of respiratory virus different in different seasons?
- How can this data be used to inform future combination vaccine development?
- What should we expect from an "enhanced influenza vaccines"

Raina McIntyre

Professor and Head | Biosecurity Program
Kirby Institute, UNSW, Australia

- What is the impact of influenza on people, especially on those with cardiac problems?
- How can prevention of influenza be a cost saving action for the health system?

Tor Biering-Sørensen

Head of Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen

- How does the data quality vary between randomized controlled trials and observational studies?
- How can randomization be applied to real world evidence for high quality data?

Visit the Sanofi Booth (Platinum 3 in Hall 3 & 4)

MAT-GLB-2405180-1.0–08/2024

Oral Presentations Listings

SUNDAY 29 SEPTEMBER 2024

11:50-12:50 Late Breaking Abstracts 1

Hannah	Stacey	EVIDENCE OF LOCAL B-CELL IMMUNITY FOLLOWING LIVE-ATTENUATED INFLUENZA VACCINATION OF HUMANS
Martha	Alexander-Miller	ANTIBODY FUNCTION PREDICTS VIRAL CONTROL IN NEWBORN AFRICAN GREEN MONKEYS IMMUNIZED WITH AN INFLUENZA VIRUS HA STEM NANOPARTICLE
Tereza	Masonou	SARS-COV-2 INFECTION OF NASAL EPITHELIAL CELLS FROM CHILDREN RESULTS IN GREATER NEUTROPHIL TRANS-EPITHELIAL MIGRATION, BUT A MORE ACTIVATED NEUTROPHIL PHENOTYPE EMERGES IN OLDER ADULTS
Goran	Bajic	CRYO-EM STRUCTURE AND PROTECTION MECHANISM OF HUMAN ANTIBODY LINEAGES THAT RECOGNIZE QUATERNARY EPITOPES ON INFLUENZA HEMAGGLUTININ

11:50-12:50 Late Breaking Abstracts 2

Colin	Russell	LATER SEASONAL INFLUENZA VIRUS VACCINE STRAIN SELECTION CAN IMPROVE MATCH OF VACCINE VIRUSES TO CIRCULATING VIRUSES
Oliver	Eales	BIASES IN ROUTINE INFLUENZA SURVEILLANCE INDICATORS USED TO MONITOR INFECTION INCIDENCE AND RECOMMENDATIONS FOR IMPROVEMENT
Benoit	Callendret	PHASE 3 SAFETY AND IMMUNOGENICITY OF AN MRNA-BASED SEASONAL INFLUENZA AND SARS-COV-2 MULTICOMPONENT VACCINE (MRNA-1083) COMPARED WITH CO-ADMINISTERED LICENSED VACCINES IN ADULTS ≥50 YEARS OLD
Rose	Miller	SPIKE-DIRECTED IMMUNITY TO MULTIPLE CORONAVIRUSES IN FERRETS

MONDAY 30 SEPTEMBER 2024

10:30-12:30 - Clinical Sciences and Vaccinology Clinical trials

Jianyu	Lai	EVALUATING MODES OF INFLUENZA TRANSMISSION (EMIT-2): AN ONGOING CONTROLLED HUMAN INFLUENZA VIRUS INFECTION TRANSMISSION TRIAL (CHIVITT)
Pamuk	Bilsel	CO-ADMINISTRATION OF INTRANASAL M2SR (M2-DEFICIENT SINGLE REPLICATION) INFLUENZA VACCINE WITH FLUZONE HIGH DOSE INDUCES SUPERIOR IMMUNE RESPONSES TO FLUZONE HIGH DOSE IN OLDER ADULTS
Alexandre	Le Vert	OVX836, A NP-BASED UNIVERSAL INFLUENZA VACCINE CANDIDATE, TRIGGERS EFFECTOR CD4+ AND CYTOTOXIC CD8+ T CELLS IN HEALTHY ADULTS
Amanda	Rudman Spergel	PHASE 1/2 SAFETY AND IMMUNOGENICITY OF MRNA-BASED SEASONAL INFLUENZA AND SARS-COV-2 MULTICOMPONENT VACCINE IN HEALTHY ADULTS
Arnold S	Monto	PHASE III CENTERSTONE STUDY OF SINGLE-DOSE BALOXAVIR MARBOXIL FOR THE REDUCTION OF TRANSMISSION OF INFLUENZA IN HOUSEHOLDS
Chikondi	Peno	INTERACTIONS BETWEEN LIVE ATTENUATED INFLUENZA VACCINE AND THE NASOPHARYNGEAL MICROBIOTA AMONG CHILDREN IN THE GAMBIA: A PHASE IV OPEN LABEL, RANDOMISED CONTROLLED CLINICAL TRIAL
Pedro	Folegatti	IMMUNOGENICITY AND SAFETY OF QUADRIVALENT RECOMBINANT INFLUENZA VACCINE (RIV4) IN CHILDREN AND ADOLESCENTS AGED 9 TO 17 YEARS AND ADULTS AGED 18 TO 49 YEARS

Oral Presentations Listings

10:30-12:30 - Interdisciplinary Session: Respiratory viruses in underserved populations		
Anders	Madsen	REDUCING INFLUENZA INFECTION AND ANTIBOIC USE IN YOUNG CHILDREN AFTER QUADRIVALENT INFLUENZA VACCINATION; INSIGHTS FROM RURAL BANGLADESH
Jorim	Ayugi	ILLNESS OUTCOMES OF IN-AND-OUT PATIENTS CO-INFECTED WITH SARS-COV-2 AND MALARIA, 2020-2022
Faletoese	Asafo	THE SOCIAL AND ECONOMIC IMPACTS OF EARLY CHILDHOOD HOSPITALISATION WITH RESPIRATORY INFECTION IN PACIFIC FAMILIES IN AOTEAROA, NEW ZEALAND.
Felicity	Ware	KOHANGA WINTER PREPAREDNESS PROJECT
Jinal	Bhiman	ANTIBODY DYNAMICS DURING PROLONGED SARS-COV-2 INFECTION IN PEOPLE LIVING WITH AND WITHOUT HIV
10:30-12:30 - Public Health and Policy Forecasting, seasonality and surveillance		
Matthew	Biggerstaff	IN-SEASON EVALUATION OF INFLUENZA FORECASTS DURING THE 2023-2024 UNITED STATES INFLUENZA SEASON
Rachael	Pung	INTEGRATING PASSIVE AND SENTINEL SURVEILLANCE FOR ROBUST EVALUATION OF SARS-COV-2 INFECTIONS
Bren	Case	CHARTING THE COURSE FOR RESPIRATORY VIRUS ACTIVITY IN THE SOUTHERN HEMISPHERE: REAL-TIME FORECASTING OF SEVERE ACUTE RESPIRATORY INFECTIONS IN PARAGUAY, 2024
Sheikh Taslim	Ali	TIME-VARYING INFERENCE OF POPULATION IMMUNITY AND PREDICTION OF INFLUENZA DYNAMICS IN HONG KONG
David	Muscatello	IMPROVING EMERGENCY DEPARTMENT SURVEILLANCE TO NOWCAST SEVERE COVID-19 AND INFLUENZA INFECTION OUTCOMES FOR EPIDEMIC INTELLIGENCE
Pejman	Rohani	FORECASTING INFLUENZA WITH ENSEMBLES OF SEASONAL MODELS
Warda	Haque	SURVEILLANCE OF RESPIRATORY VIRUS DYNAMICS IN 2021-2022: INSIGHTS FROM AN INFLUENZA VACCINE CLINICAL TRIAL IN BANGLADESH
10:30-12:30 - Virology and Pathogenesis: NIV IG Session (Avian Influenza at Species Interfaces)		
Agustina	Rimondi	OUTBREAKS OF HPAI H5N1 (2.3.4.4B) ON ARGENTINA'S ATLANTIC COAST: INCREASED EVIDENCE FOR MAMMAL-TO-MAMMAL TRANSMISSION OF A NOVEL H5N1 CLADE IN MARINE MAMMALS.
Michelle	Wille	EMERGENCE AND SPREAD OF HIGH PATHOGENICITY AVIAN INFLUENZA (HPAI) H5 IN WILDLIFE OF SOUTH AMERICA AND ANTARCTICA
Samuel	Ago	HIGHLY PATHOGENIC AVIAN INFLUENZA A(H5N1) CLADE 2.3.4.4B VIRUS DETECTED IN POULTRY IN GHANA, 2021 TO 2022.
Carrie	Reed	HUMAN INFECTION WITH HIGHLY PATHOGENIC AVIAN INFLUENZA A(H5N1) VIRUS IN A DAIRY WORKER IN THE UNITED STATES
Ghazi	Kayali	SERO-EVIDENCE OF HUMAN INFECTION WITH H5N1 AND H9N2 AVIAN INFLUENZA VIRUSES

14:00-15:30 - Interdisciplinary Session: Viral evolution and public health genomics		
John	Huddleston	EFFECTS OF DELAYED SEQUENCE SUBMISSION AND VACCINE DEVELOPMENT ON LONG-TERM FORECAST ACCURACY OF SEASONAL INFLUENZA A/H3N2
Wenjie	Han	ANTIGENIC EVOLUTION PATTERNS OF INFLUENZA B VIRUSES: INSIGHTS INTO THE DISAPPEARANCE OF B/YAMAGATA
Lu	Lu	UNVEILING THE COMPLEX REASSORTMENT PATTERNS OF HIGHLY PATHOGENIC AVIAN INFLUENZA H5 VIRUS
Yi-Mo	Deng	EXPANDED DIVERSITY OF INFLUENZA VIRUSES FOLLOWING THE COVID-19 PANDEMIC-INDUCED BOTTLENECK IN AUSTRALIA
Leo	Poon	GENOMIC SURVEILLANCE EFFECTIVENESS ON GLOBAL DISSEMINATION OF SARS-COV-2 OMICRON VARIANTS
14:00-15:30 - Other Respiratory Viruses: Respiratory virus surveillance and burden of disease		
Rhys	Wenlock	HIGH SARS-COV-2 INCIDENCE AND ASYMPTOMATIC FRACTION DURING DELTA AND OMICRON BA.1 WAVES IN THE GAMBIA
Lea	Separovic	SHIFT IN THE AGE DISTRIBUTION OF PEDIATRIC AND ADULT RESPIRATORY SYNCYTIAL VIRUS INFECTIONS RELATED TO THE COVID-19 PANDEMIC: 2014/15 TO 2023/24 SEASONS, BRITISH COLUMBIA, CANADA
Songwei	Shan	POPULATION-BASED DISEASE BURDEN ASSOCIATED WITH RESPIRATORY SYNCYTIAL VIRUS IN HONG KONG, 1998-2019
Nikki	Turner	COMPARISON OF THE BURDEN AND TEMPORAL PATTERN OF HOSPITALIZATIONS ASSOCIATED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV) BEFORE AND AFTER THE COVID-19 PANDEMIC IN NEW ZEALAND
Emily	Martin	EVALUATING THE IMPACT OF VIRAL COINFECTION ON HOUSEHOLD TRANSMISSION OF RESPIRATORY VIRUSES
14:00-15:30 – Public Health and Policy: Vaccines 1: Real-world vaccine effectiveness		
Melissa K.	Andrew	INFLUENZA VACCINE EFFECTIVENESS IN THE PREVENTION OF ADMISSION TO ASSISTED LIVING OR LONG-TERM CARE FACILITIES: A REPORT FROM THE CANADIAN IMMUNIZATION RESEARCH NETWORK SOS NETWORK
Mary Patricia	Nowalk	EXPLORING COVID-19 HOME TESTING AND ITS IMPACT ON COVID-19 VACCINE EFFECTIVENESS ESTIMATES
Aleda	Leis	EVALUATION OF TEST-NEGATIVE DESIGN ESTIMATES OF INFLUENZA VACCINE EFFECTIVENESS IN THE CONTEXT OF MULTIPLE, CO-CIRCULATING, VACCINE PREVENTABLE RESPIRATORY VIRUSES: A SINGLE-CENTER ANALYSIS
Susana	Monge	COMPARISON OF TWO METHODS FOR THE ESTIMATION OF COVID-19 VACCINE EFFECTIVENESS OF THE AUTUMNAL BOOSTER WITHIN THE VEBIS-EHR NETWORK IN 2022/23
Bette	Liu	MONITORING OF COVID-19 VACCINE EFFECTIVENESS AGAINST COVID-19 MORTALITY IN AUSTRALIA

14:00-15:30 - Virology and Pathogenesis: Virus-host cell interactions		
Anice	Lowen	DISPERSING INWARDS: HOW WITHIN-HOST DISPERSAL SHAPES INFLUENZA VIRUS DIVERSITY
Antoni	Wrobel	MOLECULAR DETERMINANTS OF INFLUENZA HAEMAGGLUTININ BINDING TO A PROTEIN RECEPTOR
Chengjun	Li	ABTB1 FACILITATES THE REPLICATION OF INFLUENZA A VIRUS BY COUNTERACTING TRIM4-MEDIATED DEGRADATION OF VIRAL NP PROTEIN
Kohei	Oishi	ARCHAEAL KINK-TURN BINDING PROTEIN MEDIATES INHIBITION OF ORTHOMYXOVIRUS SPLICING BIOLOGY
Kyle	Macauslane	INFLUENZA A VIRUS INFECTION INDUCES GLOBAL DESIALYLATION OF HOST GLYCOPROTEINS
17:00-18:30 - Interdisciplinary Session: Imprinting, Aging and viral infection		
Marios	Koutsakos	CONSERVATION OF MAJOR ANTIGENIC SITES WITHIN EACH ANTIGENIC LINEAGE UNDERPINS IMMUNOLOGICAL IMPRINTING TO THE INFLUENZA B VIRUS HAEMAGGLUTININ
Shuyi	Zhong	REPEATED VACCINATION EFFECTS ON IMMUNOGENICITY OF INFLUENZA VACCINE AMONG OLDER ADULTS IN HONG KONG
David LV	Bauer	FIRST ANTIGENIC EXPOSURES TO SARS-COV-2 SPIKE DO NOT INDELIBLY SHAPE SARS-COV-2 IMMUNITY
Esther	Kissling	VACCINE EFFECTIVENESS AGAINST INFLUENZA A(H1N1)PDM09 AND A(H3N2) AND BIRTH COHORT EFFECT: RESULTS FROM THE 2023–24 SEASON EUROPEAN VEBIS PRIMARY CARE MULTICENTRE STUDY
Isaac Cheuk Long	Chow	IMPACT OF INFLUENZA A(H3N2) VIRUS INFECTION ON THE ANTIBODY LANDSCAPES OF HEMAGGLUTININ AND NEURAMINIDASE PROTEIN IN OLDER ADULTS.
17:00-18:30 - Other Respiratory Viruses: RSV prevention and treatment		
Jeffery	Nielsen	NOVEL LIGAND-TARGETED IMMUNOTHERAPY FOR THE TREATMENT OF HUMAN RESPIRATORY SYNCYTIAL VIRUS
Lea	Separovic	RESPIRATORY SYNCYTIAL VIRUS VACCINATION AMONG OLDER ADULTS IN CANADA: NUMBER NEEDED TO VACCINATE AND ASSOCIATED COSTS TO PREVENT SEVERE OUTCOMES
Evangeline	Obodai	PROOF-OF-PRINCIPLE OF A TECHNOLOGY TRANSFER OF AN RSV NEUTRALIZATION ASSAY TO A GAVI ELIGIBLE COUNTRY
Antoine	Brault	ESTIMATES OF EFFECTIVENESS AND IMPACT OF NIRSEVIMAB ON HOSPITALISATIONS FOR RSV BRONCHIOLITIS IN FRANCE, 2023-2024 : A MODELLING STUDY
Christopher	Blyth	EVALUATING THE NIRSEVIMAB RSV PREVENTION PROGRAM IN WESTERN AUSTRALIA - EARLY INSIGHTS INTO PROGRAM IMPACT

17:00-18:30 - Public Health and Policy: Vaccines 2: from early development to the real world		
Cheng	Chang	PRE -CLINICAL COMPARISON OF SA-MRNA VS MRNA FLU VACCINES
Kelly	Lindert	EFFICACY AND IMMUNOGENICITY RESULTS OF MESSENGER RNA INFLUENZA VACCINE IN ADULTS 18-64
Hyeeun	Lee	SAFETY PROFILE AND BREAKTHROUGH INFECTIONS AMONG QUADRIVALENT INFLUENZA VACCINE(SKYCELLFLU) FOR INFLUENZA INFECTION IN SOUTH KOREA DURING 2023-2024
Danuta	Skowronski	XBB.1.5 VACCINE EFFECTIVENESS AGAINST MEDICALLY-ATTENDED COVID-19, INCLUDING JN.1-SPECIFIC CROSS-PROTECTION: ESTIMATES FROM THE COMMUNITY-BASED CANADIAN SENTINEL PRACTITIONER SURVEILLANCE NETWORK
Hannah C	Moore	INTEGRATING COMMUNITY ATTITUDES WITH POPULATION-BASED EPIDEMIOLOGICAL DATA FOR RSV IMMUNISATION POLICY: THE STAMP PROGRAM
17:00-18:30 - Virology and Pathogenesis Innate and mucosal immunity to infection		
Brendon Y	Chua	HIGH EXPRESSION OF OLEOYL-ACP-HYDROLASE UNDERPINS SEVERE AND LIFE-THREATENING RESPIRATORY VIRAL DISEASES
Philip	Mudd	CLONALLY EXPANDED TISSUE-RESIDENT CD8+ T CELLS RECOGNIZE CONSERVED INFLUENZA VIRAL PROTEINS IN THE LOWER AIRWAYS DURING ACUTE HUMAN INFECTION
Sarah	Londrigan	IDENTIFICATION OF NOVEL HOST PROTEINS THAT ARE ASSOCIATED WITH MACROPHAGE CONTROL OF INFLUENZA A VIRUS REPLICATION
Benjamin	Lindesy	MUCOSAL AND BLOOD TRANSCRIPTOME DIFFERENTIATES DIVERSE IMMUNE TRAJECTORIES FOLLOWING VACCINATION WITH LIVE ATTENUATED INFLUENZA VACCINE IN CHILDREN
Jiapei	Yu	TIME-RESOLVED SCRNA-SEQ REVEALS TRANSCRIPTION DYNAMICS OF POLARIZED MACROPHAGES WITH INFLUENZA A VIRUS INFECTION AND ANTIGEN PRESENTATION TO T CELLS

TUESDAY 1 OCTOBER 2024

11:30-13:00 - Clinical Sciences and Vaccinology: AVG IG Session		
Ultan	Power	IDENTIFICATION AND VALIDATION OF AZATADINE-DIMALEATE AS A POTENT ANTIVIRAL AGAINST SARS-COV-2: POTENTIAL FOR CLINICAL DEVELOPMENT ALONE OR IN COMBINATION WITH REMDESIVIR
Yuko	Tsuge	ANALYSIS OF THE ENSITRELVIR TREATMENT-EMERGENT AMINO ACID SUBSTITUTIONS OBSERVED IN THE SCORPIO-SR PHASE 3 TRIAL.
Nadine	Sicard	IMPLEMENTATION EVALUATION OF THE NIRMATRELVIR/RITONAVIR (PAXLOVID TM) ROLLOUT IN CANADA DURING THE COVID-19 RESPONSE: LESSONS LEARNED FOR PANDEMIC PREPAREDNESS
Ryuta	Uraki	DRUG SUSCEPTIBILITY AND THE POTENTIAL FOR DRUG-RESISTANT SARS-COV-2 EMERGENCE IN IMMUNOCOMPROMISED ANIMALS
Mirella	Salvatore	EMERGENCE OF ANTIVIRAL RESISTANCE IN THE IMMUNOCOMPROMISED HOST WITH SARS-COV2 INFECTION
11:30-13:00 - Interdisciplinary Session: Correlates of protection and immune responses to vaccination		
Brendan	Flannery	APPLICATION OF TEST-NEGATIVE DESIGN FOR SEROLOGIC CORRELATES OF PROTECTION AGAINST LABORATORY-CONFIRMED INFLUENZA AND COVID-19
Yang	Wang	POPULATION SUSCEPTIBILITY PRIOR TO OMICRON EMERGENCE, AND ANTIBODY CORRELATES OF PROTECTION AGAINST FIRST AND SECOND OMICRON WAVES: FINDINGS FROM THE HIVE STUDY
Tim	Russell	REAL-TIME ESTIMATION OF IMMUNOLOGICAL RESPONSES AGAINST EMERGING SARS-COV-2 VARIANTS
Sophie	Valkenburg	ADJUVANT ADVANTAGE IN A LONGITUDINAL RANDOMIZED CONTROL TRIAL OF ALTERNATING ENHANCED INFLUENZA VACCINES IN OLDER ADULTS
Boitumelo	Motsoeneng	HEMAGGLUTININ STALK-SPECIFIC FC-MEDIATED FUNCTIONS ARE ASSOCIATED WITH PROTECTION AGAINST INFLUENZA-ILLNESS AFTER SEASONAL INFLUENZA VACCINATION IN PREGNANT WOMEN
11:30-13:00 - Other Respiratory Viruses: SARS-CoV-2 and other virus transmission and evolution		
Carlos	Grijalva	ROLE OF IMMUNITY IN THE TRANSMISSION OF SARS-COV-2 INFECTIONS IN HOUSEHOLDS: EVIDENCE FROM CASE-ASCERTAINED STUDIES
Ooiean	Teng	BIOMARKERS OF EARLY SARS-COV-2 INFECTION PRIOR TO THE ONSET OF RESPIRATORY SYMPTOMS
Simon	Cauchemez	A NEW MODELLING FRAMEWORK TO DECIPHER THE CONTRIBUTION OF RNA VIRAL LOADS DYNAMICS ON HOUSEHOLD TRANSMISSION OF SARS-COV-2
Benjamin	Meyer	MUCOSAL IMMUNITY: THE KEY TO REDUCE SARS-COV-2 TRANSMISSION?
Sadegh	Niazi	UNVEILING AIRBORNE RISKS: ASSESSING RESPIRATORY VIRUS TRANSMISSION THROUGH COUGH PARTICLES
Harm	Van Bakel	THE ROLE OF PERSISTENT INFECTIONS IN SARS-COV-2 EVOLUTION
Amaya	Rojo-Fernandez	CIDS: A HOUSEHOLD COHORT STUDY OF COVID-19.

11:30-13:00 - Public Health and Policy: Vaccines 3: immunogenicity, efficacy and effectiveness		
Sascha	Ellington	INFLUENCE OF BIRTH COHORT ON 2023-2024 INFLUENZA VACCINE EFFECTIVENESS AGAINST A(H1N1)PDM09-ASSOCIATED ILLNESS IN THE UNITED STATES
Ausenda	Machado	COVID-19 VACCINE EFFECTIVENESS IN THE PAEDIATRIC POPULATION AGED 5–17 YEARS: A MULTICENTRE COHORT STUDY USING ELECTRONIC HEALTH RECORDS IN SIX EUROPEAN COUNTRIES
Stephany	Sánchez-Ovando	INFLUENZA VACCINE A(H1N1)PDM09 STRAIN CHANGE EFFECTS ON IMMUNOGENICITY AMONG REPEATEDLY VACCINATE HEALTHCARE WORKERS
Angie	Rose	VACCINE EFFECTIVENESS AGAINST INFLUENZA A IN OLDER ADULTS AND THE IMPACT OF CHRONIC CONDITIONS: RESULTS FROM THE I-MOVE AND VEBIS EUROPEAN HOSPITAL NETWORKS, 2015/16–2023/24
Ben	Cowling	REPEATED INFLUENZA VACCINATION EFFECTS IN A RANDOMIZED PLACEBO-CONTROLLED TRIAL (THE DRIVE STUDY)
Emily	Rayens	COMPARATIVE EFFECTIVENESS OF CELL-BASED VS. EGG-BASED INFLUENZA VACCINES IN PREVENTION OF INFLUENZA HOSPITALIZATION DURING THE 2022-2023 SEASON AMONG ADULTS 18-64 YEARS
Alicia	Stein	RELATIVE VACCINE EFFECTIVENESS OF CELL-BASED VERSUS EGG-BASED QUADRIVALENT INFLUENZA VACCINES AGAINST TEST-CONFIRMED INFLUENZA IN THE UNITED STATES 2022-23 INFLUENZA SEASON
15:00-16:30 - Clinical Sciences and Vaccinology: Antivirals and therapeutics		
James	Antoon	OSELTAMIVIR USE AND RISK OF SERIOUS NEUROPSYCHIATRIC EVENTS IN CHILDREN AND ADOLESCENTS
Fahmida	Chowdhury	ANTIMICROBIAL USE PATTERNS AMONG PATIENTS WITH INFLUENZA-ASSOCIATED SEVERE ACUTE RESPIRATORY INFECTIONS AT TERTIARY-CARE HOSPITALS IN BANGLADESH (2010–2023)
Taylor	Sandison	SAFETY DATA FROM PHASE 1 AND PHASE 2A STUDIES OF CD388, A DRUG FC-CONJUGATE FOR SEASONAL PAN-INFLUENZA PROPHYLAXIS
Jeremy. C.	Jones	BALOXAVIR ANTIVIRAL INTERVENTION PROTECTS FERRETS FROM SEVERE INFLUENZA A(H5N1) CLADE 2.3.4.4B VIRAL DISEASE AND NEUROINVASION
Larisa	Gubareva	MONITORING SUSCEPTIBILITY OF INFLUENZA VIRUSES TO BALOXAVIR: UPDATE ON TESTING ALGORITHM AND FINDINGS
15:00-16:30 - Other Respiratory Viruses: SARS-CoV-2 and other virus pathogenesis		
Louise	Rowntree	LONG COVID PATIENTS ESTABLISH AND MAINTAIN SARS-COV-2-SPECIFIC CD8+ T CELLS WITH EFFECTOR PHENOTYPE AT TWO YEARS AFTER INFECTION
Anika	Singanayagam	DEVELOPMENT AND EARLY RESULTS FROM A SARS-COV-2 DELTA VARIANT HUMAN INFECTION CHALLENGE MODEL.
Helen	Mostafavi	MECHANISMS DRIVING ENDOTHELIAL DYSFUNCTION IN ACUTE COVID-19
Jane	Sinclair	CARDIOVASCULAR SYMPTOMS OF PASC ARE ASSOCIATED WITH TRACE-LEVEL CIRCULATORY CYTOKINES THAT AFFECT THE FUNCTION OF PRIMARY HUMAN CARDIOMYOCYTES
Julie	McAuley	IDENTIFYING THE NEUROLOGICAL IMPACT OF COVID-19 IN A MOUSE OF MODEL OF SARS-COV-2 INFECTION

15:00-16:30 - Public Health and Policy: Sero-epidemiology		
Zhunan	Li	SEROLOGIC EVIDENCE OF CO-CIRCULATION OF THREE RESPIRATORY VIRUSES FROM A LONGITUDINAL POPULATION IMMUNITY STUDY IN THE UNITED STATES
Serena	Marchi	PREVALENCE OF INFLUENZA B/YAMAGATA VIRUSES FROM SEASON 2012/2013 TO 2021/2022 IN ITALY AS AN INDICATION OF A POTENTIAL LINEAGE EXTINCTION
Nokuthula	Linda	INFLUENZA SERO-PROTECTION DURING THE COVID-19 PANDEMIC: HUTS COMMUNITY COHORT STUDY, SOUTH AFRICA, 2021
Weijia	Xiong	USING ANTIBODY TITERS AS A MEASURE OF INFLUENZA POPULATION IMMUNITY: INSIGHTS FROM A LONGITUDINAL SEROLOGY STUDY IN HONG KONG, 2009-2014
Raquel	Guiomar	HIGHER SUSCEPTIBILITY IN YOUNGER ADULTS BORN FROM 1970 TO 1976 FOR INFLUENZA A(H1N1) INFECTION: RESULTS FROM A REPEATED SEROPREVALENCE SURVEY 2016 TO 2023
15:00-16:30 - Virology and Pathogenesis: Adaptive immune response to infection		
Ian	Wilson	DIVERSE BINDING MODES OF VH1-69 ENCODED ANTIBODIES TO THE INFLUENZA VIRUS HA STEM
Caroline	Page	DIFFERENTIAL IMMUNE RESPONSES ELICITED FROM CONTEMPORARY INFLUENZA B INFECTION ALLOW FOR ASYMMETRIC CROSS-PROTECTION BETWEEN THE LINEAGES
Thi Hoang Oanh	Nguyen	RECOVERY FROM SEVERE AND FATAL INFLUENZA VIRUS INFECTION RELIES ON EFFECTIVE ADAPTIVE IMMUNITY: POST-COVID-19 PANDEMIC EXPERIENCE
Kristin G-I	Mohn	IMMUNE KINETICS IN HOSPITALIZED PATIENTS FOLLOWING MODERATE AND SEVERE INFLUENZA INFECTION.
Wuji	Zhang	INTERFERON PATHWAYS ARE ENHANCED IN INFLUENZA-SPECIFIC B CELLS FOLLOWING INFLUENZA VIRUS INFECTION COMPARED TO VACCINATION
17:00-18:30 - Clinical Sciences and Vaccinology: Diagnostics and biomarkers		
Jeremy Chase	Crawford	OLAH AND ITS MAIN CATALYTIC PRODUCTS ACT AS EARLY BIOMARKERS OF LIFE-THREATENING ILLNESS FROM DIVERSE VIRAL RESPIRATORY INFECTIONS
Benjamin	Larsen	USING OCCLUDED CAS13 TO DETECT INFLUENZA MUTATIONS AT THE POINT OF CARE
Luca	Ferretti	DIGITAL CONTACT TRACING: INSIGHTS FROM A NEW TOOL TO REDUCE AND UNDERSTAND THE TRANSMISSION OF RESPIRATORY PATHOGENS
Jurre	Siegers	EVOLUTIONARY DYNAMICS AND ZOONOTIC POTENTIAL OF H6, H10, AND H11 AVIAN INFLUENZA VIRUSES: A COMPREHENSIVE STUDY FROM CAMBODIA, 2019-2022
Georgina	McCallum	THE HOST RESPONSE AS A NOVEL DIAGNOSTIC BIOMARKER FOR 'PRE-POSITIVE' VIRAL INFECTION

17:00-18:30 - Interdisciplinary Session: Epidemic and pandemic preparedness		
Marciela	De Grace	PROTECTION FROM PANDEMIC INFLUENZA ON DAY 1: BARDA'S VISION FOR INFLUENZA VACCINE DEVELOPMENT
Magdi	Samaan	PANDEMIC RISK ASSESSMENT OF AVIAN INFLUENZA A(H5N1) CLADE 2.3.4.4B VIRUSES USING THE WHO TIPRA
Honglei	Sun	POTENTIAL EPIDEMIC OR EVEN PANDEMIC OF H3NY AVIAN INFLUENZA A VIRUS: PUBLIC HEALTH CONCERN AND PREPAREDNESS
Wan Ting	Teo	A CONCEPTUAL APPROACH FOR PANDEMIC PREPAREDNESS PLANNING AGAINST DISEASE X
Alvin X.	Han	A NOVEL MATHEMATICAL FRAMEWORK TO INFORM GLOBAL ANTIVIRAL STOCKPILE SIZE AND DISTRIBUTION FOR INFLUENZA PANDEMIC MITIGATION
17:00-18:30 - Other Respiratory Viruses: SARS-CoV-2 novel treatments and prevention strategies		
Stephan	Ludwig	CLINICAL PROOF OF CONCEPT FOR A NOVEL HOST-TARGETED ANTI-INFECTIVE STRATEGY AGAINST COVID-19 AND OTHER ACUTE RESPIRATORY VIRAL DISEASES
Teresa	Aydillo	CONCOMITANT ADMINISTRATION OF SEASONAL INFLUENZA AND COVID-19 MRNA VACCINES
Rubina	Bunjun	CROSS-REACTIVE ANTIBODY RESPONSES TO SARS-COV-2 IN SOUTH AFRICA
Sam	Afkhami	A NEXT-GENERATION INHALED AEROSOL COVID-19 VACCINE FILLS THE GAP IN RESPIRATORY MUCOSAL IMMUNITY IN HUMANS
David	Hodgson	MEMORY B CELL PROLIFERATION DRIVES DIFFERENCES IN NEUTRALISING RESPONSES BETWEEN CHADOX1 AND BNT162B2 VACCINES
17:00-18:30 - Public Health and Policy: Epidemiology, transmission and control		
Sue	Huang	IMPACT OF COVID-19 AND INFLUENZA ON SHIVERS LONGITUDINAL COMMUNITY AND HOUSEHOLD COHORTS IN NEW ZEALAND
Sarah	Cox	INFLUENZA INCIDENCE AMONG CHILDREN AND ADULTS 6 MONTHS TO 49 YEARS: THE CASCADIA PROSPECTIVE COHORT STUDY, UNITED STATES, 2022-2023
Nancy Hiu Lan	Leung	MULTIPLE INTRODUCTIONS AND CO-TRANSMISSION OF RESPIRATORY VIRUSES IN SAME HOUSEHOLDS (TREV STUDY)
Jonathan	Temte	FACTORS ASSOCIATED WITH TRANSMISSION ACROSS THREE WAVES OF SARS-COV-2 IN A PROSPECTIVE COMMUNITY-BASED STUDY OF HOUSEHOLDS WITH SCHOOL-AGED CHILDREN – DANE COUNTY, WISCONSIN, 2020-2022
Cayla	Reddy	INFLUENZA ANTIBODY TITRES BEFORE AND DURING THE COVID-19 PANDEMIC: A COMMUNITY COHORT STUDY IN SOUTH AFRICA (PHIRST, PHIRST-C)

WEDNESDAY 2 OCTOBER 2024

11:30-13:00 - Interdisciplinary Session: Late Breaking Abstracts on H5N1 in new species

Amy	Baker	EXPERIMENTAL REPRODUCTION OF VIRAL REPLICATION AND DISEASE IN DAIRY CALVES AND LACTATING COWS INOCULATED WITH HIGHLY PATHOGENIC AVIAN INFLUENZA H5N1 CLADE 2.3.4.4B
Jenna	Guthmiller	A SINGLE MUTATION IN DAIRY COW-ASSOCIATED H5N1 VIRUSES INCREASES RECEPTOR BINDING BREADTH
Douglas	Reed	INHALATION OF AEROSOLIZED A/CHILE/25945/2023 (CLADE 2.3.4.4B H5N1) VIRUS TRIGGERS FEVER, SEVERE RESPIRATORY DISEASE, AND A LETHAL OUTCOME IN CYNOMOLGUS MACAQUES
Patrick	Reading	BOVINE MYXOVIRUS RESISTANCE PROTEIN 1 MEDIATES ANTIVIRAL ACTIVITY AGAINST HUMAN AND AVIAN INFLUENZA A VIRUSES
Justin	Shepard	BOVINE A(H5N1) INFLUENZA VIRUS RECEPTOR BINDING SPECIFICITY
Jonathan	Heeney	A COMPUTATIONALLY DESIGNED PAN-H5NX VACCINE INDUCES BROAD SUBTYPE NEUTRALISING ANTIBODY RESPONSES COMPARED TO WHOLE INACTIVATED H5 VACCINES
Charlotte	Kristensen	IN SITU EXPRESSION OF INFLUENZA A VIRUS RECEPTORS IN THE BOVINE MAMMARY GLAND ELUCIDATED BY LECTIN HISTOCHEMISTRY

11:30-13:00 - Other Respiratory Viruses: SARS-CoV-2 vaccines

Deborah	Cromer	PREDICTING COVID-19 BOOSTER IMMUNOGENICITY AGAINST FUTURE SARS-COV-2 VARIANTS AND THE BENEFITS OF VACCINE UPDATES
Vivek	Shinde	SAFETY AND IMMUNOGENICITY OF AN INVESTIGATIONAL INFLUENZA PROTEIN VACCINE AND COVID AND INFLUENZA COMBINATION PROTEIN VACCINE
Zifeng	Yang	A 10-VALENT COMPOSITE MRNA VACCINE AGAINST BOTH INFLUENZA AND COVID-19
Kevin	Selva	BOOSTING FOUR-MULA: CHARACTERIZING ELEVATED IGG4 FOLLOWING REPEATED COVID-19 MRNA BOOSTERS.
Carissa	Aurelia	FUNCTIONAL CONSEQUENCE OF INCREASED IGG4 LEVELS UPON REPEATED SARS-COV-2 MRNA VACCINATION.

11:30-13:00 - Public Health and Policy: Burden of disease

Jessie	Goldsmith	USING DATA FROM THE COVID PERIOD TO IMPROVE OUR UNDERSTANDING OF THE BURDEN OF INFLUENZA MORTALITY
Anand	Krishnan	INFLUENZA AMONG OLDER ADULTS IN INDIA: DISEASE BURDEN AND COST-EFFECTIVENESS OF INTRODUCTION OF A VACCINATION PROGRAM
Janine	Paynter	POPULATION-BASED SARI-INFLUENZA IN 2022 VS PRE-PANDEMIC BASELINE IN AUCKLAND, NEW ZEALAND
Jessica Y.	Wong	INFLUENZA-ASSOCIATED EXCESS MORTALITY ASSOCIATED WITH INFLUENZA B IN HONG KONG, 2014-2019
Nicole	Wolter	ATTRIBUTABLE FRACTION OF INFLUENZA AND RESPIRATORY SYNCYTIAL VIRUS IN INFANTS AGED <1 YEAR HOSPITALIZED WITH RESPIRATORY AND NON-RESPIRATORY ILLNESS IN SOUTH AFRICA, 2016-2018

11:30-13:30 - Virology and Pathogenesis: Pathogenesis and transmission		
Charlotte	Kristensen	MIND-BOGGLING: INFLUENZA A VIRUS PRESENCE IN THE BRAIN OF INOCULATED PIGS AND FERRETS
Lisa	Kercher	THE USE OF TELEMETRY AND WHOLE-BODY PLETHYSMOGRAPHY FOR ACQUIRING REAL-TIME PHYSIOLOGICAL DATA FOR IMPROVED HOST RESPONSE ANALYSIS DURING AN INFLUENZA VIRUS INFECTION IN FERRETS.
Mark	Zanin	S213P IN THE NON-STRUCTURAL PROTEIN 1 OF SUBTYPE H1N1 AVIAN INFLUENZA A VIRUSES MEDIATES AIRBORNE TRANSMISSIBILITY IN THE FERRET MODEL.
Stacey	Bartlett	THE ROLE OF NASAL INFLAMMATION IN THE TRANSMISSION OF INFLUENZA A VIRUS IN AN INFANT MOUSE MODEL
Michelle	Vu	IMPACT OF MULTIPLE DONORS ON TRANSMISSION EFFICIENCIES IN THE FERRET PLAYPEN MODEL
14:00-15:30 - Clinical Sciences and Vaccinology: Novel vaccines and platforms		
Irina	Isakova-Sivak	DEVELOPMENT OF A MODIFIED TRIVALENT LIVE ATTENUATED INFLUENZA VACCINE FOR COMBINED PROTECTION AGAINST SEASONAL INFLUENZA AND COVID-19
Tomer	Hertz	THE M2SR INTRANASAL H3N2 SINGLE-REPLICATION LIVE INFLUENZA VACCINE INDUCES MORE POTENT AND BROAD MUCOSAL SIGA RESPONSE IN OLDER ADULTS THAN THE HIGH-DOSE INACTIVATED FLUZONEHD VACCINE
Angus	Forster	LOWER DOSES OF QUADRIVALENT SEASONAL INFLUENZA VACCINE GENERATE SIGNIFICANTLY IMPROVED ANTIBODY TITRES DELIVERED WITH A SIMPLE TO APPLY SKIN PATCH (PHASE 1 STUDY)
Sean	Ray	A MINIMALIST, SELF-ADJUVANTING VACCINE ACHIEVES ROBUST IMMUNE RESPONSE TO CONSERVED INFLUENZA PEPTIDE M2E
Juan Manuel	Carreño Quiroz	DEVELOPMENT OF A MULTIVALENT NUCLEOSIDE-MODIFIED MRNA VACCINE THAT BROADLY PROTECTS AGAINST INFLUENZA A AND B VIRUSES
14:00-15:30 - Interdisciplinary Session: Past pandemics and future solutions		
Marc-Alain	Widdowson	WHO'S UNITY STUDIES: A STANDARDISED PREPAREDNESS FRAMEWORK CRITICAL FOR THE INVESTIGATION AND STUDY OF NOVEL OR RE-EMERGING RESPIRATORY PATHOGENS FOR AN EFFECTIVE AND PROPORTIONATE RESPONSE
Lauren	Steele	UNLOCKING SPATIALLY RESOLVED TRANSCRIPTOMIC AND PROTEOMIC SECRETS OF CENTURY-OLD LUNGS FROM THE 1918 'SPANISH' INFLUENZA PANDEMIC
Matthew	Miller	NEXT GENERATION APPROACHES FOR BROADLY PROTECTIVE MUCOSAL VACCINES
David	Muller	UNDERSTANDING THE ENHANCED IMMUNE RESPONSES TO HIGH-DENSITY MICROARRAY PATCH VACCINATION THROUGH SPATIAL TRANSCRIPTOMICS AND ANTIBODY REPERTOIRE ANALYSIS
Yiyang	Guo	OPTIMIZING SITUATIONAL AWARENESS DURING THE COVID-19 PANDEMIC: A SYNDROMIC SURVEILLANCE APPROACH FOR EARLY DETECTION OF SYMPTOM COMBINATIONS

14:00-15:30 - Public Health: Surveillance		
Félix Alberto Gundane	Albati	ESTABLISHMENT OF EPIDEMIC PARAMETERS AND THRESHOLDS FOR ASSESSING THE SEVERITY OF PANDEMIC INFLUENZA IN MOZAMBIQUE BETWEEN 2015 AND 2024.
Belinda L	Herring	EPIDEMIC PATTERNS OF RESPIRATORY SYNCYTIAL VIRUS IN SELECT COUNTRIES PARTICIPATING IN THE WHO PILOT SURVEILLANCE PROJECT, 2017–23
Eva	Kozanli	CO-INFECTION AND CO-CIRCULATION DYNAMICS OF SARS-COV-2 IN THE DUTCH RESPIRATORY SEASON OF 2022/2023
Camille	Esneau	THE PREVENT STUDY – AN ASSESSMENT OF VIRUS CIRCULATION IN THE HUNTER NEW ENGLAND COMMUNITY
Ariful	Islam	INTEGRATION OF SARS-COV-2 TESTING INTO INFLUENZA SENTINEL SURVEILLANCE FOR PANDEMIC PREPAREDNESS: FINDINGS FROM HOSPITAL-BASED INFLUENZA SURVEILLANCE IN BANGLADESH, 2020-2023
14:00-15:30 - Virology and Pathogenesis Zoonotic respiratory viruses: mechanisms of zoonose		
Nico Joel	Halwe	THE BAT-DERIVED H9N2 INFLUENZA A VIRUS DISPLAYS PRE-PANDEMIC TRAITS DESPITE A LIMITED HOST RANGE
Juan	Pu	AN EMERGING PB2-627 POLYMORPHISM INCREASES THE PANDEMIC POTENTIAL OF AVIAN INFLUENZA VIRUS BY BREAKING THROUGH ANP32 HOST RESTRICTION IN MAMMALIAN AND AVIAN HOSTS
Stephanie	Williams	AVIAN INFLUENZA A VIRUS POLYMERASE GENE LEADS TO TEMPERATURE-RESISTANT VIRAL RNA GENOME REPLICATION
Mark Anthony	Casel	AMINO ACID CHANGES IN HA IN HPAI H5N1 VIRUSES ALTER RECEPTOR BINDING AFFINITY AND ENHANCE VIRULENCE IN MAMMALIAN HOSTS
Francesco	Bonfante	GENETICALLY DIVERSE EUROPEAN H3NX AVIAN INFLUENZA VIRUSES RAPIDLY SELECT PRE-PANDEMIC ADAPTIVE MUTATIONS AT THE LEVEL OF THE HEMAGGLUTININ GENE UPON ONE PASSAGE IN FERRETS

EPIWATCH®

LAKE KARAKOL
250 MUTE SWANS AFFECTED
27 Dec 2023 Kazakhstan

KONOTOP RAION, SUMY OBLAST
98 CHICKENS **5** DUCKS AFFECTED
02 Jan 2024 Ukraine

LAKE KARAKOL
700 MUTE SWANS AFFECTED
07 Jan 2024 Kazakhstan

WEST BENGAL
1 HIMALAYAN GRIFFON AFFECTED
14 Jan 2024 India

KENDRAPARA DISTRICT
50 CROWS AFFECTED
20 Jan 2024 India

NIAMEY
OUTBREAK IN WILD & DOMESTIC BIRDS
04 Feb 2024 Niger

BOLHRADS'KYI, ODESSA
OUTBREAK IN WILD BIRDS
05 Feb 2024 Ukraine

NELLORE, ANDHRA PRADESH
OUTBREAK DECLARED
16 Feb 2024 India

KRASNY YAR
OUTBREAK IN WILD BIRDS
03 Mar 2024 Kazakhstan

OUAGADOUGOU
OUTBREAK AT POULTRY FARM
06 Mar 2024 Burkina Faso

TEXAS, IDAHO AND NEW MEXICO
OUTBREAK IN DAIRY CATTLE
22 Mar 2024 United States

WAHIS

28 Dec 2023 Kazakhstan
LAKE KARAKOL
227 MUTE SWANS AFFECTED

09 Feb 2024 Ukraine
BOLHRADS'KYI, ODESSA
4 MUTE SWANS AFFECTED

06 Mar 2024 India
NELLORE, ANDHRA PRADESH
1000 DOMESTIC POULTRY AFFECTED

13 Mar 2024 Burkina Faso
OUAGADOUGOU
641 POULTRY AFFECTED

25 Mar 2024 United States
TEXAS AND IDAHO
H5N1 OUTBREAK CONFIRMED

EPIWATCH® outperforms with real-time AI-driven epidemic intelligence

EPIWATCH® is an AI-driven rapid epidemic intelligence and early warning observatory that monitors a wide variety of data generated around the world 24/7 using 46 global languages. EPIWATCH® uses algorithms, ML and AI to identify early signals of potential outbreaks, prior to traditional detection by health authorities.

EPIWATCH®
The Biosecurity Program
Kirby Institute, UNSW Sydney
info@epiwatch.org
www.epiwatch.org

EPIWATCH

UNSW Kirby Institute

UNSW SYDNEY

Poster Session 1

Sunday 29 September 2024

Theme	Poster Board Numbers			
Clinical Sciences and Vaccinology	P001-P018	P175-P243	P783, P785, P787	
Interdisciplinary Session	P040-P058	P052-P057	P281-P306	
Public Health and Policy	P077-P108	P244-P306, P307-P418	P640, P781-P782	P788-P789
Virology and Pathogenesis	P141-P157	P419-P477		

Location: Great Hall

Clinical Sciences and Vaccinology 1. Diagnostics and biomarkers

P001	Olav	Hungnes	Influenza vaccine as a source of false positive PCR diagnosis of influenza during the mass vaccination period
P002	Denis	Selnihhin	A generic platform for labelling- and cell-free detection of virus neutralization
P003	Zifeng	Yang	Persistent respiratory microbiome dysbiosis in patients with severe influenza pneumonia contributes to a long course of illness and a poor clinical outcome
P004	Nicolas	Noulin	Bridging Airway Epithelial Cell Model and Human Challenge Studies
P005	Xia	Lin	Ages-specific antibody responses of H7N9 patients from 2013-2018 in China and its association with autoimmune markers and disease severity
P007	Claudia	Priddey	Does the severity of chest radiograph changes vary with the type of respiratory virus identified in patients with severe acute respiratory infections?

Clinical Sciences and Vaccinology 2. Antivirals and therapeutics

P008	Yusuf	Idres	Advances in Antiviral Strategies: siRNA-Mediated Inhibition of Human Metapneumovirus
P009	Arne	Matthys	Pan-influenza B control with an engineered single-domain antibody construct that targets hemagglutinin and neuraminidase: two birds with one stone.
P010	Hylemariam	Mengist	Novel virucidal synthetic polymers targeting enveloped viruses
P011	Mark	Sze To	Therapeutic role of anti-inflammatory synthetic immunomodulators on acute lung injury induced by influenza virus infection
P012	Melanie	Wu	Treatment with Diminazene aceturate, a putative ACE2 activator, reduces immunopathology in severe SARS-CoV-2 and influenza virus infections.
P013	Saira	Hussain	Multiple neuraminidase mutations in serial samples from an immunocompromised patient infected with A(H3N2)

Clinical Sciences and Vaccinology 3. Vaccine immunogenicity and effectiveness			
P014	Pirada	Allen	Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines
P015	Pavithra	Daulagala	MF-59-adjuvanted influenza vaccine elicits a superior anti-neuraminidase antibody response in the elderly than the standard-dose or high-dose influenza vaccines
P016	Georgia	Deliyannis	Induction of protective immune responses against SARS-CoV-2 using a receptor-binding domain (RBD) recombinant protein vaccine administered intranasally
P017	Wakaba	Fukushima	Influenza vaccine effectiveness for children aged 1 to 5 years according to the past vaccination history during the 2015-16 to 2017-18 seasons in Japan
P018	Tomoka	Matsuura	Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-naïve adults receiving the first four mRNA COVID-19 vaccine doses.
Interdisciplinary Session 1. Respiratory viruses in underserved populations			
P040	Assana	CISSE	Patterns of Non-influenza Respiratory Viruses Among Severe Acute Respiratory Infection Cases in Burkina Faso : A Surveillance Study
P041	Alexandra	Hinchcliff	Walking side by side: partnerships in research whilst enhancing vaccine access
P042	Sheikh	Jarju	Incidence and transmission of symptomatic and asymptomatic respiratory viral infections in The Gambia: results from a prospective household cohort study
P043	Adrian J	Marcato	Extending the World Health Organization Household Transmission Investigation Protocols: A pilot in Culturally and Linguistically Diverse communities in Victoria
P044	Hirono	Otomaru	Clinical characteristics of co-Infection with RSV and SARS-CoV-2 in central Vietnam
P045	Adrian	Trenholme	The feasibility of a community-based winter preparedness plan using a Samoan community-partnered research conference model
P046	Sikandar	Azam	The Circulation pattern of influenza A H3N2 in Biliran Island, Philippines, 2014-2019: insight into the global introduction and local persistence in the tropical context
P047	Michael	Otieno	Comparing the rate of pregnancy complications and birth outcomes in women with or without influenza-like illness Feb 2015 – Apr 2020
P048	Leigh	Howard	COVID-19 Pandemic Social Distancing and Declines in Human Rhinovirus, Coronavirus, Parainfluenza and Adenovirus Infections: Evidence from Household-based Cohort Studies in Lima, Peru
Interdisciplinary Session 2. Correlates of protection and immune responses to vaccination			
P049	Arada	Hirankitti	Different B cell receptor sequence and transcriptomic profiles following vaccination with BNT162b2 compared with AZD1222
P050	Rachael	Keating	Antibody signatures defined by isotype and specificity predict protection against diverse influenza A subtypes
P051	Mark	Loeb	Correlates of protection against SARS- CoV-2 infection and severity of disease in unvaccinated Canadian Hutterite Communities

Interdisciplinary Session 3. Epidemic and pandemic preparedness			
P052	Raven	Aguon	Pandemic & Epidemic Preparedness of Guam Public Health Laboratory, before, during, and after the SARS-CoV-2 Pandemic
P053	Liam	Brierley	Uncovering the contribution of environmental and ecological factors to predicted highly pathogenic avian influenza risks in wild birds
P054	Ioana	Ghiga	Strategic insights for pandemic preparedness: advancing pandemic influenza medical countermeasure stockpiling
P055	Mamadou Malado	Jallow	High circulation of avian influenza H9N2 subtype in live bird markets: a new emerging threat in Senegal
P056	Samson	Lee	BARDA Strategy to Improve U.S. Response to Influenza
P057	Jacqueline	Nolting	Kids and Pigs Sharing Flu; North American Swine-exhibitor Active Longitudinal Surveillance (NASALS) Program
P058	Kelly	da Costa	A pan-influenza monoclonal antibody neutralizes H5 strains and prophylactically protects through intranasal administration
Public Health and Policy 1. Vaccines (including but not limited to effectiveness, impact and safety)			
P077	Zubair	Akhtar	Effectiveness of standard dose influenza vaccine in preventing hospitalisation for cardiovascular diseases (CVD) among New South Wales residents aged ≥50 years in Australia during 2017
P078	Irina	Alymova	Comparing glycosylation of influenza virus rescued from epithelial human lung carcinoma and canine kidney cells: implications for MDCK-based vaccines
P079	Matthew	Biggerstaff	Pregnancy and infancy periods most at risk for influenza exposure and illness and the overlap with the influenza vaccination campaign in the United States
P080	Rovena	Daja	The impact of the COVID-19 pandemic on the behavior of pregnant women and parents of children regarding vaccination
P081	Mark	Katz	Influenza vaccination uptake and barriers to influenza vaccination among healthcare workers in Baku, Azerbaijan, September 2022- March 2023
P082	Nancy Hiu Lan	Leung	Coadministration of COVID-19 inactivated or mRNA vaccines with influenza vaccines (COVAR study)
P083	Marie Cecile	Levant	Third-year experience of high dose influenza vaccine in adults 60 years and older in Germany from a practice and safety perspective, 2021-2024
P085	Samantha	Marsh	Needle phobia, vaccine hesitancy, and knowledge of recommendations as potential barriers to uptake of influenza vaccine in New Zealand children: results from an online survey
P086	Caitriona	Murphy	Impact of reactogenicity of prior vaccination on COVID-19 booster vaccine uptake, a longitudinal observational cohort study in Hong Kong
P087	Sutthichai	Nakphook	Influenza virus circulation and vaccine effectiveness during June 2021–May 2023 in Thailand
P088	Koki	Numakura	Dynamics of serum anti-spike antibody titer across different SARS-CoV-2 infection and vaccination histories.
P089	Janine	Paynter	Examining the effectiveness of two and three doses of Comirnaty mRNA vaccine during the 2022 Omicron wave (BA.1 and BA.2 variants) in Aotearoa New Zealand

P090	Angie	Rose	Interim 2023/24 influenza A vaccine effectiveness: VEBIS European hospital multicentre study, September 2023 – January 2024
P091	Joseph	Servadio	Influenza vaccination allocation in tropical settings under constrained resources
P092	Jiatong	Sun	Influenza Vaccine Effectiveness among Primary and Secondary School Students in Shenzhen during the 2023/24 Influenza Season
P093	Peng	Yang	Risk factors for breakthrough infection following COVID-19 vaccination in Beijing, China, 2022
P094	Tatiana	Kotomina	Live attenuated influenza vaccine as a promising viral vector for the design of T cell-based vaccines against acute respiratory viruses
P095	Mark	Katz	Influenza vaccine coverage among patients hospitalized in the European Severe Acute Respiratory Infection Vaccine Effectiveness Network during the 2022-2023 and 2023-2024 influenza seasons
Public Health and Policy 2. Sero-epidemiology			
P096	Kalee	Rumfelt	RSV Pre-fusion F Antibody Titer Changes in RSV Cases and their Asymptomatic Household Contacts from 2014 to 2023
P097	Claudia Maria	Trombetta	A Comprehensive Investigation of Exposure to Influenza Viruses A, B, C And D In Dogs
P098	Claudia Maria	Trombetta	Seroprevalence investigation of influenza d virus among livestock farm workers in southern Italy
P099	Sook-San	Wong	Age-specific influenza antibody seroprevalence and waning patterns in Hong Kong between 2020 to 2023
P100	Malet	Aban	Immunity to zoonotic influenza viruses in individuals vaccinated with seasonal influenza vaccines
P101	Lorin	Adams	Characterisation of the immune landscapes of poultry workers in Bangladesh using a high-throughput live-virus neutralisation assay.
Public Health and Policy 3. Forecasting, seasonality and surveillance			
P102	David	Broderick	RSV Severity in 2021 and 2022: Applying the WHO Severity Assessment Framework
P103	Antonia	Ho	Enhanced syndromic surveillance of hospitalised severe acute respiratory illness (SARI) in adults in Glasgow, Scotland: 2022/23 and 2023/24 winter seasons
P104	Rebecca	Kondor	Overview of the Influenza “Genotype to Phenotype” and Implementation of Antigenic Inference
P105	Christine	Marizzi	How can we engage the community in pandemic preparedness and response? Meet the New York City Virus Hunters community science initiative
P106	Rita	Mark	Aetiology of influenza-like illness and severe acute respiratory illness among children ≤5years old in sentinel surveillance sites, Papua New Guinea, 2023-2024.
P107	Adamu Tayachew	Mekonnen	Predominant Circulation of RSV type B in Ethiopia: Report from ILI and SARI surveillance program, 2023-2024
P108	Kasper	Pedersen	Surveillance of Influenza A Virus in free range organic pigs on the highway of migrating birds with HPAIV

Virology and Pathogenesis 1. Virus-host cell interactions			
P141	Jenny Ching Man	Chan	Immuno-organoid Co-culture Model to Study the Replication and Pathogenesis of Influenza A Virus
P142	Rachel HH	Ching	Application of Human Respiratory Organoids for Studying Tropism and Pathogenesis of Influenza and Coronavirus Infection
P143	Vanessa	Co	Impact of SARS-CoV-2 Infection on Respiratory Sensory Neurons
P144	Camilla Tvedt	Ekanger	Human airway and lung organoid model to study influenza A(H1N1) virus infection
P145	Miria	F. Criado	Characterization of avian influenza viruses from different avian species in chicken embryo-derived primary cell cultures
P146	Brad	Gilbertson	Identification of molecular factors that influence reassortment of highly pathogenic avian influenza H5 viruses
P147	Umut	Karakus	Novel H19 influenza A virus exhibits species-specific MHC class II receptor usage
P148	Mengyao	Li	Targeting ARF4 mediated intracellular transport as broad-spectrum antivirals against pathogenic RNA viruses including influenza A virus and SARS-CoV-2
P149	Mila B.	Ortigoza	Mitigating infectiousness and transmissibility of influenza viruses in infant mice by using a broadly acting neuraminidase targeting host sialic acids in the upper respiratory tract
P150	Maximillian	Woodall	Nasal cells from older adults exhibit early pro-fibrotic responses to SARS-CoV-2, which facilitates viral replication and spread
Virology and Pathogenesis 2. Innate and mucosal immunity to infection			
P151	Betina Lyngfeldt	Henriksen	Obesity and associated meta-inflammation dysregulate the innate antiviral immune response to swine influenza A virus
P152	Dorothee	Reuss	Modelling the outcome of co-infections with SARS-CoV-2 and seasonal influenza viruses
P153	Tereza	Masonou	Single cell analysis of the expression and abundance of □2,3 sialyltransferase genes in human respiratory, oral, and corneal tissues: implications for avian H5N1 influenza virus zoonosis.
Virology and Pathogenesis 3. Adaptive immune response to infection			
P154	Marina	Good	Recent H1N1 antigenic drift in the HA receptor binding site impacts broadly neutralizing antibody binding and viral fitness
P155	Mengxiao	Luo	Ultrapotent novel class I neutralizing antibodies inhibit a broad range of SARS-CoV-2 variants including XBB.1.5, BA.2.86 and JN.1 sublineages
P156	Tejas	Menon	Generation of influenza-specific memory CD8+ T cell subsets across the human lifespan
P157	Chris Ka Pun	Mok	Sequential infections of heterologous influenza (H1N1) viruses lead to antigenic imprinting for both hemagglutinin and neuraminidase

Exhibition Hall

Clinical Sciences and Vaccinology 1. Diagnostics and biomarkers

P175	Xuemin	Chen	Development of novel functional assays of Fc effector antibody responses to SARS-CoV-2
P176	Herve	Kadjo	Setting up a sequencing platform with the MinION MK 1c for Tracking SARS-CoV-2 variants in Cote d'Ivoire (AFROSCREEN project)
P177	YUN-KYUNG	KIM	Decision support system to approach the influenza-like illness in Korean children
P178	Marie	Kirby	Update to the CDC H3 real-time reverse transcription PCR assay (ver 2) for detection of seasonal influenza A(H3N2) viruses
P179	Wanitchaya	Kittikraisak	The feasibility and performance of participant-collected mid-turbinate nasal swabs for detection of influenza virus, respiratory syncytial virus, and human metapneumovirus infections among pregnant women
P180	Yoke Lee	Low	Innovative approach in evaluating various Rapid Influenza Diagnostic Testing (RIDT) performance
P181	Victor Daniel	Miron	Predictors of hospitalization length and acute respiratory failure in patients with influenza - data from Romania
P182	Elissa	Robbins	Multi-center Clinical Performance Evaluation of a Molecular Point of Care Test for SARS-CoV-2 & Influenza A/B
P183	SANDRA	Semi	In-house Evaluation of the diagnostic capabilities of the two widely used RATs for Point of Care SARS-CoV-2 Testing in Samoa
P184	Nobuhiro	Takemae	Target capture-based next generation sequencing of respiratory viral genomes in clinical specimens
P185	Siriporn	Yomrat	A promising target for detection of further SARS-CoV-2 variants
P186	Alexandra	Rak	Strain-independent detection of SARS-CoV-2 in infected cells with a rapid simplified assay
P187	Nicolas	Noulin	Use of Multiplex PCR for screening and eligibility of human challenge study participants at entry to quarantine.
P188	Marcus	Tong	Low 1,5AG is associated with hyperglycaemic events and an impaired T cell response in response to ex vivo stimulation with influenza virus
P189	Chikondi	Peno	The potential of saliva as an accessible and sensitive sample type for the detection of respiratory pathogens: a scoping review
P190	Masatoki	Sato	Clinical and virologic impacts of respiratory viral co-infections in children with influenza
P191	Alexandra	Rak	Slow evolutionary changes in influenza nucleoprotein influence its antigenicity and cross-protective potential
P192	Jin	Gao	NA Active Site Proximity Assay Enables Rapid Determination of Inhibitory Antibody Titers and Antigenic Drift in Field Strains
P193	Na	Liu	Immune correlates with disease severity in older patients after SARS-CoV-2 BA.2 infection in Hong Kong
P194	Bingyi	Yang	Intrinsic breadth of antibody cross-reactivity in seasonal influenza A viruses

P195	Yiyang	Guo	Preliminary findings from quantification of SARS-CoV-2 viral shedding via lateral-flow rapid antigen tests
P196	Megan	Hansen	Using mathematical modeling to evaluate the impact of different distribution strategies of multiplex-PCR diagnostics for SARS-CoV-2, seasonal influenza viruses, and RSV
P197	Kevin	Kuchinski	Surveillance of highly pathogenic avian influenza viruses in sediment from wild bird habitats using targeted genomic sequencing
P198	Claire	Smith	Elevated neutrophil MPO and NE following reverse migration across RSV-infected co-cultures, replicate levels seen in the blood of infants with RSV bronchiolitis
P199	Tiffany G.	Harris	Antigen-positivity and infectiousness >14 days after SARS-CoV-2 infection among nursing home residents and staff
P200	Claudia	Priddey	Detection of multiple respiratory viruses is associated with more severe chest radiograph abnormalities in patients with severe acute respiratory infections
P201	Dmitriy	Pereyaslov	Summary Analysis of the 2023 WHO GISRS External Quality Assessment Programme for Detection of Influenza and Severe Acute Respiratory Syndrome Coronavirus 2 Viruses by RT-PCR
Clinical Sciences and Vaccinology 2. Antivirals and therapeutics			
P202	Eunseo	Bae	H1N1 nanobody development and therapeutic efficacy verification in H1N1-challenged mice
P203	Guy	Boivin	A protectin DX (PDX) analogue with in vitro and in vivo activities against influenza A(H1N1) virus
P204	Mark Anthony	Casel	Nsp8-TP25 Peptide as a Promising Therapeutic Agent Targeting the SARS-CoV-2 RdRp Complex
P205	Andrew	Catchpole	Assessing Immunomodulators in Human Challenge Studies: Insights from Wild-Type Influenza Infections in Healthy Adults and Rhinovirus Infections in Patients with Asthma"
P206	Wenqing	Gao	RNA Interference Against Respiratory Syncytial Virus: Intranasal and Intravenous Delivery Strategies
P207	Danielle	Groves	Evaluation of SARS-CoV-2 RNA polymerase inhibitors using single-molecule FRET extension assays
P208	Kenrie Pui Yan	Hui	Farnesyltransferase inhibitor Lonafarnib regulates cytokine production in influenza A virus infected human alveolar epithelial cells and macrophages
P209	Adi	Idris	Extracellular vesicles loaded with long antisense RNAs repress SARS-CoV-2 infection
P210	Tonia	Kam	Dual roles of platelet-derived growth factor receptor in avian influenza A virus infection
P211	Yeonglim	Kang	Deciphering the Role of Kallikrein Proteases in Human Betacoronavirus Pathogenesis: Insights for Therapeutic Strategies
P212	Surender	Khurana	SARS-CoV-2 hyperimmune immunoglobulins and recent lots of IVIG provide broad coverage against circulating SARS-CoV-2 variants.

P213	Surender	Khurana	MONOCLONAL ANTIBODIES TARGETING SITES IN RSV ATTACHMENT G PROTEIN PROVIDE CROSS-PROTECTION AGAINST RSV A AND RSV B
P214	Sohyun	Lee	Identifying Novel Antiviral Candidates against Respiratory Viruses through a High-Throughput Screening-based Assay
P215	Wenjun	Liu	The extracellular cyclophilin A-integrin □2 complex as a therapeutic target of viral pneumonia
P216	Angel Po Yee	Ma	Unravelling the protein cargo responsible for the therapeutic effects of mesenchymal stromal cell-derived extracellular vesicles in reversing influenza A/H5N1-associated acute lung injury
P217	Taylor	Sandison	Pharmacokinetics and Safety of CD388 Following Subcutaneous Administration in Healthy Japanese Participants
P218	Takahiro	Takazono	Real-world, retrospective comparative cohort study of severe outcomes in COVID-19 outpatients at high risk of severe illness treated with ensitrelvir or no antiviral treatment
P219	Alison	West	Naturally derived peptides as potential treatment for severe influenza
P220	Maximillian	Woodall	Remdesivir and nirmatrelvir show consistent synergistic efficacy across ancestral and newly emerged SARS-CoV-2 clinical isolates
P221	Lin	Yang	Chain Termination Effects of Chemically Modified Nucleotide Analogs on SARS-CoV-2 RNA dependent RNA Polymerase
P222	Muhammad	Yasir	Control of aerosolised coronavirus and type A Influenza virus with Catmint essential oil vapours
P223	Stella	Zhang	Use of Ribavirin in immunocompetent paediatric patients with severe RSV disease: a case series
P224	Andrew	Catchpole	Newly developed influenza challenge agent panel based on recently circulating strains demonstrate high infectivity, symptomatology and febrile illness rates
P225	Jeffery	Nielsen	Ligand-Targeted Immunotherapy for the Rapid Clearance of Influenza Infections
P226	Danlei	Liu	Seasonal influenza surveillance and antivirals selection in vitro
P227	Hillary	Vanderven	Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza
P228	Harry	Stannard	Replication of contemporary A(H1N1)pdm09, A(H3N2) and B/Victoria lineage influenza viruses in the upper and lower respiratory tract of ferrets.
Clinical Sciences and Vaccinology 3. Vaccine immunogenicity and effectiveness			
P229	Andrew	Catchpole	Vaccine and Drug Efficacy Evaluations in Viral Challenge Models: Enhancing Self-Assessment Diary Cards Through inclusion of Patient Perception Questionnaires
P230	Carolyn A	Cohen	Antibody quality from homologous and heterologous vaccination against SARS-CoV-2 infection
P231	Yulia	Desheva	The immune response to homologous and drift influenza viruses after immunization with seasonal influenza vaccines
P232	Othmar	Engelhardt	Selecting influenza viruses for the development of a Controlled Human Infection Model (CHIM)

P233	Annette	Fox	Enhanced influenza vaccines extend A(H3N2) antibody reactivity in older adults but attenuating effects of prior vaccination persist
P234	Mendel	Haag	Relative vaccine effectiveness of MF59®-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017–2020 influenza seasons
P235	Chimuka	Handabile	Immunogenicity and protective efficacy of a co-formulated two-in-one inactivated whole virus particle COVID-19/influenza vaccine
P236	Takuya	Hemmi	Exploring useful vaccine antigen by SARS-CoV-2 spike protein characterization and immunogenicity testing
P237	Tomer	Hertz	Susceptibility to SARS-CoV-2 Omicron infection corresponds with reduced ADCC activity
P238	Brittany	Hill	Antibodies from VITT patients induce a prothrombotic endothelial cell phenotype
P239	Sarah	Jalloh Lartey	Dissecting hemagglutinin and neuraminidase inhibiting antibody responses after quadrivalent inactivated influenza vaccine immunisation in European children and elderly
P240	Prathanporn	Kaewpree-dee	Superior immunogenicity of adjuvanted influenza vaccine in older adults.
P241	Ayane	Kasamatsu	Antibody response after the third COVID-19 mRNA vaccination among naïve residents in geriatric intermediate care facilities in Japan: A multicenter prospective cohort study
P242	Surender	Khurana	Cross-reactive immunity against the SARS-CoV-2 Omicron variants is low following SARS-CoV-2 infection or vaccination in children
P243	Praboda	Kuruppua-rachchi	Evaluating the antigen specific functional antibody responses and antibody quality of repeated seasonal influenza vaccination in healthy adults in Hong Kong
Clinical Sciences and Vaccinology 4. Novel vaccines and platforms			
P783	Jessica	Gallon	Six-Month Safety and Immunogenicity of Next-Generation mRNA-Based Seasonal Influenza Vaccines, Including Additional A/H3N2 Strains in Adults: Results from a Phase 1/2 Randomized Trial
P784	Jessica	Gallon	Genetic and Antigenic Variability of Circulating Influenza A/H3N2 During the 2019/20 Northern Hemisphere Influenza Season
P785	Jessica	Gallon	Six-Month Safety and Immunogenicity of an mRNA-Based Seasonal Influenza Vaccine (mRNA-1010) In Medically Stable Adults: A Randomized, Observer-Blind, Active-Controlled Phase 3 Study
P786	Jessica	Gallon	Comparison of case definitions for influenza and symptoms associated with severity in a prospective adult cohort
P787	Jessica	Gallon	Safety and Immunogenicity of an mRNA-Based Seasonal Influenza Vaccine (mRNA-1010) Compared to Standard Dose and High Dose Vaccine Comparators
P788	Jessie	Goldsmith	Variability of influenza vaccine effectiveness (VE) by subtype: a systematic review and meta-analysis of test-negative design studies
P789	Aspen	Hammond	Temporal dynamic clustering of influenza activity across the globe

Interdisciplinary Session 1. Respiratory viruses in underserved populations			
P244	Claudia	Bloy	Detection of multiple respiratory viruses is associated with more severe chest radiograph abnormalities in patients with severe acute respiratory infections
P245	Keng Yih	Chew	Elevated BMI reduces the humoral response to SARS-CoV-2infection
P246	Rita	Mark	Validation of the Flu/Sc2 Multiplex Assay for the detection of Influenza A/B and SARS-CoV-2 in Papua New Guinea (PNG), September 2023 to April 2024
P247	Victor	Opere	Cohort for Acute Respiratory Disease Surveillance among Pregnant Women and their Babies: Lessons Learned from Recruitment and Retention of Participants in Western Kenya
P248	Claudia	Priddey	Does the severity of chest radiograph changes vary with the type of respiratory virus identified in patients with severe acute respiratory infections?
P249	Masafumi	Seki	Clinical differences between COVID-19- and influenza-related pneumonia during the omicron variant surge in Japan
P250	Nikki	Turner	Respiratory illness presentation patterns to Aoteoroa New Zealand (NZ) primary care by ethnicity and social deprivation measures through the SARS-CoV2 pandemic
P252	Lin	Yang	Effects of Multiple Out-of-home Environmental Exposures on Acute Respiratory Illness in Community-Dwelling Older People: A Prospective Cohort Study
P253	Asaph	Chun	Prevalence and Risk Factors of Pediatric Depression in the COVID-19 Pandemic: a National Case Study
P254	Amita	Jain	Evolutionary analysis of Envelope gene of SARS CoV-2 variants circulating in Uttar Pradesh, India
P255	Amita	Jain	Epidemiology of Respiratory Syncytial Virus causing respiratory illnesses: 10 years' data from a tertiary care facility in Northern India
P256	Shruti	Radera	Epidemiology and clinical presentation of Influenza virus related illnesses; data from a tertiary care hospital of Northern India
P257	Zubair	Akhtar	Incidence of recurrent cardiovascular events among patients with acute MI during the first wave of COVID-19 pandemic in Bangladesh
P258	Zirke	Wiid	Estimated incidence of hospitalisations and deaths attributable to RSV infections in adults in Australia between 2010 and 2019
Interdisciplinary Session 2. Correlates of protection and immune responses to vaccination			
P259	Mariana	Alcocer Bonifaz	Understanding antibody mediated mechanisms of cross-protection against heterosubtypic influenza virus infections
P260	Samuel	Cheng	Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
P261	Annelies	De Rooij	Antibody responses against SARS-CoV-2 variants: a population-based cohort study
P262	Ruben	Donis	The Quest for Correlates of Protection for COVID-19 Vaccines: Past, Present and Future

P263	Othmar	Engelhardt	Towards establishing an international standard for antibody against the group 1 HA stalk domain
P264	Faith	Ho	Immunogenicity of Twice-annual Influenza Vaccination in Older Adults in Hong Kong: A Randomized, Controlled Trial (the RETAIN study)
P265	Faith	Ho	Homologous and heterologous antibody responses to influenza vaccination
P266	David	Hodgson	serojump: a framework to identify infections using serological data
P267	Takuma	Kobayashi	Factors influencing pre-existing anti-influenza B virus antibody levels in children admitted to the intensive care unit for influenza B virus respiratory infection
P268	Nelia Phuti	Manamela	SARS-CoV-2 vaccine modalities elicit differential Fc effector functions
P269	Nicole	Messina	Effect of BCG vaccination on immune responses to SARS-CoV-2 and COVID-19 vaccination
P270	Margarita	Mishina	Development of a pipeline to study the immunoglobulin repertoires of antibody-secreting cells and memory B cells post-influenza vaccination.
P271	Kei	Miyakawa	Rapid detection of neutralizing antibodies against influenza viruses using HiBiT-tagged virus-like particles
P272	Francesca	Mordant	Understanding the factors that influence SARS-CoV-2 neutralising antibody titres measured using different assays
P273	Van Hung	Nguyen	Modelling the relative vaccine effectiveness of ARCT-154 versus BNT162b2 in younger and older adults
P274	Sankarasubra-manian	Rajaram	Modelling the relative vaccine effectiveness of ARCT-154 versus BNT162b2 using immunogenicity data
P275	Kaori	Sano	Establishment of a high throughput bead-based, antigen specific secretory IgA antibody detection system.
P276	Stacey	Schultz-Cherry	Influenza vaccine delivery platforms induce distinct antibody profiles during pregnancy that impact protection of offspring
P277	Tanaya	Siripoon	Perspectives: Influenza Immune Correlates of Protection among High-Risk Populations
P278	Mai-chi	Trieu	Longer persistence of seroprotective antibodies after seasonal influenza vaccination than infection with A/H1N1 and B but not A/H3N2 viruses
P279	Mai-chi	Trieu	Increased neutralising antibodies and memory B cells against Omicron variants after bivalent COVID-19 booster vaccination
P280	Carol	Weiss	Antigenic assessments of SARS-CoV-2 variants using both human and hamster sera help inform decisions about the need to update variant antigens in COVID-19 vaccines
Interdisciplinary Session 3. Epidemic and pandemic preparedness			
P281	Presa	Chanthala-vanh	Supporting molecular detection and characterisation of respiratory viruses with epidemic and pandemic potential in the Asia Pacific Region.
P283	Ioana	Ghiga	Allocation of pandemic products: what have we learned and what are we doing to prepare better?
P284	Rebecca	Gillespie	A Nanoparticle Co-displaying Influenza Hemagglutinin Stem Trimers of Multiple Subtypes Elicits Protective Immunity in Nonhuman Primates from Severe H5N1 Influenza Disease

P285	Shoshanna	Goldin	Global production capacity of seasonal and pandemic influenza vaccines in 2023
P286	Chelsey	Griffin	The Impact of Influenza Vaccination of Health Workers on COVID-19 Vaccine Rollout and Uptake in Low- and Middle-income Countries
P287	Imantha	Gunasekera	Obtaining Influenza Prevalence Estimates for High Resolution Administrative Levels using Deep Learning & MCMC
P288	Chuong	Huynh	Analyses of Opportunities and Gaps to Improve U.S. Approaches to Influenza Vaccine Medical Countermeasure Development
P289	Md Saiful	Islam	Social science intelligence: A critical approach to preventing, preparing for, and responding to future pandemics.
P290	Alexander	Kennedy	Modelling the health and economics benefits of cell-based vaccine intervention in an influenza pandemic
P291	Van	Lo	The substitutions of N121T and N121S on SARS-CoV-2 spike protein affect serum neutralization and are involved in heme binding
P292	Ann	Moen	Preparedness and Resilience for Emerging Threats (PRET): operational tools, training and networks for national pandemic preparedness for respiratory pathogens
P293	Ravi	Naidu	Enhancing Pandemic Preparedness in Fiji: Lessons Learned from COVID-19 Mortality and Epidemiology Study
P294	Van Hung	Nguyen	Modelling the public health benefits of early versus late vaccination in a pandemic situation in the US: the influenza case study
P296	Mousumi	Roy	Modelling infectious disease transmission with human mobility.
P297	Nadine	Sicard	Strengthening Public Health Science Preparedness ahead of the next Pandemic: establishing multidisciplinary research priorities and science advice mechanisms for avian influenza A(H5N1) in Canada.
P298	Shidan	Tosif	Infection X – An Australian research platform for emerging infections of interest
P299	Diana	Wong	SI-Traceable Genetic Reference Materials for Pathogens of Pandemic Concern
P300	Jessica Y.	Wong	Establishing thresholds for the impact of influenza epidemics in Hong Kong
Interdisciplinary Session 3. Epidemic and pandemic preparedness, Clinical Sciences and Vaccinology 3. Vaccine immunogenicity and effectiveness			
P302	Matthew	Hohenbo-ken	A Randomized Immunogenicity, Safety and Tolerability Dose Ranging Study of Different Formulations of an Adjuvanted or Non-Adjuvanted Cell Culture-derived A/H2N3 Influenza Vaccine in Healthy Adults
P303	Kristina	Lu	Dose-sparing vaccination strategies for induction of protective immunity using A/H5 influenza virus vaccines
P304	Yuping	Duan	Evaluating COVID-19 vaccination resource allocation in 2021 in Beijing, China
P305	Jingyan	Huang	Age-specific COVID-19 model with transmissions and interventions and its applications to COVID-19 epidemics in Singapore
P306	Cong Khanh	Nguyen	High Burden of Influenza and COVID-19 Hospitalization in Post-Pandemic, Hospital Admission Survey in Quang Ninh Province, Vietnam, 2017-2022

Public Health and Policy 1. Vaccines (including but not limited to effectiveness, impact and safety)			
P307	Mathieu	Bangert	Influenza Vaccination Coverage Gaps in Older Adults in Germany: A Claims Data Analysis, 2016-2022
P308	Lauren	Bigalke	Global Influenza Vaccines R&D Roadmap: Tracking Funding and Investment
P309	Young June	Choe	Characterization of Brighton Collaboration criteria for myocarditis and pericarditis following COVID-19 vaccine in Korean adolescents
P310	Huiying	Chua	Waning over time in influenza vaccine effectiveness against influenza-associated hospitalization in children
P311	Marciela	Degrace	Protection from Pandemic Influenza on Day 1: BARDA's Vision for Influenza Vaccine Development
P312	Shuaibing	Dong	Effectiveness of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2.2 Infection in Beijing, China, 2022: A Cohabitation Retrospective Cohort Study
P313	Sascha	Ellington	2023–24 Seasonal Influenza Vaccine Effectiveness — United States
P314	Brendan	Flannery	Detecting bias in influenza vaccine effectiveness due to at-home COVID testing before healthcare seeking: implications for observational studies of vaccine effectiveness
P315	Yutaro	Furukawa	Examining the role of personal beliefs as mediators in the relationship between individual-level social capital and COVID-19 vaccine intention: A Cross-Sectional Study in Japan
P316	Balasubramani	G.K	Causal mediation framework to identify the impact of influenza vaccination on patients' self-reported severity of influenza infection
P317	Fiona	Giannini	Modelling the impact of Western Australia's first RSV immunisation program for all infants
P319	Chelsey	Griffin	Health Workers' Knowledge, Attitudes, Practices, and Perceptions on Influenza Vaccination in Nine Middle-Income Countries
P320	Megumi	Hara	Association between perception of SARS-CoV-2 and COVID-19 vaccine misinformation and COVID-19 Vaccination uptake in Japan
P321	Rebecca	Harris	Bias in simulated vaccine effectiveness estimates due to low statistical power and uncontrolled confounding: implications for meta-analysis and evidence-based decision making
P322	Michael	Ison	Persistent efficacy of the respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 years
P323	Mark	Katz	Influenza vaccine effectiveness in preventing influenza-associated hospitalisations in the WHO European Region, European Severe Acute Respiratory Infection Vaccine Effectiveness Network (EuroSAVE), October 2023–May 2024
P324	Esther	Kissling	Does SARS-CoV-2 self-testing bias vaccine effectiveness estimates in test-negative studies in primary care? A simulation study to assess magnitude, direction and control of collider bias
P325	Esther	Kissling	Effectiveness of autumn 2023 COVID-19 vaccines administered in Europe: results from the VEBIS test-negative design study at primary care level

P326	Kin On	Kwok	Reducing vaccination latency with trust: Insights from Hong Kong's COVID-19 vaccination campaign for future pandemic preparedness
P327	Karen	Laurie	Delaying the Seasonal Influenza vaccine Strain Recommendation and the impact upon vaccine availability.
P328	Marie Cecile	Levant	A nationwide retrospective cohort study to assess the relative vaccine effectiveness of high-dose compared to standard dose influenza vaccines in France during the 2022-2023 season
P329	Xing	Li	Assessment of antibodies elicited by recombinant hemagglutinin protein and hemagglutinin from an egg- or cell-grown H7n9 candidate vaccine virus
P330	Susana	Monge	Estimated impact of nirsevimab on RSV hospitalisations in children aged <1 year in Spain, season 2023/24
P331	Tomas	Mrkvan	The ever-evolving composition of seasonal influenza vaccines: aligning the science to address public health needs
P332	Caitriona	Murphy	Reactogenicity of repeated vaccination with enhanced and standard influenza vaccines: a randomized controlled trial
P333	Mallory	Myers	Commercial influenza vaccines vary in HA-complex structure and in induction of cross-reactive HA antibodies
P334	Ka Yan	Ng	Implementation of school-based influenza vaccination programme: Identifying concerns and perceived barriers among teachers in Hong Kong
P335	Sze Sze	Ning	Live-Attenuated Influenza Vaccination Among Primary School Children in Hong Kong: Side Effect Profiles, Associated Impact and Risk Factor
P336	Haruna	Nishijima	THE STRENGTH OF ANTIGEN-ANTIBODY BINDING INFLUENCES THE ROBUSTNESS OF SRID POTENCY
P337	Julie	Ostrowsky	The Influenza Vaccines R&D Roadmap (IVR) Initiative for Accelerating Progress toward Improved Influenza Vaccines
P338	Julie	Ostrowsky	The Universal Influenza Vaccine Technology Landscape
P339	Claudia	Pappas	Comprehensive analysis of influenza candidate vaccine virus (CVV) attenuation in the ferret model
P340	Tiziano	Poletti	Alternative approach to Enhanced Passive Safety Surveillance study for post-marketing monitoring of a flu vaccine in Great Britain: The Supemtek® case
P341	Duncan	Purvis	Modelling public health benefits of alternative fourth influenza strains in future quadrivalent influenza vaccines
P342	Duncan	Purvis	Public health benefits of pre-pandemic immunity through an augmented seasonal influenza vaccine: Assessment using integrated epidemiologic-social-economic modelling
P343	Angie	Rose	Effectiveness of COVID-19 vaccination against SARS-CoV-2-confirmed hospitalisation: European Severe Acute Respiratory Infection Vaccine Effectiveness (Euro-SAVE) network, 2022–2023
P344	Angie	Rose	2023/24 COVID-19 vaccine effectiveness against hospitalisation: VEBIS European hospital multicentre study, October 2023–January 2024

P345	Camelia	Savulescu	The role of clinical case definitions for estimating the COVID-19 vaccine effectiveness against laboratory-confirmed SARS-CoV-2 infection, VEBIS multi-centre hospital healthcare worker cohort, season 2023–2024
P346	Noriko	Shimasaki	Characteristics of human sera vaccinated with covid-19 miRNA vaccine and influenza ha vaccine potentially affecting the breakthrough infection and the emergence of antigenic variants
P347	Shreya	Shrikhande	The role of healthcare professionals in patient knowledge and communication on influenza vaccines in cardiac patients
P348	Yun Sang	Tang	Evaluating T-cell immunity against emerging SARS-CoV-2 variants in adults receiving homologous or heterologous fourth dose booster in Hong Kong
P349	Nicole Ngai Yung	Tsang	Relative changing impact of vaccination and natural immunity in preventing SARS-CoV-2 incidence
P350	Verna	Welch	Potential Increases in Willingness to be Vaccinated due to the Introduction of a Combined Influenza/COVID-19 Vaccine
P351	Cao	Yanlin	Hesitancy regarding providing influenza vaccine recommendations among clinicians in China: Analysis based on the behaviour and social drivers model
P352	Benjamin	Young	Retrospective assessment and optimization of COVID-19 vaccination policies during Omicron BA.2 outbreak in Hong Kong: a modelling study
P353	Jie	Zhang	Characterizing the dynamics of BCR repertoire from repeated influenza vaccination
P354	Jennifer	Ku	Comparative effectiveness of licensed influenza vaccines in preventing influenza-related medical encounters and hospitalizations in the 2022-2023 influenza season among adults ≥65 years of age
P355	Lauren	Immink	Defining the impacts of obesity on influenza vaccine-elicited memory B cells.
P356	Briony	Fanslow	Household transmission study of SARS-CoV-2: a prospective longitudinal study in New Zealand, 2022
P357	Zhirong	Jia	Influenza virus internal proteins as vaccine targets
P358	Tatiana	Kotomina	Supplemented immunization with inactivated influenza vaccine and peptides corresponding to linear B-cell epitopes of influenza A neuraminidase induces cross-protective immunity in mice
P359	Shoshanna	Goldin	Assessing the relationship between influenza vaccination programmes and national COVID-19 vaccination performance
P360	Md. Tanvir	Kabir	Potential of bioengineered polyester bead-based vaccines to fight against influenza viruses
P361	Shoshanna	Goldin	Seasonal influenza vaccination: a global review of national policies in 194 WHO Member States
P362	Yuxi	Liu	Multifaceted Analysis of Preferences and Drivers for Adult Vaccination Clinic Site Selection: A Cross-Sectional Study
P363	Perrine	Marcenac	From Pages to Policies: Mapping Global Influenza Branch Publications on the Path to Influenza Vaccine Policy (2004-2023)
P364	Shreya	Shrikhande	Influenza vaccinations in cardiac patients across five countries: Findings and implications from a World Heart Federation study

P365	Amanda	Howa	Impact of Vaccination on Influenza Symptom Severity Among Ambulatory Children: Evidence from case-ascertained household transmission studies
P366	Hannah	Maier	Existing Anti-Neuraminidase Antibodies Reduce the Susceptibility to and Infectivity of Influenza A/H3N2 Virus
P367	Eulhae	Ga	Study of animal vaccine for zoonotic disease prevention
Public Health and Policy 2. Sero-epidemiology			
P368	Junbo	Chen	The transplacental transfer efficiency of maternal antibodies against influenza A(H1N1)pdm09 virus, and dynamics of naturally acquired antibodies in children: A longitudinal, paired mother–neonate cohort study
P369	Kin On	Kwok	A seroepidemiology study after the Omicron surge in elderly homes in Hong Kong
P370	Seunghyun	Lee	Findings from a community-based longitudinal seroprevalence survey for COVID-19 in Korea
P371	Heidi	Peck	Circulation of and seropositivity to influenza b/Yamagata-lineage viruses prior to and after the covid-19 pandemic in Australia
P372	Kalee	Rumfelt	A Sensitivity Analysis to Assess RSV Pre-fusion F IgG Antibody Titer as a Correlate of Protection
P374	Wilhelmina	Strasheim	Respiratory syncytial virus (RSV) pre-fusion antibody levels among adults in a community-based cohort in South Africa, 2022-2023
P375	Tim K.	Tsang	Joint reconstruction of influenza A(H1N1) and A(H3N2) antibody dynamics to estimate the risk of influenza virus infection
P376	Eric	Vos	SARS-CoV-2 hybrid immunity in persons at-risk for severe COVID-19 in 2023: a Dutch nationwide population-based prospective sero-epidemiological cohort study
P377	Yanmin	Xie	Incidence of influenza virus infections in older adults: A cohort study in Eastern China, 2015-2017
P378	Yanmin	Xie	Hemagglutinin and Neuraminidase Antibodies as Protective Factors against Influenza A Virus in Older Adults: A Comparative Analysis of Symptomatic and Asymptomatic/Subclinical Infections
P379	Juan	Yang	The sero-epidemiological characteristics of SARS-CoV-2 variants infections after the end of dynamic zero-COVID policy in China in 2023
P380	Kangwei	Zeng	Singapore's COVID-19's Epidemiological Landscape: Cumulative Incidence, Sero-Incidence, and Ascertainment Fraction in a Community Cohort and Healthcare Staff
P381	Jade Yangyupei	Yang	Population susceptibility prior to Omicron emergence, and antibody correlates of protection against first and second omicron waves: findings from the HIVE study
P382	Maria Giovanna	Marotta	Harnessing the potential of pseudotyped virus libraries to explore respiratory virus infection and immunity
P383	Cheng	Xiao	Incidence of seasonal coronaviruses and post-infection antibody responses in older adults between 2015 to 2017 in Southeastern China
P384	Patrick	Nguipdop-Djomo	Investigating cross-reactive anti-hemagglutinin stalk antibodies in live bird markets workers with occupational exposure to avian influenza viruses in Dhaka, Bangladesh

Public Health and Policy 3. Forecasting, seasonality and surveillance			
P385	Steffen	Albrecht	Forecasting acute respiratory infection hospitalizations with explainable machine learning models
P386	Steffen	Albrecht	Challenges in integrating laboratory tests within the forecasting of acute respiratory infection hospitalizations using machine learning
P387	Sheikh Taslim	Ali	Extrinsic drivers for COVID-19 transmission and seasonality: a systematic review and meta-analysis
P388	Ria	Allman	Delaware Public Health Laboratory's Experience with the CDC-APHL Right Size Roadmap
P389	Nathalie	Bastien	A Retrospective Synopsis of the 2023/2024 Influenza Season in Canada: Assessing genetic evolution, viral antigenicity and the emergence of antiviral resistance in circulating strains.
P390	Nathalie	Bastien	A Canadian Perspective for a National SARS-CoV-2 Surveillance Program: Monitoring viral evolution, antigenicity and antiviral susceptibility of circulating strains by integrating genomic and phenotypic characterization.
P391	Louise	Blair	Forecasting the true burden and timing of seasonal influenza: evaluation of machine learning based methodologies
P392	Hind	Bouguerra	Comparative Influenza and SARS-CoV-2 activity in Tunisia (2021-2023)
P393	Hind	Bouguerra	Epidemiological patterns of Respiratory Syncytial Virus infection in Tunisia in 2021-2023
P394	Catherine	Bozio	Identification of clinically meaningful subgroups of adults hospitalized with influenza– FluSurv-NET, 2017–2019 seasons
P395	Jian	Chen	Trends and factors influencing over-the-counter cold and cough medication sales in Guangzhou, China: 2011-2017
P396	Yilin	Chen	Global pattern and determinant for interaction of seasonal influenza viruses
P397	Saeyeon	Cheon	Impact of Patient Variability on Seasonal Influenza Symptoms: Artificial Intelligence Approach
P398	Fahmida	Chowdhury	Shifting Patterns of Influenza Seasonality in Bangladesh Following the COVID-19 Pandemic
P399	Sarah	Cox	Genomic diversity and household transmission patterns of influenza in the United States: the Cascadia prospective cohort study, 2022-2023
P400	Jessica	Gallon	Understanding real world influenza and COVID-19 vaccination patterns in US adults: Evidence from the 2022-2023 season
P401	Shuyu	Deng	Respiratory syncytial virus seasonality, transmission zone, and implication for seasonal prevention strategy in China: a systematic analysis
P402	Tanya	Diefenbach-Elstob	Influenza in Australian FluCAN and PAEDS sentinel hospitals in 2023
P403	Tony	Dowell	Disrupted variation in respiratory illness presentation patterns in New Zealand (NZ) primary care before and after the SARS-CoV2 pandemic
P404	Raquel	Guiomar	Antigenic and Genetic characterization of Influenza viruses, circulating in Portugal during 2023/2024 season.

P405	Aspen	Hammond	Retrospective correlation analysis between SARS-CoV-2 test positivity from sentinel and universal system reported to WHO at the country, area or territory level, January 2020-June 2022
P406	Rebecca	Harris	Revealing Seasonal Patterns in the Post-Pandemic Era: A Comparative Analysis of Seasonality and Burden of Influenza and COVID-19 in Europe
P407	Helena	Jirincova	Virological surveillance of influenza and respiratory viruses and experience with the inclusion of SARS-CoV-2 in sentinel surveillance in the Czech Republic in 2019-2024
P408	Herve	Kadjo	integrated epidemiological and genomic surveillance of influenza, RSV and SARS-CoV-2 through sentinel influenza surveillance in Côte d'Ivoire (2022 – 2023)
P409	Herve	Kadjo	Identification of SARS-CoV-2 variants in Côte d'Ivoire, Comparative study of real-time qPCR screening and NGS sequencing (MinION MK 1C)
P410	Chiharu	Kawakami	Impact of COVID-19 on respiratory virus infections in children in Yokohama, Japan, 2018 to 2023
P411	Bryan MH	Keng	Macrolide-resistant Mycoplasma pneumoniae in Singapore - findings from a national surveillance programme
P412	Soukphadeth	Keok-honenang	Review Avian Influenza Surveillance System from 03 Sentinel Sites in Luangnamtha, Oudomxay and Xiengkhouang provinces, 2020-2022
P413	Alexandra	Kerr	Recruitment and retention strategies for respiratory illness participatory surveillances systems: Insights from FluTracking Australia and New Zealand
P414	Wanitchaya	Kittikraisak	The added value of serologic testing in influenza surveillance studies: a comparison of influenza incidence among pregnant persons based on molecular-based surveillance versus serologic testing
P415	Mengyao	Li	Application of LSTM in Early Warning of Influenza Epidemics in Beijing, China
P416	Ausenda	Machado	Assessment of a Severe Acute Respiratory Infections Surveillance System based in electronic health registry in Portugal
P417	Tania Ken Lin	Mah	Evaluating Acute Respiratory Infection and Influenza-Like Illness case definitions for community COVID-19 and influenza surveillance
P418	Perrine	Marcenac	Mapping global trends in seasonal influenza epidemics: insights from time series clustering and genetic sequencing data from 143 countries, 2011-2019
P640	Ahmed Abdul	Quadeer	A path integral approach for inferring effects of mutations on SARS-CoV-2 transmission from genomic time-series data
P781	Sukanta	Chowdhury	Impact of keeping overnight poultry on detection of avian influenza viruses at live poultry markets in Bangladesh: A randomized experimental study
P782	Marco	Del Riccio	Influenza in the time of COVID-19: contributions from three years of the FluCov Project
P788	Jessie	Goldsmith	Variability of influenza vaccine effectiveness (VE) by subtype: a systematic review and meta-analysis of test-negative design studies

Virology and Pathogenesis 1. Virus-host cell interactions			
P419	Danica Fae	Besavilla	Kinetic MUNANA assay as a tool to identify antibodies against functional epitopes of influenza A virus neuraminidase
P420	Shao Ming	Chan	Understanding changes in host cell calcium signalling during coronavirus infection.
P421	Rubaiyea	Farrukee	Investigating the role of interferon stimulated genes in host responses to influenza A infections in ferrets.
P422	Antoine	Gerodez	Virus-host interaction to assess the zoonotic potential of avian influenza viruses?
P423	Zhimin	Jiang	Influenza viruses induce host mitophagy through a novel mitophagy receptor to limit the innate immunity.
P424	Zhimin	Jiang	The Znf_RING protein RBBP6 binds viral RNA and drivers cell death by mediating ubiquitination of RIPK3
P425	Rachael	Keating	Assessing the impact of CMV infection on IVF outcomes
P426	Bitgoeul	Kim	Adaptive mutational profiles of avian influenza viruses in chicken upper respiratory tract
P427	Yingyin	Liao	Influenza NS1-Mediated N(6)-Methyladenosine Modification Controls NS mRNA Splicing and Nuclear Exportation
P428	Jasmina	Luczo	Development of ex vivo models of nasal epithelia to elucidate the mechanism of Bordetella bronchiseptica-mediated blockade of influenza virus replication in the nasal cavity.
P429	Shing Yui	Mao	Ambivalent role of miR-124-3p on Influenza A Virus in vitro: Enhancing replication by attenuating innate immunity while causing defects in virion production
P430	Dongbin	Park	Diverse infection dynamics of beta-coronavirus in human bronchial epithelial organoids.
P431	Patrick	Reading	Restriction factor SAMHD1 does not inhibit influenza A virus replication in human epithelial- or macrophage-like cells.
P432	Xiao	Shang	Delayed Antiviral Immune Response in Alveolar Type 2 Cells Increases Susceptibility to Influenza Virus
P433	Melkamu Bezie	Tessema	Mouse guanylate-binding proteins of the chromosome 3 cluster do not inhibit influenza A virus in vitro or in vivo.
P434	Carla Bianca	Victorio	[18F]FDG lung uptake is a marker of severe lethal influenza inflammation in the mouse model
P435	Carla Bianca	Victorio	[18F]FDG lung uptake is an inflammation imaging biomarker in a self-limiting rhinovirus infection model
P436	I-Hsuan	Wang	Regulation and function of endolysosome-mediated SARS-CoV-2 egress
P437	Chung Hin	Wong	Pathogenesis Study of Emerging Coronavirus and Influenza Viruses Infection in Human Airway Organoid using Transcriptomics
P438	Xin	Ye	The circRNA circVAMP3 restricts influenza A virus replication by interfering with NP and NS1 proteins
P439	Yaqin	Bai	Amino acids in the polymerase complex of shorebird-isolated H1N1 influenza virus impact replication and host-virus interactions in mammalian models

P440	Peter	Cheung	Genome-wide Mapping of Viral Polymerase Dynamics
P441	Anja	Kukic	Influenza Non-structural Protein 1 (NS1)-Induced Read-through Transcription Produces MicroRNA-146a to Modulate Viral Replication and Immune Response
P442	Marcus	Tong	Mapping the cellular interactome of the lung during infection
Virology and Pathogenesis 2. Innate and mucosal immunity to infection			
P443	Yulia	Desheva	Study of factors of nonspecific protection against homologous and heterosubtypic influenza infection shortly after immunization with live influenza vaccine
P444	Elizaveta	Elshina	Aberrant transcription by influenza A virus RNA polymerase generates a novel RIG-I ligand.
P445	Cheng Xiang	Foo	Intranasal administration of oxysterols regulates macrophage infiltration and disease severity in SARS-CoV-2 infection
P446	Isabelle	Hocking	Hyperglycaemia is associated with trained immunity and an enhanced innate immune response to influenza virus infection
P447	Tony Chun Hei	LEI	Differential Transcriptomic Responses in Paediatric Nasal Epithelial Cells to Influenza Infections Compared to Adults and the Elderly
P448	Sho	Miyamoto	Relationship between SARS-CoV-2 shedding duration and mucosal antibody response latency
P449	Ellesandra	Noye	Natural killer cells in children with obesity have a 'trained' immune phenotype and heightened pro-inflammatory responses to ex vivo influenza virus A stimulation
P450	Ellesandra	Noye	A history of obesity increases the severity of influenza virus infection via the induction of innate immune training
P451	Sarah	Rosli	Gasdermin deficiency limits the severity of pulmonary disease during influenza A virus infection
P452	Kerstin	Skovgaard	Big Models and Tiny Regulators: Pigs and MicroRNAs in the Study of Influenza A virus infections
P453	Julian	Sng	Innate immune training in murine model of the post-acute sequelae of COVID-19
P454	Andrew	Teo	Targeting neutrophil myeloperoxidase in influenza virus infection
P455	Yanshan	Zhu	The Role of Children in Influenza Virus Transmission: Insights into Viral Titers and Shedding Duration in Nasal Epithelium
P456	Ka Yi	Leung	Live attenuated influenza virus vectored vaccine ameliorates SARS-CoV-2 infection in PBMC-cocultured human lung epithelial cells
P457	SUH CHIN	WU	Intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit
P458	Sumit	Chanda	Synthetic Interferon Exhibits Potent Antiviral Activity Across both DNA and RNA Viruses with Limited Pro-inflammatory Gene Induction
P459	Charles	Jones	Deciphering Immune Responses: A Comparative Analysis of Influenza Vaccination Platforms
P460	Larisa	Labzin	Targeting human inflammatory epithelial-macrophage cell networks to limit epithelial damage during influenza infection

P461	Claire	Smith	Nasal epithelial cells from children are primed for an early interferon response, restricting productive SARS-CoV-2 replication and spread.
P462	Xiaohui	Wang	Human macrophages sense replicating influenza virus RNA through cytosolic RNA sensors to drive rapid and robust cytokine responses
P463	Wenlong	An	The role of HDAC6 on anti-viral innate immune signalling during Influenza A virus infections
P464	Rachel	Tam	Modulation of mucosal immunity and tissue resident memory formation by NS1- deficient influenza A virus
P465	Yona	Tugg	Investigating the role of broadly-neutralizing IgA antibodies in response to influenza A virus infection
P466	Rifqa	Fayaz	Elucidating the role of Cytokine-Inducible SH2-containing protein (CISH) in the antiviral response following influenza A infection
Virology and Pathogenesis 3. Adaptive immune response to infection			
P469	Calvin	Duong	HA antigenic cluster recognition may differ between humans and ferrets
P470	Lukas	Hoen	Validating Human Airway & Lung Organoid Models as an in Vitro Biomimetic System for Modelling Influenza Evolution in Response to Humoral Immunity
P471	Samantha	Kaweski	Live virus microneutralization assay reinforces greater cross-reactive SARS-CoV-2 response to emerging variants among previously infected and vaccinated individuals: age-based cross-sectional serosurvey analysis
P472	Perrine	Marcenac	Cytokine profile of pregnant women with mild COVID-19: A cohort study in Western Kenya, May 2020 through July 2021
P473	Lydia	Mendoza	Characterization of H3N2 viruses that circulated in two recent Influenza seasons in Philadelphia, Pennsylvania
P474	Christie	Noble	Characterising the SARS-CoV-2 nucleocapsid protein antibody response
P475	Masashi	Shingai	Extraction of the CDRH3 sequence of the mouse antibody repertoire selected upon influenza virus infection by subtraction of the background antibody repertoire
P476	Ian	Wilson	Antibody recognition of highly conserved sites on SARS-CoV-2 and variants: Implications for pan-coronavirus vaccines and therapeutics
P477	Suyun	Moon	H3N1 Novel Canine Influenza strain fully protects from the Canine Influenza H3N1 and pandemic (2009) H1N1 virus infection in mice

Poster Session 2

Monday 30 September 2024

Theme	Poster Board Numbers			
Clinical Sciences and Vaccinology	P019-P039	P059-P76	P478-P546	P797-P798
Interdisciplinary Session	P059-P076	P547-P609	P790-P791	P795, P799
Public Health and Policy	P084, P109-P128	P610-P685	P686-P721	P796-P798, P800-P802
Virology and Pathogenesis	P130-P140	P158-P174	P722-P779	P793-P794

Location: Great Hall

Clinical Sciences and Vaccinology 3. Vaccine immunogenicity and effectiveness

P019	Nicole	Messina	BCG vaccination for protection against COVID-19: outcomes from an international randomised controlled trial
P020	George N.	Okoli	Estimates of SARS-CoV-2 vaccine effectiveness against COVID-19-associated hospitalisation in paediatric patients in Hong Kong from April 2022 to February 2024: A test-negative design study
P021	Nancy A.	Otieno	Impact of HIV Infection and Malaria Parasitemia on Immunogenicity of Inactivated Influenza Vaccine in Pregnant Women and on Mother-to-Child Vaccine-induced Antibody Transfer
P022	Masafumi	Seki	Prognosis of adult, hospitalized, non-vaccinated COVID-19 patients during the omicron variant surge in Japan
P023	Seung Eun	Son	Development of safe, effective, and productive live attenuated H1N1 vaccine strain by tuning PB2 activity
P024	JINHA	SONG	Strategic Enhancement of Neuraminidase Immunogenicity in Whole Inactivated Vaccines Through NA Stalk Length and HA Glycosylation Manipulation
P025	Ingeborg	Yddal	Immunogenicity after quadrivalent influenza vaccination in young children < 5 years old in rural Bangladesh
P026	Shuyi	Zhong	Frequency of consistently lower antibody response to repeated vaccination with influenza vaccine among older adults in Hong Kong
P027	Xiu-Feng (Henry)	Wan	Effects of Antigenic Differences on Vaccine Effectiveness During Repeated Influenza Vaccination

Clinical Sciences and Vaccinology 4. Novel vaccines and platforms

P028	Jaehyun	Hwang	Development of Live Vaccine Candidates for Influenza Virus Using Naturally Truncated NS1 Gene for Oral Mucosal Administration
P029	Jessica	Cotterell	mRNA booster vaccines against SARS-CoV2 induce suboptimal de novo germinal centre responses
P030	Guohua	Deng	A broad-spectrum vaccine candidate against H5 viruses bearing different sub-clade 2.3.4.4 hemagglutinin genes
P031	Angus	Forster	Microarray patch delivery of unadjuvanted recombinant spike protein vaccine induces potent and broad-spectrum immune responses in a phase I clinical study
P032	Irene	Hoxie	Development of a broadly protective neuraminidase-based, intranasal influenza virus vaccine

P033	Changkeun	Lee	MF59 adjuvanted recombinant RSV protein vaccine development: A new vaccine design with six helix bundle (6HB)
P034	Bin	Zhou	Influenza mRNA vaccine protects ferrets from lethal infection with highly pathogenic avian influenza A(H5N1) virus
P035	Kirill	Vasilev	T-cellular immune response to sequential vaccination with chimeric hemagglutinin split influenza vaccines
P036	Suh Chin	Wu	Glycan masking of NTD loops with a chimeric RBD of the spike protein as a vaccine design strategy against emerging SARS-CoV-2 Omicron variants
P037	Brandon	Rosen	Development of vaccination constructs for the elicitation of broadly-neutralizing antibodies against highly pathogenic avian influenza subtypes H5N1 and H7N9
P038	Keiko	Baba	Characterization of reverse genetics-derived SARS-CoV-2 viruses with amino acid substitutions observed in ensitrelvir in vitro virus passage study
P039	Teerada	Ponpinit	Mutations in the favipiravir-binding site in the RNA-dependent RNA polymerase of SARS-CoV-2 during treatment in Thai patients
Interdisciplinary Session 3. Epidemic and pandemic preparedness			
P059	Alberto	Bresciani	Artificial Intelligence to Discover Drugs for Pandemic Preparedness
P060	Chengyao	Zhang	Interplay between viral shedding, age, and symptoms on individual infectiousness of influenza cases in households
P061	Sheng En Alexius Matthias	Soh	Enhancing Uptake of Antiviral Treatment: Understanding the Drivers of COVID-19 antiviral medication (Paxlovid) in Singapore
P062	Kiyoko	Iwatsuki-Horimoto	SARS-CoV-2 transmission from virus-infected dead hamsters
P063	JIMAN	KANG	Return of Kawasaki Disease and Temporal Association with Preceding Respiratory Virus Epidemics in the Post-Coronavirus Disease (COVID-19) Era: A National Observational Study in Korea, 2016-2023
P064	Min	Levine	Immune Imprinting by Natural Infection vs Egg-based Vaccination Impacts Antibody Responses to Influenza Vaccination Later in Life
P065	Anastasia Jessica	Hadiprodjo	Influenza vaccine responses among young children first exposed to influenza antigens via infection versus vaccination
P066	Tingting	Jia	Expanded immune imprinting and neutralization spectrum by hybrid immunization of SARS-CoV-2 variants breakthrough infections after 3-dose vaccination
P067	Vanessa	Guerra Canedo	Longitudinal Analysis of Intra-Host diversity of Avian Influenza H5N1 Virus Infection in Non-Human Primates: Insights from Experimental Challenge Study of a Universal Vaccine Candidate
P068	Mamadou Malado	Jallow	High circulation of Respiratory Syncytial Virus in pediatric patients hospitalized with severe acute respiratory infection in Senegal, 2022-2023.
P069	Juliana	Leite	SARS-CoV-2 genomic surveillance in Latin America and the Caribbean: dispersion patterns of the Lambda, Mu and Gamma variants unveiled
P070	Norosoa Harline	Razanaja-tovo	Temporal dynamic pattern of influenza circulating in Madagascar based on a genetic approach, 2019-2022.

P071	Wanying	Sun	Global migration and reassortment of avian influenza virus in Hong Kong from 2010-2020
P073	Jianzhong	Shi	Evolution of H7N9 highly pathogenic avian influenza virus in the context of vaccination
P074	Tavis	Anderson	The role of imperfect vaccination on the emergence of within-host variants of influenza A virus in swine
P075	Carl	Hutter	Impact of Maternal Antibodies and Weaning Stress on the Evolutionary Dynamics of Human H3N2 Influenza A Virus in Piglets
P076	Adam	Lauring	The impact of viral and host factors on the influenza A virus transmission bottleneck
Public Health and Policy 1. Vaccines			
P084	Bette	Liu	Effect of maternal influenza vaccination on respiratory infections in infants
Public Health and Policy 3. Forecasting, seasonality and surveillance			
P109	Soledad	Ruiz	Long-term study of influenza A virus in important wetlands throughout Chile and its association with ecological drivers
P110	Bounthanom	Sengkeo-praseuth	Lao PDR's Sentinel Surveillance Cost Assessment
P111	Ikuyo	Takayama	SARS-CoV-2 genomic surveillance in Japan
P112	Jonathan	Temte	Comparison of K-12 school-based surveillance methods with methods implemented elsewhere in the same community to monitor influenza and SARS-CoV2 activity: Dane County, Wisconsin, 8/19/2021—12/16/2023
P113	Tim K.	Tsang	An adaptive weight ensemble approach to forecast influenza activity in the context of irregular seasonality
P114	Rakhee	Yadav	Annual trends in the distribution of Influenza A and B cases in a Malaysian Tertiary Hospital
P115	Ann-claire	Gourinat	RSV seasonality over ten years and projected economic impact of nirsevimab on prevention in New Caledonia
P116	Krista	Kniss	Assessment of Novel Data Sources for Influenza Surveillance in the US
P117	Kym	Lowry	Tracking Emerging Infectious Diseases in Local Wastewater using Two NGS Hybrid Capture Enrichment Methods
P118	Kym	Lowry	The Molecular Profile of Rhinovirus Infection in Children During the Initial Phase of the COVID-19 Pandemic
P119	Ahmed Abdul	Quadeer	Seasonal antigenic prediction of in uenza A H3N2 using machine learning
P120	Yoke Lee	Low	Impact of COVID-19 Pandemic on Respiratory Syncytial Virus Epidemiology and Prevalence
P121	Emily	Martin	A Novel Approach to Respiratory Aerosol Sampling from Young Children at Short Ranges
P122	Raquel	Saludo	Burden of Respiratory Syncytial Virus (RSV) in Guam
P123	Md Ariful	Islam	Phylodynamics of high pathogenicity avian influenza virus in Bangladesh: Identifying domestic ducks as the amplifying host reservoir

Public Health and Policy 4. Disease control policy			
P124	Amelia	Coggon	Pre pandemic and risk assessment of viruses circulating at the human animal interface in Bangladesh's Live Bird Markets.
P125	Nzisa	Liku	Factors associated with very severe disease presentation and death among patients hospitalized with influenza in Kenya.
P126	Rajneeta	Saraf	Knowledge, attitudes and behaviours towards respiratory illness and non-pharmaceutical interventions (NPIs) in the Healthy Lungs Cohort.
P127	Jonathan	Temte	Effects of K-12 grade school district non-pharmaceutical interventions on community-level prevalence of acute respiratory infection during the COVID-19 pandemic: December 2019 to October 2022
P128	Yanshan	Zhu	Association between COVID-19 border closures, absence of viral burden and respiratory bacterial carriage in Healthy Children aged 4-5 years in Western Australia
Virology and Pathogenesis 3. Adaptive immune response to infection			
P158	Fan	Zhou	Phenotypic and functional changes of human follicular T helper cells over decades of life
P159	Dinah	Aziz	Conventional risk factors may not be major contributors to severe influenza A infection – prospective epidemiological study reveals need for more analysis of influenza pathogenesis
P160	Nicola	Chiwandire	The Role of Household Relationships in SARS-CoV-2 Transmission Dynamics: a US case-ascertained study, 2021-2023
P161	Thomas	Fabrizio	Reassortment and evolution of A(H5N1) clade 2.3.4.4b viruses within the Americas has led to transmissible phenotypes in the ferret model.
P162	Eun-Kyo	Hong	Infectivity of an avian-origin reassortant H2N2 influenza virus
P163	Daiki	Kobayashi	Loss of multiple N-glycosylations in the neuraminidase stalk domain contribute to the enhanced pathogenicity of an H7N7 high pathogenicity avian influenza virus to chickens
P164	Thao-Quyen	Nguyen	Emergence and interstate spread of highly pathogenic avian influenza A(H5N1) in dairy cattle
P165	JIE	ZHOU	Characterising Viable Virus from Air Exhaled by SARS-CoV-2 Infected Hamsters
P166	Liam	Brierley	An AI for an AI: can the next zoonotic avian influenza spillover be identified straight from its genome?
P167	Md Ariful	Islam	High pathogenicity avian influenza A (H5N1) clade 2.3.2.1a virus in Indian flying fox (Pteropus medius) bats in Bangladesh
P168	Matthew	Gartner	Comparative analysis of seasonal and pathogenic coronavirus infections in four physiologically relevant models of the human respiratory tract
P169	Ray	So	Reduced cell entry with the clade B MERS-CoV spike in 2018-2019 may partially explain lower numbers of zoonotic MERS
P170	Huihui	Kong	The SUMO-interacting motif in NS2 promotes adaptation of avian influenza virus to mammals
P171	Olivia	Platt	Elucidating Influenza A virus genome packaging interactions in the context of infection

P172	Lei	Sun	SARS-CoV-2 nonstructural protein 6 triggers endoplasmic reticulum stress-induced autophagy to degrade STING1
P173	Helena Aagaard	Laybourn	Analysis of host responses in the upper respiratory airway to human- and swine-adapted influenza A viruses
P174	Katina	Hulme	Long term evolution of seasonal A/H3N2 in differentiated human airway epithelial pathways reveals diverse evolutionary potential

Location: Exhibition Hall

Clinical Sciences and Vaccinology 3. Vaccine immunogenicity and effectiveness

P478	Alexandre	Le Vert	OVX836, a NP-based broad-spectrum influenza vaccine candidate, is safe, immunogenic and triggers cross-reactive immune response in older adults (>65 years old)
P479	Alexandre	Le Vert	Results of a second phase 2 study evaluating the concomittant administration of OVX836 with standard flu vaccines: compelling safety and immunogenecity
P480	Litao	Liu	Immunization with a turkey herpesvirus vector vaccine expressing hemagglutinin from the H9N2 subtype avian influenza virus improved the production efficiency of broilers in the field.
P481	Yi	Liu	Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines translates into stronger B cell responses among vaccinees with break-through infections
P482	Yi	Liu	Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines
P483	Yee-Chen	Liu	Defining conserved sites of vulnerability on the Influenza B HA Using Human Monoclonal Antibodies
P484	Christopher	Locher	A Matrix 2 Protein Vaccine from Bacterial Vesicles Protects Against Diverse Strains of Influenza
P485	Nidhi	Mittal	Design and characterization of a dodecameric complex of influenza HAs from H1 and H3 subtypes
P486	Nidhi	Mittal	Immunogenicity and protective efficacy of RBD-S2 fusion immunogens against heterologous SARS-CoV-2 challenge
P487	Nedzad	Music	A MF59-adjuvanted A/Astrakhan Zoonotic Influenza vaccine candidate is Immunogenic in ferrets and induces substantial neutralizing antibodies against the H5N1 genotype 2.3.4.4b circulating globally.
P488	Huong	Nguyen	Interim effectiveness of cell culture-based inactivated influenza vaccine against medically-attended, laboratory-confirmed influenza in Wisconsin, US, 2023-24
P489	Lam	Nguyen	Modulating enzymatic activity of influenza virus neuraminidase by a single substitution in the catalytic site framework while retaining antigenic and biophysical properties

P490	Marumi	Ohno	Development of inactivated whole virus particle vaccine for COVID-19
P491	Yusuke	Okada	Comparison of the immunogenicity of bivalent self-amplifying mRNA and mRNA vaccines against various SARS-CoV-2 variants up to six months postvaccination
P492	Rashmi	Rai	Addition of a hemagglutinin stem immunogen enhances the protective efficacy of a recombinant influenza vaccine formulation.
P493	Gabrielle	Scher	Effects of immunization with a 20HA mRNA-LNP vaccine on subsequent heterologous HA mRNA-LNP vaccinations
P494	Toshiki	Sekiya	Development of Inactivated Intact Whole Virus Particle Vaccine Against Seasonal and Pandemic Influenza
P495	Shilpee	Sharma	Antibody determinants of Influenza immunity in vaccinated subjects across three different age groups: elderly, children and infants
P496	Svetlana	Shcherbik	Analysis of the genetic stability of influenza A live attenuated influenza vaccine virus reassortants
P497	Danuta	Skowronski	2023/24 influenza vaccine effectiveness estimates, including clade-specific, from the community-based Canadian Sentinel Practitioner Surveillance Network (SPSN)
P498	Nigel	Temperton	Correlation between influenza and coronavirus pseudotype-based and authentic virus neutralisation assays
P499	Esther	Van Twuijver	Immunogenicity of heterologous booster vaccinations with an MF59-adjuvanted, cell culture-derived H5N6 influenza vaccine in adults primed with MF59-adjuvanted, cell culture-derived H5N1 influenza vaccine or unprimed
P500	Wim	Vermeulen	Immunogenicity and safety of an MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older: phase 2 randomised controlled trial
P501	Bingyi	Yang	Evaluating Antibody Breadth Following Various Enhanced Influenza Vaccines in Older Adults
P502	Hyeongcheol	Yun	Immune interference assessment of multivalent vaccine for influenza epidemic strain in 2022-2023 and efficacy evaluation
P503	Ziheng	Zhu	Unpacking the attenuating effects of repeated influenza vaccination
P504	Louise	Carolan	Antibody responses against influenza A decline with successive years of annual influenza vaccination
P505	Savannah	Hammerton	Using a defined titer-protection model to estimate vaccine efficacy and difference in vaccine efficacy in age- and dose-based groups
P506	Felicia	Hwa	Decoding longitudinal antibody and Fc-effector functions against SARS-CoV-2 variants
P507	Wen Shi	Lee	Sooner or later? Impact of COVID-19 booster intervals on antibody responses.
P508	Marcos	Vieira	Do non-responders exist? Inconsistent individual responses to influenza vaccination across seasons and vaccine components
P509	Hui-Wen	Chen	A highly effective M2e nanoshell vaccine for broad and durable influenza protection under a single dose regimen

P510	Shiho	Chiba	Influenza H3 hemagglutinin vaccine with scrambled immuno-dominant epitopes elicits antibodies directed toward immuno-subdominant head epitopes
P511	Shoshanna	Goldin	Advancing Influenza Vaccines: A Review of Next-Generation Candidates and their Potential for Global Health Impact
P512	Delphine	Guyon-Gellin	A mix of OVX836, a NP-based T-cell influenza vaccine candidate, with a commercial seasonal vaccine is immunogenic and synergistically protective in mice
P513	Cyrus	Haas	One-component protein nanoparticle design for a next-generation influenza vaccine
P514	Tsoi Man Mandy	Ho	Generation of live attenuated influenza vaccine (LAIV) carrying avian codon usage bias with an H3N2 virus
P515	Irina	Isakova-Sivak	MDCK cells as a substrate for the production of engineered live attenuated influenza vaccine candidates expressing SARS-CoV-2 immunogenic epitopes
P516	Seungji	Kim	Efficient production of SARS-CoV-2 Virus-like particle synthesized in vitro based on the baculovirus dual-expression system.
P517	Alexandre	Le Vert	OVX033, N-based T-cell broad-spectrum vaccine candidate against all sarbecovirus is safe and immunogenic in non-human primates
P518	Zhibin	Liang	Revolutionizing Influenza A Virus Research: A Novel Fluorescent Capped RNA Primer for Real-Time RdRp Transcription Analysis
P519	Ying	Liu	An intranasal nucleocapsid-based vaccine offers broad-spectrum protection against SARS-CoV-2 variants in preclinical models
P520	Abby	Martin	The Reactogenicity of Linear versus Circular RNA Vaccines.
P521	Yasushi	Muraki	Potency of polymyxin B as a mucosal adjuvant for intranasal influenza vaccine
P522	Danyn	Patel	Establishing principles of influenza virus genome engineering for development of LAIV as a co-vaccine
P523	Daniel	Perez	Non-Transmissible, Reassortment-Impaired Modified Live Virus H9N2 Avian Influenza Vaccine for Mass Vaccination
P524	Daniel	Perez	RAM-IGIP: A Novel Live Attenuated Influenza Vaccine Eliciting Enhanced Humoral and Mucosal Immune Protection
P525	Aaron	Schmidt	An engineered hyperglycosylated immunogen to epitope-focus anti-neuraminidase humoral immunity
P526	Justin	Shepard	A self-adjuvanting influenza glycoconjugate vaccine elicits superior protection compared to adjuvanted protein vaccines
P527	Ekaterina	Stepanova	Development of Cross-Reactive Live Attenuated Influenza Vaccine Candidates against Both Lineages of Influenza B Virus
P528	Ekaterina	Stepanova	Safety and immunogenicity study of a bivalent vaccine for combined SARS-CoV-2 and Influenza prophylaxis in non-human primates
P529	NIGEER	TE	Development of Live Attenuated SARS-CoV-2 Vaccines with Atypical Codon Usage
P530	Sean	Tucker	Elevated cross-strain nasal IgA predicts protection against influenza infection in a human challenge model

P531	Eve	Versage	Safety of heterologous booster vaccinations with an MF59-adjuvanted, cell culture-derived H5N6 influenza vaccine in adults primed with MF59-adjuvanted, cell culture-derived H5N1 influenza vaccine or unprimed
P532	Yingxia	Wen	Comprehensive Characterization of sa-mRNA Quadrivalent Influenza Vaccines Using Integrated Mass Spectrometry Assay
P533	Yukihiro	Yagi	Self-amplifying mRNA COVID-19 vaccine induces a superior immune response compared with mRNA vaccine that persists to 12 months postvaccination
P534	Seiya	Yamayoshi	Development of a live attenuated vaccine against COVID-19
P535	Yadana	Zaw	Expanding neutralising antibody breadth with a polyvalent SARS-CoV-2 mRNA vaccine expressing three linked-RBD domains from different variants
P536	Byung Hyun	Ahn	An Animal and Cell Vector System for Evaluating Protective Immunity
P537	Sabiha Jahan	Akhee	Immunogenicity of a polyvalent swine influenza DNA vaccine, based on inferred ancestral hemagglutinin and neuraminidase sequences
P538	Jaeseok	Choi	Canine flu mRNA vaccine efficacy test
P539	Annie	Dosey	Immune focusing of influenza hemagglutinin RBDs displayed on protein nanoparticles improves neutralizing antibody responses
P540	Deborah	Fuller	Multigenic universal influenza DNA vaccine delivered into the epidermis via needle-free gene gun induces broad immunity against diverse influenza viruses in mice and nonhuman primates
P541	Mendel	Haag	Relative Vaccine Effectiveness of Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aQIV) vs High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-QIV) Against Test-Confirmed Influenza During the 2022-2023 Influenza Season
P542	Tomomi	Kawakita	COVID-19 vaccine formulated with ARNAX enhances antigen-specific CD4+ and CD8+ T cell responses and neutralizing antibody induction
P543	Soner	Yildiz	Re-engineering segment 8 to generate a novel rewired live-attenuated influenza a virus vector expressing a secretory protein
P544	Andrew	Catchpole	State-of-the-art facilities contribute substantially to human clinical trial efficacy outcomes
P545	Sarang	Yoon	Interim Estimate of Vaccine Efficacy of Novavax and Pfizer-BioNTech's 2023-2024 updated COVID-19 vaccines (XBB.1.5) in Preventing Symptomatic Infections in U.S. adults and older adults
P546	Victoria	Hall	Influenza-specific B-cell but not T-cell immune responses are dependent on underlying haematological malignancy: secondary analysis of a randomised trial of influenza vaccination strategies

Interdisciplinary Session 3. Epidemic and pandemic preparedness, Public Health and Policy 5. Burden of disease			
P547	Kishor Kumar	Paul	Epidemiology and outcomes of COVID-19 infections seen in NSW emergency departments
P548	Asaph	Chun	Measuring Accessibility to COVID-19 Hospitalization and Evaluating its Association with Health Risks: A National Study in Korea
P549	Md Pear	Hossain	Characterizing the clinical outcomes and case profile by predicting onset to viral load peak delay for COVID-19 in Hong Kong
P550	Md Pear	Hossain	Impact of pre-pandemic influenza transmission on the emerging dynamics of SARS-CoV-2 outbreaks: a multinational syndromic study
P551	FANGYU	YAN	Exploring Incidence of COVID-19 Among Foreign Residents in Japan using National Surveillance Data
P552	Emma	Grant	CD8+ T cell epitope conservation in emerging H5N1 viruses suggests global protection
P553	A.J.	Campbell	Influenza H5N1 and H1N1 viruses remain infectious in unpasteurized milk on milking machinery surfaces
P554	Teresa	Aydillo	Immunological imprinting and the serological signatures of cross-reactive immune responses in COVID19
P555	David	Broderick	Paediatric Respiratory Illnesses pre- vs post- COVID changes in severity and treatment
P556	Danuta	Skowronski	Varying age distribution of co-circulating influenza A(H1N1), A(H3N2) and B(Victoria) viruses during the 2023/24 respiratory season: potential imprinting effects
P557	Oliver	Eales	The effect of antigenic seniority on the timescales of influenza infection risk following vaccination
P558	Serena	Marchi	The role of the stalk in protective immunity to H1N1 influenza haemagglutinin of pandemic strains
P559	Sarah	Leach	HA-immune complexes may reinforce IAV group-specific imprinting bias
P560	Zaolan	Liang	A(H2N2) and A(H3N2) influenza pandemics elicited durable cross-reactive and protective antibodies against avian N2 neuraminidases.
P561	Ian	Barr	Genetic Surveillance of RSV: Insights from 25 RSV Project Countries, 2019-2023
P562	Simon	de Jong	Statistically principled precision respiratory virus genomic epidemiology and outbreak investigation
P563	Annelies	De Rooij	Predictability of seasonal A/H3N2 haemagglutinin evolution differs between epitope and non-epitope substitutions
P564	THI HOAI THU	DO	Serological and molecular analyses define the antigenic evolution of the influenza B virus neuraminidase over 81 years
P565	Xiaomin	Dong	A rapid and sensitive ONT workflow for RSV whole-genome sequencing of clinical samples
P566	Haogao	Gu	Nosocomial Infection Dynamics of SARS-CoV-2 After Relaxed Hospital Visiting Policies in Hong Kong, 2022: A Phylogenetic Analysis

P567	Raquel	Guiomar	RSV co-detection with other respiratory viruses among hospitalized children in Portugal
P568	Anne	Hahn	Escalating combinations of enhanced infectivity and immune escape define SARS-CoV-2 Omicron lineage replacement
P569	Antonia	Ho	Research investigation into the outbreak of unexplained severe hepatitis in Scottish children in 2022
P570	Vu Mai Phuong	Hoang	Molecular evolution of respiratory syncytial virus collected in Northern Viet Nam, 2017-2020
P571	Yusuke	Ichikawa	Whole-Genome Analysis of Influenza B Virus in Japan and Myanmar, 2016□2020
P572	Lauren	Jelley	Genomic epidemiology of respiratory viruses in Aotearoa, New Zealand.
P573	Hye Kwon	Kim	Random mutation and selection balance observed from computational simulation of SARS-CoV-2 replication
P574	Adamou	Lagare	First identification of the SARS-COV-2/XBB.1.5 sublineage among indigenous COVID-19 cases through the influenza sentinel surveillance system in Niger
P575	Adam	Lauring	Influenza A virus within-host evolution and positive selection in a densely sampled household cohort over three seasons
P576	Dong-Wook	Lee	Analyzing decreased substitution rates in SARS-CoV-2 through tracking lineage dynamics in South Korea.
P577	Hui	Lei	Phenotyping influenza A (H3N2) viruses from 1968 to 2019 to track their mammalian adaptation trajectory.
P578	Weiwen	Liang	Epistasis mediates evolution of receptor binding mode in recent human H3N2 hemagglutinin
P579	Jingzhi	Lou	Predicting seasonal influenza virus evolution considering site-based mutation dynamics
P580	Anice	Lowen	Influenza A virus evolutionary dynamics in humans: what conditions support adaptive evolution at the within-host scale?
P581	Mahesh	Moorthy	Phylodynamics of A/H1N1 and A/H3N2 at a tertiary care hospital in India, 2022-23
P582	Jordan	Ort	Development of H5 datasets for Nextclade enables rapid and accurate clade assignment
P583	Andrew	Pekosz	Interplay of antigenic drift and replication fitness in human seasonal influenza viruses
P584	Daniel	Perez	Immunization affects the evolutionary pathway of human-origin H3N2 influenza virus in pigs and selects for mutations in the HA receptor-binding site
P585	Pejman	Rohani	Predicting antigenicity of human influenza A/H3 virus and vaccine recommendation using Convolutional Neural Networks and self-attention
P586	Suzana	Sabaiduc	Whole genome sequencing applied to outpatient sentinel surveillance reveals substantial intrasubtypic reassortment among A(H3N2) viruses: 2021/22 to 2023/24 seasons, Canada

P587	Lara	Schwab	Antigenic evolution of the Influenza B virus haemagglutinin over 81 years
P589	Yi	Song	Genotype Network of H5Nx High Pathogenic Avian Influenza A Viruses
P590	Kelvin	TO	Intrahost evolution of influenza A(H9N2) infection
P591	Nidia S.	Trovao	Comparative evolution of influenza A virus H1 and H3 head and stalk domains across host species
P592	Nidia S.	Trovao	Phylodynamic Modeling Reveals Multiple RSV Introductions with Resistance Mutations into Nicaragua
P593	Nidia S.	Trovao	Evolutionary and spatiotemporal analyses reveal multiple introductions and cryptic transmission of SARS-CoV-2 VOC/VOI in Malta
P594	Nahara	Vargas-Maldonado	Characterization of within-host and expelled viral diversity by individuals experimentally infected with influenza A virus
P595	Gregory	Walker	Characterising the surge of RSV detections in Sydney following relaxation of COVID-19-related public health measures
P596	Mingyang	Wang	Identification of molecular factors that influenced reassortment and the emergence of the 1957 and 1968 pandemic influenza viruses
P597	Ruixuan	WANG	RSV epidemiology and evolution in Australia during COVID-19
P598	Ruopeng	Xie	Deep learning of SARS-CoV-2 outbreak phylodynamics with contact tracing data
P599	Jing	Yang	Novel avian influenza virus (H5N1) Clade 2.3.4.4b reassortants in migratory birds, China
P600	Zengyang	Shao	Predictive efficacies of COVID-19 Vaccines with Fractional Dosing against SARS-CoV-2 Variants using genetic distance
P601	Amita	Jain	Evolutionary analysis of Envelope gene of SARS CoV-2 variants circulating in Uttar Pradesh, India
P602	Samantha	Kaweski	Age-related variation in influenza A(H5N1) versus A(H5N6) risk: potential role of neuraminidase
P603	Chonticha	Klungthong	Coxsackievirus A24 Variant Associated with Acute Hemorrhagic Conjunctivitis Outbreak in Bhutan, 2023
P604	Benjamin	Rambo-Martin	MIRA: Portable, Interactive Application for High-Quality Influenza and SARS-CoV-2 Genome Assembly, Annotation, and Curation
P605	Sebastian	Maurer-stroh	Insights at your fingertips, the enhanced tool ecosystem on the GISAID platform
P606	Kesavardana	Sannula	Molecular virologic factors determining the emergence of 2.3.4.4b clade H5N1 as a panzootic virus
P607	Shashank	Tripathi	Genomic interrogation of a COVID-19 Cohort reveals Pathogenicity hotspots in the SARS-CoV-2 proteome.
P608	Aaron	Schmidt	Antigenic drift expands viral escape pathways from imprinted host humoral immunity
P609	Wanting	Wei	SARS-CoV-2 evolutionary dynamics during prolonged infection in immunocompromised hamsters

Public Health and Policy 3. Forecasting, seasonality and surveillance			
P610	Perrine	Marcenac	Utility of Influenza Sentinel Surveillance Platforms for Monitoring SARS-CoV-2 Activity: Evidence from Analysis of Kenya Influenza Sentinel Surveillance Data
P611	Sandra	Mathew	Sequence comparison of influenza virus inoculum and post-infection nasal washes of ferrets during antisera production for antigenic characterization.
P612	Susana	Monge	RESPIRATORY VIRUS COINFECTIONS IN THE LAST THREE SEASONS IN CASTILLA Y LEÓN (SPAIN)
P613	Piers	Mook	Development of sentinel respiratory virus surveillance systems in the WHO European Region following two pandemics, 2008-2023
P614	Paulo	Notiço	Relationship Between Influenza and RSV in Children under 15 Years Old and Climatic Factors in the Maputo City, Mozambique (2015-2020)
P615	Mingyue	Pan	Comparison of Three Influenza Surveillance Data for Timely Onset Detection of Epidemics in Beijing and Chengdu, China
P616	Joshua	Petrie	Seasonal incidence of symptomatic RSV during the COVID-19 pandemic in a rural community cohort: Wisconsin, USA 2021-2023.
P617	Jee Eun	Rhee	Increased Trend of Adenovirus Activity After COVID-19 Pandemic in South Korea: Analysis of National Surveillance Data
P618	Sukhyun	Ryu	Community based sentinel surveillance evaluation of influenza like illness in South Korea, 2017-2022
P619	Sukhyun	Ryu	Evaluation of the sentinel surveillance for hand, foot, and mouth diseases in South Korea
P620	Joseph	Servadio	Medium-term forecasting for non-annual influenza dynamics in the tropics
P621	Ewan	Smith	A 6-year trend and impact of funding on influenza vaccine uptake in New Zealand children.
P622	Kirsten	St. George	Development of a digital RT-PCR multiplex assay for influenza and RSV and results of one year of application for wastewater analysis
P623	Yoshihiro	Takadate	Phylogenetic analysis of H5N1 and H5N2 high pathogenicity avian influenza viruses (Clade 2.3.4.4b) isolated from poultry in Japan during 2022/2023 season.
P624	Jonathan	Temte	Descriptive epidemiology of pathogens associated with acute respiratory infection in a community-based study of K-12 school children, 2015-2023
P625	Nikki	Turner	Comparing changes in patterns for influenza and RSV epidemiology post interruption of transmission
P626	Nuno	Verdasca	Dynamics of the Influenza and RSV circulation after the onset of SARS-CoV-2
P627	Gregory	Walker	Epidemiology of respiratory syncytial virus within a NSW-based multi-centre health district between 2018-2023
P628	Xiling	Wang	Characteristics of influenza epidemic in the first two seasons after lifting the non-pharmaceutical interventions for COVID-19

P629	Haowei	Wang	Forecasting regional-level COVID-19 hospitalisation in England as an ordinal variable using the machine learning method
P630	PENG	WU	Seasonality of Respiratory Syncytial Virus in Hong Kong, 1998-2019
P631	Benny	Yeo	Comparative Analysis of Pre- and Post-COVID-19 Pandemic Respiratory Infection Prevalence in Singapore's Adult and Pediatric Populations
P632	Tasoula	Zakis	The circulation of human influenza in Australia post the COVID-19 pandemic (2022-2024).
P633	Chenkai	Zhao	Characterising the variations in the timing of re-circulation of common human respiratory viruses following the onset of the COVID-19 pandemic: a global-level systematic analysis
P634	Anne Maree	Baldwin	Epidemiology of COVID-19 cases in Sunshine Coast-Gympie residential aged care facilities (RACFs)
P635	Jared	Edgeworth	The detection of an unusual respiratory disease outbreak using the artificial intelligence derived event-based surveillance system EPIWATCH.
P636	Walter	Harrington	Active influenza surveillance in wild and domestic birds reveals sex- and host-specific patterns in Bangladeshi avian populations
P637	Yiu-Chung	Lau	Improved inference of Time-Varying Reproduction Number through Epidemic Curve Reconstruction Based on predicted Infection Time
P638	Yun	Lin	Real-time estimation of transmission risks using population viral load in complicated real-world and simulation settings
P639	Ian	Plumb	Association between acute respiratory symptoms and detection of respiratory viruses in a prospective community-based cohort in the United States, August 2021–July 2022
P641	Sandra	Carlson	FluTracking's contribution to understanding COVID-19 activity in Australia, New Zealand, and Hong Kong
P642	Dorothy Hui Lin	Lin	Unrecognised impact of viral moderate-to-severe community-acquired pneumonia in Singapore.
P643	Keita	Wagatsuma	Quantifying the burden of seasonal influenza morbidity attributable to climate variability: a nationwide time-series modelling study in Japan, 2000–19
P644	Jade Yangyupei	Yang	Characteristic differences among a population infected during the first and second Omicron waves: findings from the HIVE study
P645	Yuping	Duan	Clinical manifestation and disease Severity of Multi-Respiratory Pathogen Infections: A Case-Series Study
P646	Hualei	Xin	Comparison of excess deaths and laboratory-confirmed COVID-19 deaths during a large Omicron epidemic in 2022 in Hong Kong
P647	Peter	Cronin	Seasonal influenza circulation and diversity in Singapore during 2023–2024
P648	Chidozie Declan	Iwu	Clinical and molecular epidemiology of influenza in community-based versus clinical settings in Seattle Metropolitan Area, 2018-2022
P649	Howon	Kim	Genetic diversity and reassortment analysis of low pathogenic avian influenza viruses in wild waterfowl in Korea

P650	Raphael Tze Chuen	Lee	FluCluster-AI and EmergingVariants: Visualization Platform that Predicts the Antigenic Distances and Growth Rates of Emerging Influenza Virus Variants and Highlights Mutations that correlate with Phenotypes
P651	SHRUTI	RADERA	Genetic diversity of influenza A (H1N1) strains circulating in Northern India; a 7 year surveillance study (2017-2023)
P652	Natasha	Halasa	Influenza Detection and Vaccination Coverage among Hospitalized Children with Acute Respiratory Illness in Amman, Jordan (2007–2023)
P653	Rifaldy	Fajar	Deep Reinforcement Learning for Optimized Influenza Vaccine Distribution: A Novel Approach to Mitigate Seasonal Outbreaks
P654	Tianxiao	Hao	Predicting immune protection against outcomes of respiratory infections from population-level effectiveness data with application to COVID-19
P655	Jean-Michel	HERAUD	Public Health Research Agenda for Influenza: Update 2024
P656	Xiangjun	Du	Antigenic Surveillance and Vaccine Recommendation for Influenza and SARS-CoV-2 Based on Artificial Intelligence Models
P657	James	Hay	Reconstructed influenza A/H3N2 infection histories reveal variation in incidence and antibody dynamics over the life course
P658	Christopher	Benton	Going with the flow: Monitoring Influenza in a low population state
P659	Peter	Daly	Surveillance for Novel Influenza A Viruses Via Cloud Implementation
P660	Xiaohan	Si	Title: Particulate matter 2.5, population movement and seasonal influenza transmissions in elderly population in Mainland, China: A spatial analysis based on climate zones
P661	Anne Maree	Baldwin	Co-detection of SARS-CoV-2, influenza and respiratory syncytial virus (RSV): frequency and impact in the Sunshine Coast-Gympie region of Queensland, 2022 to March 2024
P662	David	Boettiger	Self-swab respiratory virus surveillance for monitoring pathogen-specific symptoms and asymptomatic infection in the community – The PREVENT pilot study
P663	David	Broderick	Comparison of three surveillance system for accurate assessment of the hospitalised influenza burden.
P664	Briony	Fanslow	Epidemiological patterns in the burden and seasonality of Influenza- and Human metapneumovirus-associated adult hospitalisations in Aotearoa New Zealand
P665	Amanda	Howa	Estimating the Undetected Burden of Respiratory Syncytial Virus Associated-Hospitalizations in Adults Through Capture-Recapture Methods
P666	Taro	Kamigaki	Nartionwide school absenteeism surveillance of COVID-19 during pandemic in Japan
P667	Emily	Martin	Environmental Contamination by Respiratory Viruses in Child Care Centers and Concurrent Community Respiratory Infection Surveillance
P668	Patrick	Sotto	Exploring the driving forces for differences in influenza and COVID-19 trends, Guam 2023

P669	Sarah	Bassiouni, MPH	Comparison of RSV shedding patterns in a prospective longitudinal state-wide cohort
P670	Michelle	Wille	Evolutionary ecology of avian influenza viruses in Australia, and how this may inform our preparation for HPAI
P671	Dillon C	Adam	Reconstructing the SARS-CoV-2 epidemic in Hong Kong
P672	Liling	Chaw	Factors associated with onward SARS-CoV-2 transmission in household and worker dormitory settings in Brunei Darussalam, August 2021 – February 2022
P673	Dongxuan	Chen	Investigating potential biases in forward and backward contact-tracing when estimating pathogen superspreading potential
P674	Kathy	Dempsey	FRAMED – New South Wales- Australia Infection prevention and control response and escalation framework for the management of in hospital COVID-19, ARI and beyond!
P675	Tony	Dowell	Multi-viral Rapid Antigen point of care testing in primary care: from feasibility to enthusiastic adoption in practice.
P676	Md Ariful	Islam	Knowledge, attitude, practice and barriers associated with influenza vaccination among health care personnel in Bangladesh
P677	Charles	Jones	In Silico Prediction of Pathogen's Pandemic Potential using Viral Trait Assessment for Pandemics (ViTAP) model
P678	George N.	Okoli	Impact of universal seasonal influenza vaccination policy on seasonal influenza vaccine uptake in the Province of Manitoba, Canada: a population-based interrupted time series analysis
P679	Sonja	Olsen	The estimated impact of COVID-19 non-pharmaceutical interventions on influenza burden in the United States
P680	Hana Apsari	Pawestri	Public health laboratory capacity development: external quality assessment of SARS-COV-2 sequencing
P681	Wayne	Ramkrishna	Seasonal influenza vaccination, during the COVID-19 pandemic, in South Africa (2011-2023)
P682	Maria	Stubbe	'I had no idea it was influenza, just thought it was a cold': Community views on public health measures to reduce transmission of respiratory infections
P683	Lin	Yang	An Artificial Intelligence System for Indoor Contract Tracing COVID-19 in Residential Care Facilities in Hong Kong
P684	Hui	Yao	Superior effectiveness and acceptability of saliva samples for the detection of SARS-CoV-2 in China
P685	Erica E.	Zeno	Assessing the effectiveness of mask use to prevent influenza in observational studies

Public Health and Policy 5. Burden of disease			
P686	Josefina	Abedin	Prevalence of asymptomatic influenza virus infection in human and animal populations: a systematic review and implications for enhanced surveillance.
P687	Rebecca	Dawson	Changes and distributions of educational absences in the UK from 2019 to 2023 during the COVID-19 pandemic.
P688	Hanne-Dorthe	Emborg	The burden of respiratory infections on the healthcare system in Denmark has become evident after introducing an integrated surveillance strategy in season 2023/24
P689	Hanne-Dorthe	Emborg	Excess mortality in Europe during the COVID-19 pandemic (2020-2023) and previous influenza seasons (2014-2019): A time-series analysis from EuroMOMO
P690	Shikha	Garg	Prevalence and Characteristics of Invasive Bacterial or Fungal Coinfections among Patients Hospitalized with Influenza, FluSurv-NET, 2022-2023
P691	Luca	Giurgea	Comorbidities Underlie Gender and Demographic Differences in COVID-19 but Female Gender is an Independent Risk Factor in Fertile Age Women
P692	Lian	He	The severity of influenza, respiratory syncytial virus, human metapneumovirus and human parainfluenza virus in young children by age and country income groups: a systematic analysis
P693	Jyoti	Jethani	Incidence of influenza & other respiratory viral infections in adults following Hematopoietic Stem Cell Transplant (HSCT) recipients at a tertiary care hospital in India.
P694	Grace	Kambach	Outcomes of adults with COPD hospitalized with laboratory-confirmed influenza
P695	Byung Ok	Kwak	Examining the Effectiveness of Influenza Vaccines and Trends in Antiviral Drug Use Over Five Decades: A Machine Learning Approach
P696	Jan	Kyncl	Mortality related to influenza in the Czech Republic during the 21-seasons period
P697	Alexandra H. T.	Law	Estimating disease burden associated with COVID-19 and changes in life expectancy in Hong Kong from 2020 to 2022
P698	Aleda	Leis	Six Month Physical and Quality of Life Outcomes Following Hospitalization with RSV Disease Versus COVID-19 Among Adults in the United States
P699	Ruiyun	Li	The changing health effects of air pollution exposure for respiratory diseases: a multicity study during 2017–2022
P700	You	Li	Global disease burden of and risk factors for RSV in preterm-born children in 2019: a systematic analysis of aggregated and individual participant data
P701	Bette	Liu	Clinical characteristics and in-hospital outcomes in children with RSV-ALRI compared to non-RSV-ALRI
P702	Hannah	Maier	1st, 2nd, and 3rd+ SARS-CoV-2 infections: associations of prior infections with protection and severity

P703	Evangeline	Obodai	Incidence of Respiratory Syncytial Virus Infection among Confirmed COVID-19 Cases in Ghana
P704	Juan	Pu	Influenza-associated excess respiratory mortality in Chinese mainland, 2012–2019: a retrospective population-based statistical modeling study
P705	Rachael	Pung	Assessing the impact of co-circulating SARS-CoV-2 and influenza virus on hospitalisation and mortality in Singapore
P706	Carrie	Reed	Estimating Influenza Hospitalization Burden in the United States Using a Bayesian Hierarchical Model
P707	Katie	Reinhart	Assessing influenza mortality using death certificate data in the U.S.
P708	Dong	Wang	Modelling of influenza hospital admission burden across the age groups in Hong Kong using multi-stream surveillance data
P709	Dong	Wang	The COVID-19 transmission dynamics in mainland China: a higher-order spatiotemporal modeling study
P710	Shigui	Yang	Global Patterns and Trends in Deaths of Influenza-Associated Lower Respiratory Tract Infections from 1990 to 2019
P711	Siddhartha	Saha	A household investigation study of transmission dynamics of influenza and novel severe acute respiratory syndrome coronavirus (SARS CoV-2) over multiple transmission periods in India
P712	Qing	Wang	Prevalence and preference of healthcare utilization for acute respiratory infection post-COVID-19 pandemic
P713	Qing	Wang	Prevalence and preference of healthcare utilization for acute respiratory infection post-COVID-19 pandemic
P714	Larisa	Gubareva	Emergence and intercontinental spread of influenza A(H1N1)pdm09 viruses displaying reduced inhibition by oseltamivir
P715	Jennifer	Laplante	COMPARISON OF TWO PHENOTYPIC INFLUENZA ANTIVIRAL SUSCEPTIBILITY ASSAYS, HINT AND IRINA
P716	SeongCheol	Min	In Vitro and In Vivo Characterization of Ensitrelvir-Selective Resistance in SARS-CoV-2
P717	Nikita	Deshpande	Comparison of human influenza virus susceptibilities to neuraminidase inhibitors before and after the COVID-19 pandemic in the Australia - Asia Pacific region.
P718	Konstantin	Andreev	Antiviral drugs against highly pathogenic avian influenza A(H5N1) clade 2.3.4.4b viruses in vitro and in vivo
P719	Slim	Fourati	Characterization of RSV full-length viral genomes after Nirsevimab breakthrough infections in a large national observational real-world study conducted in France
P720	Charlie	Holland	Systematic review of non-specific effects of respiratory vaccines on acute lower respiratory infection hospitalisations and related outcomes in children under 5 years of age
P721	Kyueun	Lee	Trend in Inpatient and Outpatient Influenza Antiviral Use in the United States

Virology and Pathogenesis 3. Adaptive immune response to infection, Clinical Sciences and Vaccinology			
P722	Hayley	Colton	Relative preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1 nCoV-19 (AZD1222) vaccine compared to mRNA vaccines in haematopoietic stem cell transplant recipients.
P723	Kelly	da Costa	A novel dual pseudo-Micro-Neutralisation (pMN) assay to distinguish SARS-CoV-2 and influenza neutralising antibody responses.
P724	Jenna	Guthmiller	Identification of Rare Human Memory B Cells Targeting Known and Novel Broadly Neutralizing Hemagglutinin Epitopes
P725	Sooyeon	Lim	Analysis correlation between the respiratory microbiome and the clinical course of carbapenem-resistant Acinetobacter baumannii pneumonia in intubated patients in intensive care units
P726	Jessica	Belser	Identification of differential predictive correlates of influenza A virus transmission in the ferret model
P727	Dongxuan	Chen	Estimating the latent period of COVID-19 using detailed contact tracing and viral load data from Hong Kong
P728	Alex Wing Hong	Chin	SARS-CoV-2 Omicron EG.5 and JN.1 variants induce enhanced pathogenicity in K18-hACE2 mice than the early Omicron variants
P729	Nicola	Chiwandire	The Role of Household Relationships in Influenza Transmission Dynamics: a US case-ascertained study, 2021-2023
P730	Alba	Escalera	The impact of S2 mutations on Omicron SARS-CoV-2 cell surface expression and fusogenicity
P731	Yuri	Furusawa	SARS-CoV-2 XBB.1.5 shows increased replicative ability at low temperatures
P732	Marta Maria	Gaglia	The Influenza A virus immunomodulator PA-X reduces dendritic cell recruitment to infected lungs and promotes expression of lung repair genes
P733	Peter	Halfmann	Hamster Models for Studying SARS-CoV-2 Transmission, Pathogenicity, and Persistent Infections
P734	Koyu	Hara	Antiviral peptides targeting phosphoprotein oligomerization of HRSV and paramyxoviruses
P735	Kenrie Pui Yan	Hui	Virological characteristics of the SARS-CoV-2 JN.1 and EG.5.1 variants in ex vivo human bronchial and lung tissues
P736	Chae-Eun	Kim	Molecular characterization and infectivity of an avian-origin reassortant H1N3 influenza virus.
P737	Jeong-Eun	Kim	Long-term Surveillance of Avian Coronaviruses from Wild Bird in Korea
P738	Dong Hoon	Lee	Deglycosylation of human influenza A/H3N2 hemagglutinin enhances infectivity and virulence during mouse adaptation
P739	Siwen	Liu	Virological characterization and biological significance of the spike furin cleavage site in the Omicron variant of SARS-CoV-2 in vitro and in vivo.
P740	Heather	Machkovech	Interrogation of influenza A transmission bottleneck dynamics in ferrets using molecularly barcoded viruses

P741	Hannah	Maier	High SARS-CoV-2 anti-spike immunity reduces infectivity, and other findings from a household transmission study
P742	Daniel	Perez	Development of a novel calm-aerosol system to study aerosol transmission of influenza A viruses.
P743	Aaron	Schmidt	Development and validation of a sampling platform for detection of infectious influenza virus in respiratory emissions
P744	Douglas	Reed	H3N2 survives longer than type B (Victoria) influenza viruses in aerosols and on surfaces.
P745	Chi Yueng	Shuen	Mechanism of SAR-CoC-2 inactivation on copper-containing coatings
P746	Yipeng	Sun	Increased public health threat of avian-origin H3N2 influenza virus caused by its evolution in dogs.
P747	Jonathan	Temte	Household transmission of human metapneumovirus and seasonal coronavirus
P748	Sarang	Yoon	Infectivity and pathogenicity of H7N9 influenza A virus is influenced by route of inoculation in ferrets
P749	Mina	Yu	Persistent Immune Dysregulation and Neutrophil Activation in Long COVID: Insights from a P. roborovskii Hamster Model
P750	jialu	Zheng	Recombination and Selection Trajectory during the Adaptation in Human Population for Monkeypox Viruses
P751	Wenting	Zuo	The association between the persistence of SARS-CoV-2 and long COVID symptoms: a cohort study
P752	Ann Kathrin	Ahrens	Emergence and spread of multiple new reassorted highly pathogenic avian influenza viruses in Germany 2023/2024
P753	Susan	Detmer	In-vitro bronchiolar attachment compared to ex-vivo replication and neutralization models of zoonotic pdmH1N1 strains using pig tissues
P754	Tonia	Kam	Viral characterization of the reassortants between canine influenza H3N2 and pandemic (2009) H1N1 and avian H9N2 viruses in canine ex vivo tracheal explants
P755	Kobey	Karamendin	Genetic characterization of a mixed bat and avian influenza A virus strain
P756	Junna	Kawasaki	Progress and Pitfalls of Genome-Based Machine Learning Models for Predicting Zoonotic Potential of Respiratory Viruses
P757	Dawon	Kim	The decreased evolutionary rate of 2.3.4.4b clade highly pathogenic avian influenza virus following the introduction into wild birds
P758	Ji-Yun	Kim	Comparative Phylogeographic Analysis of Highly Pathogenic Avian Influenza H5 Outbreaks in South Korea Revealed Changed Dynamics and Transmission Patterns
P759	Aidyn	Kydyrmanov	A new candidate hemagglutinin subtype (H19) of influenza a viruses
P760	Jisu	Lee	Assessment of the Potential for Human Transmission of H3N2 Canine Influenza Virus Variants

P761	Yuan	Liang	Mammalian-adapted high pathogenicity avian influenza viruses detected on poultry farms
P762	Denys	Muzyka	Diversity of avian and mammalian influenza viruses in Ukraine in wild and domestic animals
P763	Philipp Peter	Petric	Contribution of the Eurasian avian-like swine IAV H1N1 NS segment to zoonotic spillover infections in Denmark
P764	Anne	Pohlmann	Retrospective differentiation of genotypes in highly pathogenic avian influenza viruses (HPAIV) from the goose/Guangdong lineage in Germany
P765	Elizabeth	Pusch	Genetic and antigenic characterization of a Eurasian lineage 1C.2.5 influenza A(H1N2) variant virus resulting in a human infection
P767	Lauren	Steele	Preventing the next influenza pandemic: Neuropilin-1, sema3A, and the genesis of highly pathogenic avian influenza viruses
P768	Haley	Stone	Enhancing Avian Influenza Phylogenetic Analysis: Insights from Integrated Genomic and Epidemiological Dataset
P769	Foong Ying	Wong	Development of a high-throughput multiplex assay for rapid diagnosis and serological differentiation of zoonotic influenza A viruses
P770	Li	Wang	Development and characterization of humanized monoclonal antibodies targeting clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses
P771	Matthew	Dover	Public Health Laboratory Response to 2024 HPAI Outbreak in Michigan, USA
P772	Xiu-Feng (Henry)	Wan	The evolutionary trajectories of SARS-CoV-2 and their impact on wildlife susceptibility
P773	Kimberly	Edwards	Regional impact of HPAI H5Nx 2.3.4.4b reintroductions in Asia
P774	Julia	Frederick	Deep sequencing methodologies to measure the intra-host variation of avian influenza A(H5N1) viruses detected in human clinical specimens
P775	Kevin	Kuchinski	Detection of a reassortant swine- and human-origin H3N2 influenza A virus in farmed mink in British Columbia, Canada
P776	Ramona	Trebbien	One Health in one tube: Unifying the workflow for whole genome sequencing of Influenza A viruses of human, swine, and avian origin
P777	Kesavardana	Sannula	Specific molecular principles determine the pairing and fitness of avian HA and NA and the resurgence of 2.3.4.4b clade H5N1
P778	Antoni	Wrobel	Evolution of the receptor binding in SARS-CoV-2 spike
P779	Taronna	Maines	Assessing the Risk of Airborne Transmission of Highly Pathogenic Avian Influenza A(H5N1) Virus using the Ferret Model

Clinical Sciences and Vaccinology 1			
P797	Chanida	Ruchisrisarod	Development of Metrics for Assessing Impact of COVID-19 Vaccine Related Adverse Effects and Long COVID-19
P798	Chanida	Ruchisrisarod	Rapid screening of SARS-CoV-2 variants from respiratory specimens involves targeting critical genetic mutations in the spike glycoprotein and ORF1ab polyprotein
Interdisciplinary Session 3. Epidemic and pandemic preparedness			
P795	Mathias	Romar	Characterization of Danish swine and human Influenza A viruses growth kinetics and adaptation in respiratory cell lines of swine and human origin
P799	Min-Suk	Song	Mammalian Adaptation Risk in HPAI H5N8: A Comprehensive Model Bridging Experimental Data with Mathematical Insights
Public Health and Policy 1. Vaccines (including but not limited to effectiveness, impact and safety)			
P790	Lorens	Maake	Antibody responses following influenza infection in a community cohort study, PHIRST, South Africa, 2016-2017
P791	Edin	Mifsud	Relative Effectiveness of Cell-Based Influenza Vaccines versus Egg-Based Influenza Vaccines: A Review of Test-Confirmed and Clinical Diagnosis-Based Outcomes
Virology and Pathogenesis 5. Zoonotic respiratory viruses			
P793	Henintsoa	Ravololona	A live-bird markets surveillance of avian influenza viruses in Antananarivo, Madagascar, June 2021 to December 2023
P794	Douglas	Reed	Inhalation of a highly pathogenic avian influenza H7N9 virus triggers acute respiratory distress in cynomolgus macaques
Public Health and Policy 5. Burden of disease			
P796	Chanida	Ruchisrisarod	Antibodies response in symptomatic and asymptomatic SARS-CoV-2 infected persons in Thailand
P800	Mathieu	Bangert	Assessment of ICD Influenza Diagnosis Codes against RT-PCR Results in Hospitalized Adults from Valencia Region, Spain, 2012/13-2017/18
P801	Mathieu	Bangert	Risk of influenza-associated hospitalizations in individuals with chronic diseases: A population-based study
P802	Mengmeng	Jia	Estimated number and incidence of influenza-associated acute respiratory infection cases in winter 2021/22 in Wanzhou District, China

Exhibition

Exhibition Floor Plan



Exhibitor Listing

- Platinum 1 – Sanofi
- Platinum 2 – CSL Seqirus
- Exhibition Booth 1 & 2 – Moderna
- Exhibition Booth 3 – GSK
- Networking Area – ISIRV
- Exhibition Booth 5 – GISAID
- Exhibition Booth 6 – Roche
- Exhibition Booth 7 – Pfizer
- Exhibition Booth 8 – hVIVO
- Exhibition Booth 9 – ESWI
- Exhibition Booth 10 – AstraZeneca
- Exhibition Booth 12 – Cellular Technology Limited
- Exhibition Booth 13 & 14 – Vaxxas

Sponsor and Exhibitor Profiles

Sanofi

Booth Number: Platinum 1

Contact: Scott McNeil
Email: scott.mcneil@sanofi.com
Web: www.sanofi.com.au

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of our ambitions.

Scientific discoveries don't happen overnight or without hard work. But our determination to find answers for patients motivates us to develop breakthrough medicines and vaccines. And to never settle.

CSL Seqirus

Booth Number: Platinum 2

Contact Email: corporate.mail@csl.com.au
Web: www.cslseqirus.com

As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to public health through the prevention of influenza and pandemic preparedness. With state-of-the-art production facilities and leading R&D capabilities, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.

In Australia, CSL Seqirus operates the only manufacturing facility for seasonal and pandemic influenza vaccines, and produces a range of unique medicines in the national interest including antivenoms and the only human vaccine for Q fever. Our commitment to Australia's health also extends to providing access to paediatric and adult vaccines, and innovative pharmaceuticals for patients living with allergies, cardiovascular disease, severe pain, dry eye disease, iron deficiency, kidney diseases, rare diseases and neurological conditions.

Moderna

Booth Number: 1 & 2

Contact Email: wecare@modernatx.com
Web: www.modernatx.com

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines.

Moderna's mRNA platform is enabling the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets. Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com.

Sponsor and Exhibitor Profiles

GSK

Booth Number: 3

Web: www.gsk.com/en-gb/

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of more than 2.5 billion individuals by 2031, with ambitious plans for growth and continuing to make GSK a company where everyone can thrive.

ISIRV

Networking Area

Web: https://isirv.org/site/

The International Society for Influenza and other Respiratory Virus Diseases (ISIRV) is an independent and international scientific professional society promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases.

ISIRV was founded in 2005 as the first scientific society with a fully worldwide remit focussed on influenza and respiratory virus disease. A particular stimulus for its creation was also the need for an organisation to ensure continuation of the Options for the Control of Influenza conferences which were growing ever larger.

Influenza and acute respiratory virus disease is a field of public health of major international importance. Recent epidemiological events - the 2009 pandemic of H1N1 influenza, first identified in Mexico; the occurrence of human cases of avian influenza A(H7N9) in China; the emergence of Middle East Respiratory Syndrome (MERS-CoV); and ongoing outbreaks of virulent avian influenza A(H5N1) in several countries; continue to highlight the requirement for international collaboration on respiratory virus research and development.

These ongoing events serve as a reminder of the importance of clinical and laboratory research, scientific communication and global collaboration to contribute to the early detection and containment of respiratory virus outbreaks.

GISAID

Booth Number: 5

Contact Email: media@gisaid.org
Web: www.gisaid.org

GISAID is known for providing transparent access to the world's largest collection of genomic and associated metadata of high-priority pathogens. With ~20 million curated viral genomes, GISAID remains an essential asset for the WHO GISRS-network enabling genomic surveillance for Influenza, RSV, SARS-CoV-2, in addition to Mpox and Arboviruses e.g. Dengue.

Sponsor and Exhibitor Profiles

Roche

Booth Number: 6

Contact: Adriano Souza
Email: adriano.souza.as1@roche.com
Web: www.roche.com

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Pfizer

Booth Number: 7

Contact: Carolina Campisi
Email: carolina.campisi@pfizer.com
Web: www.pfizer.com

About Pfizer: Breakthroughs That Change Patients' Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

hVIVO

Booth Number: 8

Contact email: BD@hvivo.com
Web: www.hvivo.com

hVIVO is a specialist contract research organisation and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials, providing end-to-end early drug development services (Venn Life Sciences), clinical experts in industry leader in virology clinical trial support (hLAB) and volunteer recruitment experts (FluCamp).

ESWI

SCIENTISTS FIGHTING INFLUENZA AND OTHER ACUTE RESPIRATORY VIRUSES

Booth Number: 9

Contact: Dagmar Degraef
Email: dagmar.degraef@eswi.org
Web: www.eswi.org

The European Scientific Working group on Influenza and other Respiratory Viruses (ESWI) is a network organisation that aims to reduce the burden of influenza and other acute respiratory viruses in Europe. At the core of the group are leading scientific experts from different disciplines working with public health officials, healthcare professionals, and high-risk groups.

Sponsor and Exhibitor Profiles

AstraZeneca

Booth Number: 10

Web: www.astrazeneca.com

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.

Cellular Technology Limited

Booth Number: 12

Contact: Tameem Ansari
Email: tameem.ansari@immunospot.com
Web: www.immunospot.com

Cellular Technology Ltd (CTL) offers instrumentation and consumable products for standardized/validated cellular assays

- High-throughput visible and fluorescent Analyzers
  - Viral titer and microneutralization
  - ELISPOT/FluoroSpot
- T and B cell ELISPOT Kits including for measuring Ferret B cell
- Human PBMC with variable Ig class and subclass usage against influenza and SARS-CoV-2 surface glycoproteins
- Contract Laboratory Services

Vaxxas

Booth Number: 13 & 14

Contact Email: info@vaxxas.com
Web: www.vaxxas.com

Vaxxas is developing a needle-free vaccine technology, the high-density microarray patch (HD-MAP). Easy to use, with potential to be more effective at lower doses and distributed without refrigeration, our technology could transform vaccination in the future. We're targeting initial applications in infectious diseases and oncology. Visit us at Options XII to learn more.

Thank you to our Sponsors and Supporters

Platinum Sponsors

CSL Seqirus

AstraZeneca

Roche

sanofi

moderna

Pfizer

Supporters

Tourism & Events Queensland

Business Events Australia

brisbane australia

The University of Queensland Australia

vaxxas

VISMEDERI
ANALYSES FOR LIFE IMPROVEMENT

sanofi

moderna

OPTIONS XII
for the Control of INFLUENZA

29 September - 2 October 2024
Brisbane Convention and Exhibition Centre
Queensland, Australia

Hosted by

isirv
International Society for Influenza and other Respiratory Virus Diseases

EVENT MANAGEMENT

ICMS AUSTRALASIA PTY LTD
CELEBRATING 55 YEARS 1966-2021

www.icmsaust.com.au